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Abstract 
 
Risk factors for community-acquired urinary tract infections (UTI) caused by extended-
spectrum beta-lactamase-(ESBL) and AmpC beta-lactamase-(ACBL) producing 
Enterobacteriaceae were investigated in a prospective case-control study conducted 
between August 2015 and September 2017. Both cases and controls were from the 
Auckland and Northland regions of New Zealand. A telephone questionnaire was 
delivered to participants, and the results analysed for putative risk factors for human 
infections. Analysis was performed using regression models, including factors around pet 
ownership and any other animal contact. Faecal samples were submitted from some 
households; this included samples from both people and companion animals. Isolates 
collected from index case urine samples and ESBL- or ACBL-producing faecal samples 
were sequenced and subsequently analysed through a bioinformatics pipeline. Pet 
ownership was not found to be a risk for human ESBL- or AmpC-producing infections in 
this study. Another important finding of this research was that E. coli ST-131 was the most 
commonly found bacteria associated with the UTI from people recruited into the case-
control study. The strains of this sequence type were likely to have entered New Zealand 
in multiple introductions over the last 20 years. Transmission of ESBL-/ACBL-
producing E. coli was also suspected to have occurred within households where a person 
had been recently infected with the same bacteria (in the form of a UTI) caused by an 
ESBL-/ACBL-producing Enterobacteriaceae. The results of this study as a whole 
indicate that while pets may not be a major risk for acquisition of ESBL/ACBL-producing 
bacteria, they are likely to play a role in the transmission of bacteria within homes and the 
community, and therefore warrant attention in future work.  
iv 
 
  
v 
 
presentations & publications 
 
Oral presentation: “Exploring pet ownership as a risk factor for community-acquired 
extended spectrum -lactamase and AmpC -lactamase infection in humans”, One 
Health Aotearoa Symposium: Wellington, New Zealand, December 2018 
Poster presentation: “The ‘resist-home’: household transmission of antimicrobial 
resistant E. coli”, One Health Aotearoa Symposium: Wellington, New Zealand, 
December 2018 
Oral presentation: “Exploring pet ownership as a risk factor for ESBL infection in 
humans”, ANZCVS Science Week: Gold Coast, Australia July 2018 
Oral presentation: “Faecal carriage of ESBL- and AmpC–producing Escherichia coli 
from co-habiting people and pets”, ARAE 2017 the 7th Symposium on Antimicrobial 
Resistance in Animals and the Environment: Braunschweig, Germany June 2017 
Publication: Toombs-Ruane LJ, Benschop J, Burgess S, Priest P, Murdoch DR, 
French NP. 2017. Multidrug resistant Enterobacteriaceae in New Zealand: a current 
perspective. New Zealand Veterinary Journal 65:62-70. 
 
  
vi 
 
  
vii 
 
Acknowledgements 
 
The work contained within this dissertation was made with support of my wonderful team 
of supervisors (Jackie, Sara, Anne, Patrick, Jonathan and Nigel) and project advisors (Zoë 
Grange, Dragana Drinkovic, Mick Roberts, Michael Baker and Jeroen Douwes). Thank 
you all for your generosity and insights. The case control study (Chapter 3) would not 
have been possible without the hard work of Dragana Drinkovic for her invaluable 
contributions to case recruitment. Thanks also to Tracey Whaanga for her role in case 
follow-up and questionnaire delivery. The laboratory work in Chapter 3 and 4 was 
assisted by Maggie Chan, Jacinda Aplin, Lynn Rogers, Rukhshana Akhter, Harry 
Cookson, and Ahmed Fayaz from mEpilab at Massey; Matilda Germanov at Labtests 
Auckland, and Tina Littlejohn at Medlab Central. Ji Zhang, David Wilkinson, and Samuel 
Bloomfield provided additional bioinformatics support, and Ahmed Fayaz was architect 
and builder of the database for this study. Thank you all for your wisdom and work.  
Special thanks to all the people and pets who gave their time (and poo) without which this 
research would not have been possible. Thanks also to the Health Research Council of 
NZ for providing funding for both this research and my PhD scholarship. 
Finally, to my family: Dolly, Keith, Henry, Julia, and Matt. I appreciate your forbearance 
and patience and I would not have survived this without you.  
  
viii 
 
  
ix 
 
Table of contents 
 
1 Introduction ............................................................................................................ 1 
1.1 Overview ................................................................................................................. 1 
1.2 An introduction to antimicrobial resistance ............................................................ 2 
1.3 Why is antimicrobial resistance important? ............................................................ 5 
1.4 Antimicrobial resistance and animals ..................................................................... 6 
1.5 Antimicrobial use and resistance ............................................................................ 9 
1.6 The role of genomics in understanding antimicrobial resistance .......................... 10 
1.7 Thesis objectives .................................................................................................. 12 
1.8 Thesis structure .................................................................................................... 14 
2 Multidrug resistant Enterobacteriaceae in New Zealand: a current perspective
 .................................................................................................................................. 15 
2.1 Introduction ......................................................................................................... 15 
2.2 Antimicrobial resistance mechanisms .................................................................. 17 
2.3 Occurrence and prevalence of ESBL enzymes ..................................................... 22 
2.4 Reservoirs and transmission pathways ................................................................. 24 
2.5 Discussion ............................................................................................................ 28 
2.6 Conclusions .......................................................................................................... 35 
x 
 
3 Companion animals as a risk for community-acquired extended-spectrum beta-
lactamase and AmpC beta-lactamase producing Enterobacteriaceae infections: a 
prospective case-control study ................................................................................ 39 
3.1 Abstract ................................................................................................................ 39 
3.2 Introduction ......................................................................................................... 41 
3.3 Materials and methods ......................................................................................... 44 
3.4 Results .................................................................................................................. 56 
3.5 Discussion ............................................................................................................ 79 
3.6 Conclusions .......................................................................................................... 85 
4 Transmission of extended spectrum beta-lactamase- and AmpC beta-
lactamase-producing Escherichia coli between people with a community-acquired 
urinary infection, their family, and pets in the household: The “resist-home” ..... 87 
4.1 Abstract ................................................................................................................ 87 
4.2 Introduction ......................................................................................................... 88 
4.3 Materials and methods ......................................................................................... 91 
4.4 Results .................................................................................................................. 99 
4.5 Discussion ........................................................................................................... 112 
4.6 Conclusions ......................................................................................................... 117 
5 New Zealand community-acquired extended spectrum beta-lactamase-
producing Escherichia coli ST-131 in a global context .......................................... 119 
5.1 Abstract ............................................................................................................... 119 
xi 
 
5.2 Introduction ....................................................................................................... 120 
5.3 Materials and methods ........................................................................................ 121 
5.4 Results ................................................................................................................ 127 
5.5 Discussion .......................................................................................................... 139 
5.6 Conclusions ........................................................................................................ 143 
6 General discussion .............................................................................................. 145 
6.1 Overview ............................................................................................................ 145 
6.2 Antimicrobial resistance as a societal issue ........................................................ 147 
6.3 Antimicrobial resistance ecology ........................................................................ 149 
6.4 Antimicrobial resistance and plasmids ................................................................ 151 
6.5 Recommendations to reduce and manage the community burden of ESBL-
producing bacteria ..................................................................................................... 153 
6.6 Concluding remarks ........................................................................................... 154 
 
  
xii 
 
  
xiii 
 
Table of figures 
 
 
Figure 1.1 Acquisition of antimicrobial resistance in bacteria through mutation and 
horizontal transmission via bacteriophage, plasmid, and free DNA [adapted from Levy 
and Marshall (2004)] ....................................................................................................... 2 
Figure 3.1 Neighbour joining tree of the ribosomal MLST (51 genes) of 126 clinical E. coli 
isolates with MLST and Clermont phylogrouping. 51 ribosomal genes used to construct 
distance matrix from which the tree was constructed using the Neighbour Joining 
method. ......................................................................................................................... 77 
Figure 3.2 Neighbour joining tree of the whole genome MLST of 126 clinical E. coli 
isolates, from 2654 shared-loci alleles (reference genome LT8144a) ............................ 78 
Figure 3.3 Neighbour joining tree of cgMLST of five clinical Klebsiella pneumoniae 
isolates, from 4254 shared-loci alleles (reference genome LT8007a) ............................ 79 
Figure 4.1 Bacterial genome outputs workflow: selection of households and processing of 
isolates after sequencing ................................................................................................ 95 
Figure 4.2 Whole genome MLST of 125 E. coli isolates from 11 households; 3022 alleles 
used to construct distance matrix in Fast-GeP genome profiler (Zhang et al. 2018). .. 105 
Figure 4.3 Household Neighbour-Joining SNP trees for 125 ESBL- and/or ACBL-
producing E. coli isolates from 11 households (range 5-28 per household). Reference 
genomes for core SNP alignments given in Table 4.2 and full SNP distances for these 
figures are in Appendix VI. ........................................................................................... 110 
xiv 
 
Figure 4.4 Neighbour Joining tree of core SNP phylogeny of E. coli ST-131 isolates from 
four households. Core SNP alignment using 12,454 SNPs ........................................... 111 
Figure 5.1 Whole genome MLST Neighbour Joining tree from 236 E. coli isolates; 3011 
alleles [Genome profiler: Fast GeP (Zhang et al. 2018)]. ............................................. 132 
Figure 5.2 Pan-genome of 236 ST-131 E. coli isolates using 13713 genes; 3603 core genes, 
224 soft-core genes, 1534 shell genes, 8314 cloud genes. Neighbour-joining tree 
(unrooted) from whole genome MLST (Figure 5.1 and using 3011 alleles ), genome output 
from pan-genome presence-absence matrix [Roary version 8.0 (Page et al. 2015)] ...... 133 
Figure 5.3 NeighborNet trees of Snippy outputs from clades A, B and C combined (using 
the reference genome JJ1886) of 236 isolates of E. coli ST-131 [Snippy version 3.1 
(Seemann 2015)] .......................................................................................................... 134 
Figure 5.4 NeighbourNet trees of E. coli ST-131 clades A, B and C (using the reference 
genome JJ1886); 25 isolates in clade A, 10 isolates in clade B, 201 isolates in clade C. Scale 
is variable, and shown for each clade [Snippy version 3.1 (Seemann 2015)] ................. 135 
Figure 5.5 Neighbour Joining tree of core SNP alignment (as in Figure 5.4) of 236 isolates 
of E. coli ST-131 (using reference genome JJ1886) using 14949 SNPs. ........................ 136 
Figure 5.6 Evolutionary phylogeny for E. coli ST-131 ‘clade A’ isolates. SNP alignment 
with recombinant regions removed used to generate evolutionary trees [BEAST 2.0 
TreeAnnotater (Bouckaert et al. 2014); Gubbins was used to remove recombinant regions 
(Croucher et al. 2015)]. ................................................................................................ 138 
Figure 6.1 Algorithm for detection of phenotypic ESBLs. EUCAST guidelines, and 
AmpC interpretation from Halstead et al. (2012) ........................................................ 162 
Figure 6.2 Questionnaire dataset LASSO regression modelling (λmin = 0.0123) where 
ln(λ) dotted lined indicate λ min and λ min +1SE .............................................................. 224 
xv 
 
Table of tables 
 
 
Table 1.1 Overview of antimicrobials used to treat urinary tract infections (UTI) and key 
resistance mechanisms .................................................................................................... 4 
Table 1.2 Contemporaneous research in antimicrobial resistance (AMR) in 
Enterobacteriaceae isolated from companion animals ..................................................... 8 
Table 2.1 Beta-lactamase enzymes involved in antimicrobial resistance of 
Enterobacteriaceae [adapted from Rubin and Pitout (2014] .......................................... 21 
Table 2.2 A summary of results of selected reports of antimicrobial resistant 
Enterobacteriaceae from New Zealand .......................................................................... 23 
Table 3.1 Antimicrobial zone diameters used in Kirby-Bauer disk diffusion phenotypic 
assays (EUCAST 2018) ................................................................................................. 49 
Table 3.2 Summary of demographic and heath variables of 141 case and 525 control 
participants .................................................................................................................... 57 
Table 3.3 Summary of travel, home, hygiene and food related variables from 141 case and 
525 control participants ................................................................................................. 58 
Table 3.4 Summary of animal-related variables from 141 case and 525 control participants
 ....................................................................................................................................... 59 
Table 3.5 Odds ratios (OR) for risk factors for urinary tract infections caused by ESBL- 
or ACBL-producing Enterobacteriaceae in the community, based on questionnaire data 
from 141 case and 525 control participants .................................................................... 63 
Table 3.6 Descriptions and tests for the multivariate regression model in Table 3.5 .... 64 
xvi 
 
Table 3.7 Self-reporting vs government data (NHI) for systemic antimicrobial community 
prescriptions (n=99 cases) ............................................................................................. 65 
Table 3.8 Summary of characteristics of case-control subset where antimicrobial 
prescription history was known. Odds ratios (OR) are results of univariate and 
multivariate analysis. ..................................................................................................... 66 
Table 3.9 Descriptions and tests for multivariate regression model in Table 3.8 .......... 67 
Table 3.10 Population attributable fractions (AF) for binary outcomes [final model risk 
factor odds ratios (OR) recoded] from questionnaire data ............................................. 67 
Table 3.11 Population attributable fractions (AF) for binary outcomes [final model risk 
factor odds ratios (OR) recoded] from case-control subset where antimicrobial 
prescription data was known ......................................................................................... 68 
Table 3.12 LASSO/elastic net regression model outputs where coefficients for the logistic 
model were used to calculate odds ratios (OR) for risk factors at the minimum lambda 
(λmin) and at minimum lambda plus one standard error (λmin + 1SE) ............................. 69 
Table 3.13 Random forest regression of questionnaire dataset ...................................... 70 
Table 3.14 Fifteen MLST types of E. coli from community acquired urinary tract 
infections in New Zealand (2015-2017) ......................................................................... 73 
Table 3.15 Antimicrobial susceptibility test results from 126 clinical urinary E. coli isolates 
with an ESBL- and/or ACBL-producing phenotype from the NZ community (EUCAST 
2018) .............................................................................................................................. 75 
Table 4.1 Summary of reference genomes used for intra-household core SNP comparison 
of isolates [using Snippy 3.0 (Seemann 2015)] ............................................................... 98 
Table 4.2 Summary of sources of samples from fourteen households ......................... 100 
xvii 
 
Table 4.3 ESBL, ACBL and plasmid-mediated quinolone resistance (PMQR) genes from 
Enterobacteriaceae in 14 households ........................................................................... 103 
Table 4.4 A summary of multi-locus sequence type (MLST) and serotying (O- and H- 
antigen) of 125 E. coli isolates from 11 households ...................................................... 104 
Table 4.5 Antimicrobial resistance genes in 125 E. coli isolates from 11 households ... 106 
Table 4.6 Results of antimicrobial susceptibility testing of 125 E. coli isolates from 11 
households ................................................................................................................... 107 
Table 4.7 Virulence genes in 125 E. coli isolates from 11 households .......................... 108 
Table 5.1 Model parameters for BEAST phylogenetic models for 25 E coli ST-131 clade 
A isolates ..................................................................................................................... 127 
Table 5.2 Description of select metadata for 48 NZ community-acquired E. coli ST-131 
isolates ......................................................................................................................... 128 
Table 5.3 A description of five virulence genes in 236 E. coli ST-131 isolates ............. 130 
Table 6.1 Appendix III chapter 3 isolates ..................................................................... 166 
Table 6.2 Appendix III chapter 4 isolates .................................................................... 169 
Table 6.3 Appendix III chapter 5 isolates ..................................................................... 172 
Table 6.4 Chapter 4 household HH008 SNP distances for Figure 4.3 ........................ 226 
Table 6.5 Chapter 4 household HH0015 SNP distances for Figure 4.3 ....................... 226 
Table 6.6 Chapter 4 household HH0015 SNP distances for Figure 4.3 ....................... 227 
Table 6.7 Chapter 4 household HH0024 SNP distances for Figure 4.3 ...................... 228 
Table 6.8 Chapter 4 household HH0026 SNP distances for Figure 4.3 ...................... 228 
Table 6.9 Chapter 4 household HH0039 SNP distances for Figure 4.3 ....................... 229 
Table 6.10 Chapter 4 household HH0040 SNP distances for Figure 4.3 .................... 230 
Table 6.11 Chapter 4 household HH0048 SNP distances for Figure 4.3 ..................... 231 
xviii 
 
Table 6.12 Chapter 4 household HH0064 SNP distances for Figure 4.3 ..................... 231 
Table 6.13 Chapter 4 household HH0065 SNP distances for Figure 4.3 ..................... 232 
Table 6.14 Chapter 4 household HH0086 SNP distances for Figure 4.3 ..................... 232 
 
 
  
xix 
 
Abbreviations 
 
ACBL: AmpC beta-lactamase(s) 
ACBL-E: AmpC beta-lactamase-producing Enterobacteriaceae 
AIC: Akaike information criterion 
AmpC: Ampicillin hydrolysing beta-lactamase  
AMR: Antimicrobial resistant / antimicrobial resistance 
DANMAP: Danish Integrated AMR Monitoring and Research Program 
DNA: Deoxyribonucleic acid 
ESBL: Extended-spectrum beta-lactamase(s) 
ESBL-E: Extended-spectrum beta-lactamase -producing Enterobacteriaceae 
LASSO: Least absolute shrinkage and selection operator 
MALDI-TOF MS: Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry 
MDR: Multidrug resistant / multidrug resistance 
MELAA: Middle Eastern, Latin American, and African 
MLST: Multi-locus sequence type 
wgMLST: Whole genome multi-locus sequence type 
rMLST: Ribosomal multi-locus sequence type 
(P)AF: (Population) attributable fraction 
PCR: Polymerase chain reaction 
PFGE: Pulse-field gel electrophoresis 
ROC: Receiver operating characteristic 
SNP: Single nucleotide polymorphism 
ST: Sequence type 
UPEC: uropathogenic E. coli  
UTI: urinary tract infection 
WHO: World Health Organization 
xx 
 
  
1 
 
1 Introduction 
1.1 Overview 
The research presented in this thesis focusses on risks for bacterial infections caused by 
antimicrobial resistant Enterobacteriaceae in the New Zealand community. Some of these 
bacteria produce enzymes able to break down third and fourth generation cephalosporin 
antimicrobials, and these drugs are usually reserved for second-line treatment and 
considered critically important by the World Health Organisation (Anonymous 2014b; 
Weese et al. 2015). Community-acquired infections (i.e. those not acquired in healthcare) 
caused by multidrug resistant bacteria [e.g. extended-spectrum beta-lactamase (ESBL) 
producing Enterobacteriaceae] worldwide are a public health concern, and in New 
Zealand these are predominantly urinary tract infections (Heffernan et al. 2018). 
Therefore, assessment of risk factors not associated with healthcare is important to 
reducing spread of these bacteria. Companion animals in the home are one such exposure 
that could play a role in community transmission of these bacteria. 
The family pet plays a central role in the lives of many people. In New Zealand, over 60% 
of homes report having a companion animal, which is one of the highest rates in the world 
(Anonymous 2016a). Some antimicrobials used for treatment in pets are similar to those 
reserved for second-line therapies in people. For example, third generation 
cephalosporins (cefpodoxime and cefovecin) are available for use in companion animals 
and include a long-acting injectable formulation (Anonymous 2016b). Resistance to these 
antimicrobials has been reported to increase in tandem with their use in a population 
(Burow et al. 2014), and other studies have implicated pets in multidrug resistant bacterial 
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carriage or infection in people (Meyer et al. 2012; Johnson et al. 2016). Therefore, this is 
an area worth investigating further in this pet-loving country. 
1.2 An introduction to antimicrobial resistance 
Almost as soon as antimicrobials (i.e. antibiotics) were used to treat bacterial infections 
in people, instances of bacterial resistance to those antimicrobials were described 
(Abraham and Chain 1940; Barber 1947). Barber observed Staphylococcus resistance to 
penicillin from clinical samples in the mid-1940s, the same decade that penicillin became 
widely available (Barber 1947; Quinn 2013). Many therapeutic antimicrobials aimed at 
treating or preventing bacterial infection originated from antibacterial compounds 
produced by organisms such as Penicillium or Streptomyces to kill or inhibit bacterial 
growth. As such, antimicrobial resistance (AMR) developed in the absence of therapeutic 
antimicrobial use for millennia and has been observed in ancient soil samples and 
uninhabited parts of the world (D’Costa et al. 2011; Perron et al. 2015). Since the 1940s, 
AMR in bacterial pathogens has increased and this increase can be interpreted as a 
reflection upon the use of antimicrobials (MacFadden et al. 2018). 
 
Figure 1.1 Acquisition of antimicrobial resistance in bacteria through mutation and horizontal 
transmission via bacteriophage, plasmid, and free DNA [adapted from Levy and Marshall 
(2004)] 
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The acquisition of antimicrobial resistance in bacteria occurs through two main 
mechanisms: (1) mutation in bacterial chromosomal DNA, and (2) through horizontal 
gene transfer. A summary of these mechanisms can be found in Figure 1.1. Genetic 
mutations change the efficacy of an antimicrobial in various ways, for example, a mutation 
may change the target site for the antimicrobial. Selection pressure in favour of these 
mutations occurs when bacterial population become exposed to antimicrobials, such as 
gyrA/B mutations subsequent to ciprofloxacin exposure (Martinez and Baquero 2000). 
Horizontal transfer of antimicrobial resistant genes between bacteria (as shown in Figure 
1.1) can be through the incorporation of free DNA into a bacterial chromosome 
(transformation and recombination), bacteriophages (transduction and transposition), 
and plasmids (conjugation) (Alekshun and Levy 2007). The last of these, plasmids, are 
self-replicating units of DNA and may remain discrete in the bacterial cytoplasm or 
become incorporated into the chromosomal DNA through transposition and 
recombination (Alekshun and Levy 2007; Carattoli 2009). The rate of horizontal gene 
transmission can also be accelerated by external factors (such as exposure of bacteria to 
antimicrobials), and in these instances AMR plasmids may spread faster through 
populations and allow bacteria to survive future challenges (Beaber et al. 2004).  
In Table 1.1, AMR mechanisms for different types of antimicrobial treatment for urinary 
tract infections are outlined. Importantly, many of the antimicrobial resistance 
mechanisms outlined in Table 1.1 are mediated by plasmids, such as fluoroquinolone 
resistance (e.g. qnr), colistin resistance (e.g. mcr), resistance to third generation 
cephalosporins (blaESBL), and fosomycin resistance (e.g. fosA). 
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Table 1.1 Overview of antimicrobials used to treat urinary tract infections (UTI) and key 
resistance mechanisms 
Antimicrobial 
Group  
Examples for 
treatment of 
UTI 
Key bacterial resistance mechanism(s)  
in Enterobacteriaceae Reference 
Beta-lactams: 
-Penicillins 
 
Amoxicillin 
Ampicillin 
Mecillinam 
 
Target site mutation, drug modification 
(ACBL and ESBL enzymes, other beta-
lactamase enzymes) 
 
(Alekshun and Levy 2007)   
-Cephalosporins Cephalexin 
Cefaclor 
Cefuroxime  
Drug modification (ESBL enzymes) (Iredell et al. 2016) 
 
 Cefpodoxime Drug modification (ESBL enzymes) 
-Cephamycins Cefoxitin Drug modification (ACBL enzymes) 
-Carbapenems Meropenem 
Impipenem 
Ertapenem 
Drug modification (Carbapenemases) 
    
Fluoroquinolones Ciprofloxacin 
Norfloxacin 
Target site mutation, efflux pumps, 
gyrase protection, drug acetylation  
(Jacoby et al. 2014)  
    
Aminoglycosides Gentamicin 
Amikacin 
Target site mutation, efflux pumps, 
reduced uptake, drug deactivation 
(Garneau-Tsodikova and 
Labby 2016)  
    
Polymixins Colistin Reduced drug affinity for outer membrane (MacNair et al. 2018) 
    
Others Fosfomycin Target site mutation, decreased transport, 
drug modification (FosA enzyme) 
(Ito et al. 2017) 
     
Nitrofurantoin Target site mutation, efflux pumps (Sekyere 2018) 
     
Trimethoprim  
(+/- 
Sulphonamide) 
Resistant target site (Sköld 2001) 
    
ACBL – AmpC beta-lactamase; ESBL – Extended spectrum beta-lactamase  
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The specific antimicrobial resistance mechanisms which are the focus of this thesis are 
enzymes that act by hydrolysing the beta-lactam ring, similar to the beta-lactamases 
described by Abraham and Chain (1940). Cephalosporins are a broad-spectrum 
antimicrobial class used to treat many types of infection in both humans and animals. 
They also share molecular heritage with penicillin as they too contain a beta-lactam ring. 
The enzymes that inactivate third and fourth generation cephalosporins are termed 
extended-spectrum beta-lactamase (ESBL) enzymes. Bacterial transmission and 
propagation of ESBL enzymes [along with other similar resistance enzymes such as 
AmpC beta-lactamase (ACBL) type enzymes] have been facilitated by horizontal gene 
transmission via plasmids (Carattoli 2009). The role these ESBL- and/or ACBL-
producing Enterobacteriaceae play in human and animal health will be further discussed 
in Chapter 2 and 3.  
1.3 Why is antimicrobial resistance important? 
Antimicrobials revolutionized medicine in the 20th century, and allowed medical 
research to focus on non-infectious diseases (Quinn 2013). The importance of these 
advances to the quality and quantity of human life that resulted from the discovery of 
antimicrobials cannot be overstated. The corollary of this means that bacterial infection 
once again becomes a serious threat when antimicrobials no longer work. In the 2016 
O’Neill report, a review on global AMR, it was estimated that the human cost of AMR 
would be 10 million lives per year by 2050, just over a century after antimicrobials came 
into general use (Anonymous 2016c). This death rate is attributable to both AMR in 
pathogenic bacteria, as well as the increased risk of routine procedures. It is therefore 
important to try to slow or reverse AMR in bacteria through changing use (and therefore 
selection pressure) or create a new paradigm of infectious disease prevention or 
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treatment. Part of this process is through understanding the role that different elements 
play in the propagation of AMR, hence the research question central to this dissertation: 
is the family pet a risk for multidrug resistant infections? 
Since the early 2000’s, ESBL enzymes have become increasingly associated with 
pathogenic bacteria such as extra-intestinal pathogenic E. coli (Carattoli 2009; Nicolas-
Chanoine et al. 2014). In a 2001 review, it was estimated that 3% of Enterobacteriaceae 
causing clinical disease in the USA were resistant to third generation cephalosporins 
(Bradford 2001). A decade later, the Centres for Disease Control reported this to be 14% 
for E. coli, and 23% for Klebsiella spp. cultured from clinical infections (Anonymous 
2013b). Carriage of ESBL-producing Enterobacteriaceae in the gastrointestinal tract of 
human populations has been reported at over 50% in some countries (Woerther et al. 
2013). An increase in both treatment failure and cost will be inevitable if the trend towards 
increasing colonisation (and therefore increasing infection) of people with ESBL-
producing bacteria continues (Smith and Coast 2013; Anonymous 2016c). 
1.4 Antimicrobial resistance and animals 
Overall, food-producing animals have been the primary focus of work done in AMR in 
animals (Chatterjee et al. 2018). Pig farmers who manage herds where ESBL-producing 
Enterobacteriaceae or methicillin resistant Staphylococcus aureus were detected are more 
likely to be carriers of these strains (Schmithausen et al. 2015; Nüesch-Inderbinen and 
Stephan 2016). Poultry workers have also been found to carry the multidrug resistant 
bacterial strains present in their flocks (Dorado-García et al. 2017). Likewise, when 
attributing relative risks of sources of AMR bacteria, production animals have been the 
focus of much research. Cattle in the United States have been found to carry blaESBL gene-
containing E. coli (predominantly ST-10 and related STs), with ESBL genes similar to 
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those predominant in human samples (i.e. blaCTX-M-15/14/27) (Afema et al. 2018). No such 
comparable study has been published from food animals in New Zealand.  
Bacteria associated with human disease, and harbouring ACBL and/or ESBL resistance 
genes, continue to be cultured from companion animals around the world (Table 1.2). In 
the studies from Japan and Switzerland described in Table 1.2, ESBL-producing E. coli 
isolates from companion animals were human associated strains (e.g. STs 131, 38, 12, 410, 
or 1193). The use of antimicrobials (especially those usually reserved for second- or third-
line treatment) in companion animals is something that should be carefully considered, 
as pets have been consistently found to carry bacteria associated with disease both in 
humans and in animals (Pomba et al. 2017). Increasing selection pressure in disease 
causing bacteria [e.g. uropathogenic E. coli (UPEC)] is undesirable from both human and 
animal perspectives. It should also be noted that companion animals have been found to 
share ESBL-producing E. coli with their human owners (Johnson et al. 2009; Johnson et 
al. 2016), and this will be explored in a New Zealand context further in Chapter 4. 
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Table 1.2 Contemporaneous research in antimicrobial resistance (AMR) in Enterobacteriaceae 
isolated from companion animals 
Bacterial 
species 
ESBL/AmpC 
enzyme type 
Most 
common 
MLST type(s) 
Country Prevalence/presence Reference 
UPEC  
(E. coli) 
CTX-M-15 
(49% of 
ESBL-
producers),  
CTX-M-
1/55/14/27 
also reported 
ST-410 (then 
ST-131, ST-
73, ST361) 
Switzerland ESBL-producing UTI 
from cats and dogs 
(Zogg et al. 2018) 
E. coli CTX-M-27 
(19% of 
ESBL/ACBL 
producers), 
CMY-2 (19% 
of 
ESBL/ACBL 
producers), 
CTX-M-
15/14/55 also 
reported 
ST-131 (then 
ST-1193, ST-
38, ST-12, 
ST-372) 
Japan Clinical samples from 
cats and dogs 
(Maeyama et al. 
2018) 
Klebsiella 
pneumoniae 
CTX-M-15 
(40% of 
ESBL-
producers), 
CTX-M-2, 
CTX-M-14 
ST-15 (then 
ST-655, ST-
11, ST-147, 
ST-307, 
ST709) 
Japan Clinical samples from 
cats and dogs 
(Maeyama et al. 
2018) 
E. coli CTX-M group 
1 type most 
common, 
CTX-M group 
9 type and 
group 2 also 
detected 
Not reported United 
Kingdom 
Faecal carriage of 
AMR E. coli in dogs 
pre- and post- 
antimicrobial 
treatment 
(Schmidt et al. 
2018) 
ACBL – AmpC beta-lactamase; ESBL – Extended spectrum beta-lactamase; UPEC - 
uropathogenic E. coli; UTI – urinary tract infection 
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1.5 Antimicrobial use and resistance 
As already alluded to in this chapter, there are many interconnected exposures and 
drivers to increase bacterial resistance to antimicrobials. At a basic level, exposure of 
bacteria to antimicrobials is a key driver; however, the environment and interactions 
surrounding this exposure can be complex (Holmes et al. 2016). Even in cases where 
antimicrobial use may play a role in the emergence of bacterial resistance, fitness of the 
bacteria is not necessarily compromised and there may be antimicrobial-independent 
reasons for spread of an AMR-containing bacteria (Baker et al. 2013). 
Therapeutic antimicrobial use is a major driver of resistance in bacteria in human and 
animal populations, especially in pathogenic bacteria in those populations. Specific 
examples of this are seen when looking at surveillance data from both AMR and 
antimicrobial use in respective human and animal populations (Williamson et al. 2013; 
Andersen et al. 2015). Antimicrobial use in animals does not commonly spill over into 
AMR in disease causing bacteria in humans, however examples of this have occurred 
(Anonymous 2015). For example, the increase in vancomycin resistant Enterococcus in 
people has been widely attributed to the use of avoparcin as a growth promoter in food 
animals (Smith et al. 2002). Other instances of this include the recent emergence of 
colistin-resistant E. coli in extra-intestinal infections in people, subsequent to years of 
prophylactic polymyxin use in food animals (Liu et al. 2016). On the other hand, 
community use of antimicrobials in humans is a predictor for prevalence of bacteria AMR 
in a country (MacFadden et al. 2018). Although large scale studies in New Zealand have 
not examined the relationship between use of antimicrobials and resistance in E. coli, 
community-use of antimicrobials in New Zealand has been estimated to be more than 70% 
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of OECD countries, so this should be considered a putative risk for AMR here (Thomas 
et al. 2014; Williamson et al. 2016).  
1.6 The role of genomics in understanding antimicrobial resistance  
Molecular tools, whether specific genes or the whole of the bacterial DNA is used, are an 
important part of the science around AMR (McArthur and Wright 2015), and these are 
utilised throughout the analytic chapters in this thesis. New sequencing technologies have 
become part of clinical microbiologic workup as well as having utility in outbreaks and 
epidemiologic research (Bertelli and Greub 2013). Resistance gene characterisation using 
sequenced reads (or assembled genomes) can be done through extensive databases such 
as the Comprehensive Antibiotic Resistance Database (CARD) or ResFinder (Zankari et 
al. 2012; Jia et al. 2017).  
Whole genome sequencing has also changed source attribution research, where 
nucleotide-level differences between isolates can highlight differences in bacteria that 
would not be evident otherwise. For example, identification of poultry associated E. coli 
ST-131 cultured from human UTI would not be discernible if only examining seven genes 
as in MLST (Liu et al. 2018). This is in contrast to low-resolution methods such as 
multiplex PCR, where only (pre-determined) primers matching genes will be detected in 
tested samples (Pérez-Pérez and Hanson 2002; Cattoir et al. 2007). Although they are 
not explored in the work presented in this thesis, PCR-based methods are still used for 
screening for known epidemic types of ESBL genes. For example, where an important 
characteristic is known (i.e. specific blaESBL genes from cattle isolates), it may be useful to 
select only isolates with that trait (Afema et al. 2018). There will continue to be many 
instances where this continues to be true in the broader field of molecular epidemiology.  
11 
 
When using outputs of high throughput platforms (such as Illumina HiSeq) careful 
quality control needs to be done to ensure the best inferences are made, and genomes will 
never be as reliably accurate as those from platforms where both sequence and structure 
of the genome are considered (Minoche et al. 2011; Caporaso et al. 2012; Bertelli and 
Greub 2013). Tools like bioinformatics pipelines have been developed to facilitate analysis 
subsequent to the recent boom in the accessibility of whole genome sequencing of 
bacteria. A bioinformatics pipeline is a standardised sequential way of taking raw genetic 
data and making it useful, usually by passing that data through a number of different tools 
in a stepwise manner. This involves processing inputs (e.g. raw sequenced reads) and 
returning assembled genomes; these genomes may also have genes annotated [e.g. using 
Prokka (Seemann 2014)] or identified by some other method like ResFinder and 
VirulenceFinder (Thomsen et al. 2016). The outputs of these pipelines may be used for 
further analyses. A nucleotide-based analysis is also useful, and may be incorporated into 
a bioinformatics pipeline, as it is when using Nullarbor (Seemann 2015; Seemann et al. 
2016). Single nucleotide polymorphisms (SNP) are variations in the genomic sequence 
between an isolate (i.e. sequenced reads) and a reference genome (i.e. assembled and 
annotated), as used by Snippy (Seemann 2015). The abundance and variation of these 
tools is a reflection on the need to process the outputs of sequencing now commonplace 
in many studies (Levy and Myers 2016).  
Inferences of transmission events between individuals may be inferred from SNP 
distances (Harris et al. 2010), or based upon gene similarity (Zhang et al. 2018), or both 
methods (Weterings et al. 2017). This approach appears to be generally supported, 
although within-host diversity and the effect of the transfer of heterogeneous bacteria in 
a transmission event means that this is often more complicated than early work suggested 
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(Worby et al. 2014). With this caveat, both SNP-based and gene-based tools are useful, 
however directionality and likely transmission pathways should be estimated with 
caution. 
1.7 Thesis objectives  
The research objectives of this thesis (outlined below) all aim at better understanding 
community-acquired ESBL-/ACBL-producing infections in New Zealand. While there 
has been research into this area from a surveillance perspective, this is still relatively 
unexplored in the New Zealand context (Heffernan et al. 2013; Rogers et al. 2014; 
Heffernan et al. 2018). The other unique part of this research stems from the central 
research question around the risks of companion animal contact. As previously 
mentioned in this introduction, there are many instances of human-associated strains of 
ESBL-producing E. coli cultured from both clinical and non-clinical samples from 
companion animals (Table 1.2). Other observational studies have looked at companion 
animal exposure as a risk for carriage or infection with ESBL-producing bacteria, however 
to my knowledge this is the first study to focus on these exposures (Rogers et al. 2014; 
Leonard et al. 2018). The genesis of this research was a grant awarded by the Health 
Research Council of New Zealand in 2014, to fund the question that also lends its name 
to the title of this thesis “is the family pet a risk for multidrug resistant infections in 
people?”  
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As part of understanding the bacteria cultured in this research, modern molecular 
techniques were used to describe and analyse the bacterial causes of these infections. The 
results presented in this thesis are the first (to the best of my knowledge) where the 
molecular relatedness of community-acquired ESBL-/ACBL- Enterobacteriaceae from 
the New Zealand community are presented in this way. 
1.7.1 Research aims: 
1. To identify knowledge gaps in AMR in Enterobacteriaceae in both New Zealand’s 
human and animal populations (Chapter 2); 
2. To describe the bacterial causes of human community-acquired ESBL- and 
ACBL-producing urinary tract infections in both the New Zealand and global 
contexts (Chapter 3, Chapter 5); 
3. To assess risk factors for community-acquired ESBL- and ACBL-producing 
urinary tract infections in New Zealand, with particular reference to pet-related 
risks (Chapter 3); 
4. To explore transmission of  ESBL- and ACBL-producing E. coli in New Zealand 
households (Chapter 4) 
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1.8 Thesis structure 
Chapter 2, an invited literature review, is aimed at giving the reader an overview of AMR 
in New Zealand with a particular focus on Enterobacteriaceae such as Escherichia coli and 
Klebsiella pneumoniae. This review was published in the New Zealand Veterinary Journal 
in 2017, and as presented here remains largely unchanged from that published form. Parts 
of the introduction given in Chapter 1 are aimed to provide contemporaneous global 
updates on the literature provided in Chapter 2. In Chapter 3, the prospective case 
control study that forms the backbone of this thesis is presented. Chapter 4, a cross-
sectional study that was nested in the case control study, examines the potential 
transmission of AMR E. coli between members of several households. The final analytic 
chapter is Chapter 5, this chapter describes a group of E. coli isolates (ST-131) collected 
both globally and as part of Chapter 3. As indicated, Chapters 2 to 5 are presented in 
publication style, with their own introductions and discussions. Inevitably, there will be 
some overlap of concepts as these chapters are intended to be understood as stand-alone 
pieces of work. The final part of this dissertation is a general discussion of the themes 
presented in the thesis as a whole. 
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2 Multidrug resistant Enterobacteriaceae in New 
Zealand: a current perspective 
Published as: 
Toombs-Ruane, L. J., Benschop, J., Burgess, S., Priest, P., Murdoch, D. R., & French, N. 
P. (2017). Multidrug resistant Enterobacteriaceae in New Zealand: a current perspective. 
New Zealand Veterinary Journal, 65(2), 62-70. doi:10.1080/00480169.2016.1269621 
2.1 Introduction 
A medical revolution occurred over the last century with the discovery of antimicrobials. 
However, bacterial resistance to antimicrobials was evident shortly after each discovery, 
leading to newer and broader spectrum antimicrobials such as potentiated 
sulphonamides, cephalosporins and fluoroquinolones (Levy and Marshall 2004). 
Bacterial resistance, especially to commonly used antimicrobials, limits treatment 
options, which may prolong the severity or length of disease (Weese et al. 2015). In 
addition, resistance to some antimicrobials, defined as critically important by the World 
Health Organisation (WHO), is concerning in both human and veterinary medicine 
because these antimicrobials are often last-line therapies and are important in increasing 
bacterial resistance (Weese et al. 2015). Understanding of the mechanisms of bacterial 
resistance has improved over the last two decades, and molecular investigation of specific 
mechanisms of resistance has emerged as the predominant tool in understanding 
antimicrobial resistance (AMR) (Prescott 2014).  
Enterobacteriaceae, the group of gram-negative bacteria that include Escherichia coli and 
Klebsiella pneumoniae, are omnipresent and form part of the normal flora of the 
mammalian gastrointestinal tract, and are transmitted between humans and animals 
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(Ewers et al. 2012; Liebana et al. 2013). Human and animal gastrointestinal tracts have 
been identified as prime potential locations for horizontal gene transfer, including the 
transfer of resistance genes to other pathogens (Broaders et al. 2013; Holmes et al. 2016). 
Most strains of E. coli and K. pneumoniae are able to be carried as commensal organisms 
and they have the potential to become opportunistic pathogens. In humans, both these 
species can also be a cause of urinary tract infections, septicaemia, and pneumonia (Iredell 
et al. 2016). It is the development of multidrug resistance in pathogenic strains of 
Enterobacteriaceae that is of particular concern with respect to human health 
(Anonymous 2014b). Infections caused by these strains are often harder to treat, resulting 
in increased severity and duration of infection (Iredell et al. 2016). Globally, some strains 
of Enterobacteriaceae, which produce extended spectrum beta-lactamases (ESBL), are 
recognised as playing a substantial role in the treatment failure of many infections in 
people, including infections of the bloodstream, urogenital tract and abdomen 
(Anonymous 2014a). In addition to ESBL-production, these strains are often associated 
with other mechanisms of resistance, causing them to be multidrug resistant (MDR). In 
New Zealand, the incidence rate of infections in humans associated with 
Enterobacteriaceae producing ESBL in 2014 was 95.5 per 100,000 people with 
176/359(49%) infections being community related (Dyet et al. 2014). From 2006 to 2009 
there was a four-fold increase in human infections caused by ESBL-producing bacteria 
(Dyet et al. 2014). The animal burden of MDR bacterial disease, particularly that caused 
by ESBL-producing bacteria, is likely to be much less. However, there is insufficient 
research in New Zealand to accurately assess that burden; although we know that ESBL-
producing Enterobacteriaceae have been isolated from some clinical infections in 
companion animals (Karkaba et al. 2017b). 
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This review will focus on the mechanisms and potential transmission pathways of 
multidrug resistance in Enterobacteriaceae, with an emphasis on ESBL production. We 
aim to illustrate some of the broader challenges associated with AMR, including how the 
development of AMR in animals, humans and the environment is interlinked. Due to the 
interconnectedness of the health of animals, humans and the environment, we propose a 
One-Health approach for controlling AMR with emphasis on antimicrobial stewardship, 
in addition to the continued surveillance and study of transmission dynamics. 
2.2 Antimicrobial resistance mechanisms 
The development of AMR can occur via two processes: mutations in certain genes or by 
the horizontal transfer of genes encoding resistant mechanisms. These resistant genes are 
often found on genetic mobile elements or on plasmids, which by their nature are able to 
be transferred between bacteria without being the result of cell division, i.e. they can be 
horizontally transmitted between bacteria (Broaders et al. 2013). They can therefore 
contribute to the spread of AMR between bacterial species as well as to other members of 
the same species (Mathers et al. 2015). The control of plasmid-mediated AMR is 
therefore of particular importance in the effort to reduce the prevalence of AMR and the 
emergence of new, resistant strains. 
Antimicrobial resistance in the Enterobacteriaceae family includes resistance to three 
important classes of antimicrobials: beta-lactams, aminoglycosides and fluoroquinolones. 
Resistance to the beta-lactam class of antimicrobials, e.g. penicillins and cephalosporins, 
is mainly driven by the production of beta-lactamase enzymes, which hydrolyse the beta-
lactam ring, rendering the antimicrobial ineffective (Pitout and Laupland 2008). The 
main focus of this review is on the production of ESBL. However, bacteria that produce 
ESBL enzymes are often resistant to other classes of antimicrobials, making them MDR 
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(Mathers et al. 2015); some of these other mechanisms of resistance will also be described 
and are summarised in Table 2.1. 
2.2.1 Extended-spectrum beta-lactamases 
The ESBL produced by Enterobacteriaceae are generally defined as those beta-
lactamases which confer resistance to third generation cephalosporins, thus resulting in a 
wider resistance range compared with the penicillinases (the first group of beta-lactamase 
enzymes to be described), but these bacteria have no carbapenemase activity (Livermore 
2008). There are different types of ESBL, for example TEM, SHV, CTX, which are 
based on the DNA sequence of the gene encoding for these enzymes. The enzyme types 
are further classified into variants, e.g. CTX-M-15. 
The ESBL-coding genes are generally found on plasmids and they emerged from two 
different evolutionary pathways. The first ESBL types to be described evolved from the 
mutations in the parent TEM and SHV variants resulting in new TEM and SHV enzymes 
with a broader resistance spectrum (Pitout and Laupland 2008). More recently, the CTX-
M type emerged as a result of horizontal gene transfer, most probably from the 
chromosome of Kluyvera species to become plasmid-borne (Poirel et al. 2002; Rodríguez 
et al. 2004). The CTX-M type, especially CTX-M-15, is now the dominant ESBL type 
globally and has spread rapidly by plasmids in E. coli (Woerther et al. 2013). 
2.2.2 AmpC beta-lactamases 
Genes encoding for ampicillin hydrolysing beta-lactamase (AmpC) enzymes can be found 
on both the bacterial chromosome and on plasmids. In E. coli and Klebsiella species the 
genes for AmpC enzymes are generally plasmid encoded and their acquisition is a more 
recent event compared with the chromosomally encoded AmpC in other members of the 
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Enterobacteriaceae family such as Enterobacter, Citrobacter and Serratia species (Carattoli 
2009). AmpC production is of clinical importance as a mutant-type may develop in-vivo 
that produces substantially more AmpC compared with the wild-type (Jacoby 2009). 
AmpC producers (like ESBL-producers) are often also resistant to other classes of 
antimicrobials (Carattoli 2009; Hasman et al. 2015); both of these mechanisms can result 
in an infection that can be more difficult to treat. Chromosomally encoded AmpC are 
induced by some beta-lactam antimicrobials, including the beta-lactamase inhibitor 
clavulanic acid. As a result, AmpC-producers are not inhibited by clavulanic acid. 
Susceptibility to clavulanic acid is often used for the identification of an ESBL-producing 
isolate; therefore, the presence of an inducible AmpC encoding gene can mask the ability 
to detect whether a strain is also an ESBL-producer in a diagnostic laboratory (Paterson 
and Bonomo 2005). It is important to differentiate ESBL and AmpC-producers from both 
an epidemiological perspective, i.e. for determining the origin of the strain and its 
antimicrobial resistant genes, as well as from a clinical perspective (Drinkovic et al. 2015). 
2.2.3 Carbapenemases 
Carbapenem antimicrobials (e.g. imipenem) have classically been reserved as the beta-
lactam therapy of last resort, and resistance by Enterobacteriaceae to these drugs is a 
substantial public health concern (Heffernan et al. 2014; Mathers et al. 2015). 
Carbapenemase-producing Enterobacteriaceae can be grouped into three categories: the 
serine carbapenemases (e.g. the KPC type from K. pneumoniae), the metallo-beta-
lactamases, and the OXA type carbapenemases. Of clinical concern are those 
carbapenemase-producing Enterobacteriaceae that have a minimum inhibitory 
concentration above the resistance breakpoint, referred to as the carbapenem resistant 
Enterobacteriaceae. The most recent example of a new carbapenemase sub-type is the 
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NDM-1 metallo-beta-lactamase, which emerged in 2009 in New Delhi, India (Martirosov 
and Lodise 2015). 
2.2.4 Other mechanisms of resistance 
An emergent form of resistance in Enterobacteriaceae is plasmid-mediated colistin 
resistance (mcr-1), which was first described in 2015 (Liu et al. 2016). Colistin is a 
polymyxin and until the identification of this plasmid, polymyxin resistance was only 
associated with chromosomal mutations (Liu et al. 2016). Plasmid-mediated colistin 
resistance was first described in China as a result of surveillance reports showing an 
increase in colistin resistance in food producing animals, particularly pigs (Liu et al. 2016). 
Plasmid-mediated colistin resistance has now been found in other Asian countries 
(Kawanishi et al. 2017), Europe (Hasman et al. 2015), Northern America (McGann et al. 
2016), Southern America (Fernandes et al. 2016), and Africa (Poirel et al. 2016). To my 
knowledge, mcr-1 has not been identified in New Zealand. The spread of colistin 
resistance is of clinical concern as, like carbapenem, colistin is an antimicrobial of last 
resort and used for the treatment of carbapenem resistant Enterobacterial infections.  
Fluoroquinolone resistance was reported in >50% of clinical isolates of E. coli in one study 
in the United States of America (Rattanaumpawan et al. 2015). In New Zealand, the 
prevalence appears to be lower, with approximately 10% of clinical human isolates being 
reported to be resistant to fluoroquinolones in 2014 (Anonymous 2014a). 
Fluoroquinolone antimicrobials target the enzymes DNA gyrase and topoisomerase IV. 
Initially fluoroquinolone resistance was associated with mutations in the genes encoding 
these enzymes. Subsequently plasmid-mediated resistance also developed, with the 
emergence of a plasmid encoding a gene for QnrA; this protein prevents fluoroquinolones 
from binding to DNA gyrase (Jacoby 2005). 
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Table 2.1 Beta-lactamase enzymes involved in antimicrobial resistance of Enterobacteriaceae [adapted from Rubin and Pitout (2014] 
Enzyme Enzyme type Antimicrobial resistance spectrum Inhibitors 
Extended spectrum 
beta-lactamase 
 
CTX-M, TEM (other than parent type TEM–1, 2, and 13), 
SHV (other than parent type SHV-1) 
Penicillins, cephalosporins, monobactams Clavulanic acid, tazobactam, 
sulbactam, avibactam 
Penicillinase 
 
 
TEM-1,2, 13, SHV-1 Penicillins and first generation 
cephalosporins 
As above, predominantly 
clavulanic acid, sulbactam 
AmpC beta-lactamase 
 
 
AmpC, CMY-2 Penicillins, cephalosporins, monobactams, 
cephamycins 
Avibactam, Boronic acids 
Carbapenemase 
 
 
 
Serine carbapenemase (KPC, GES, SME1) Carbapenems, penicillins, cephalosporins, 
aztreonam 
Taxobactram boronic acids, 
avibactam, clavulanic acid 
(minor inhibition) 
 
 
 
 
Metallo-carbapenemase (IMP, NDM, VIM, IND) All beta-lactams except aztreonam Metal chelators e.g. EDTA, 
mercaptopurine, dipicolinic 
acid, 
  OXA Carbapenems, penicillins, cephalosporins, 
aztreonam 
Avibactam, NaCl 
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2.3 Occurrence and prevalence of ESBL enzymes 
The prevalence of human faecal carriage of Enterobacteriaceae that are MDR varies 
globally, as shown by a meta-analysis of 66 studies that included results from 28, 909 
people in total; prevalence in the Americas was 2 (95% CI=2–5%), in Europe was 4 (95% 
CI=2–5)%, and in the Western Pacific was 46 (95% CI=29–6)% (Karanika et al. 2016). It 
should be noted that while New Zealand falls into the Western Pacific region, no 
prevalence studies from New Zealand or Australia were included in the meta-analysis.  
At this time and to my knowledge, there have been no published prevalence studies on 
ESBL carriage in healthy communities of human or animal populations in New Zealand. 
A summary of reports of AMR in Enterobacteriaceae from various New Zealand sources 
is shown in Table 2.2. Amongst isolates obtained from human clinical urine samples in 
2006, ESBL-producing Enterobacteriaceae, were found in 86/9,453 (0.9%), compared 
with 2/1760 (0.1%) isolates in 2000 (Heffernan et al. 2009). Infections caused by 
transmissible AmpC-producing bacteria have also been reported from human urine 
samples (Drinkovic et al. 2015) and in isolates from infection sites in companion animals 
(Karkaba et al. 2017b). Carbapenemase-producing bacterial infections have also reported 
from humans in this country (Heffernan et al. 2014). Isolates of E. coli and Salmonella 
enterica, cultured from New Zealand food sources in 2009–2010, showed low-to-no 
phenotypic resistance to antimicrobials associated with ESBL and AmpC-production 
(Heffernan et al. 2011). The presence and prevalence of resistance genes (notably ESBL) 
in bacteria from New Zealand pre-slaughter ruminant food animals have not yet been 
described. 
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Table 2.2 A summary of results of selected reports of antimicrobial resistant Enterobacteriaceae from New Zealand 
Resistance Bacterial species  Resistance quantification Host species/ 
source 
Type of sample Year(s) Reference 
Ampicillin 
resistance 
  
E. coli 9/296 (3%) isolates Pigs Prevalence study 2001 (Nulsen et al. 2008) 
ESBL-production 
 
E. coli 57/8,707 (0.7%) isolates Human  Clinical (urine) 2006 (Heffernan et al. 2009) 
ESBL-production 
 
K. pneumoniae 31/746 (4.2%) isolates Human  Clinical (urine) 2006 (Heffernan et al. 2009) 
ESBL-production 
 
 
E. coli 0/407 isolates Poultry  Surveillance 
(post-slaughter) 
2006 (Pleydell et al. 2010) 
Cefoxitin resistance 
 
 
E. coli 9/999 (1%; min 0.3, max 2.2%) 
isolates  
Pig, poultry, calves, 
produce 
Surveillance (food 
products) 
2009–2010 (Heffernan et al. 2011) 
Carbapenem-
resistance 
 
Enterobacteriaceae 35 isolates Human Clinical (multiple) 2009–2014 (Heffernan et al. 2014) 
Plasmid-mediated 
AmpC-production 
 
E. coli 101/26,007 (0.4%) isolates Human Clinical (urine) 2011 (Drinkovic et al. 2015) 
Cephalothin 
resistance 
  
E. coli 467/1,107 (42%) isolates Dogs, cats Clinical (urine) 2005–2012 (McMeekin et al. 2017) 
Ceftiofur resistance 
  
E. coli 13/24 (54%) isolates Horses Clinical  2004–2014 (Toombs-Ruane et al. 2015) 
ESBL and/or 
AmpC-production 
Enterobacteriaceae 
resistant to 
amoxicillin-
clavulanic acid 
58/95 (61%) isolates Companion Animals Clinical (multiple) 2012–2013 (Karkaba et al. 2017b) 
AmpC=AmpC beta-lactamase; ESBL=extended-spectrum beta-lactamase
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When ESBL-producing Enterobacteriaceae were typed using PCR-based genotyping, two 
types predominated in human urine samples collected in 2006. In ESBL-producing E. coli 
and K. pneumoniae the most prevalent type was CTX-M-15 (63/83 (78%) isolates), 
followed by CTX-M-14 (11/83 (14%) isolates (Heffernan et al. 2009). A subsequent study 
in 2013, found 342/352 (97%) human ESBL isolates were CTX-M types (Heffernan et al. 
2013). Enterobacteriaceae are also described by multilocus sequence type (ST), and in 
the 2013 national survey, 122/224 (54.5%) ESBL-producing E. coli isolates were ST-131 
(Heffernan et al. 2013); this sequence type is internationally associated with ESBL-
producing E. coli (Mathers et al. 2015). In ESBL and AmpC-producing 
Enterobacteriaceae from clinical animal samples from New Zealand, 6/89 E. coli isolates 
were ST-131 (Karkaba et al. 2017b). 
2.4 Reservoirs and transmission pathways 
2.4.1 Environmental transfer 
The natural environment has been identified as a potential reservoir of AMR bacteria, 
including ESBL and AmpC-producing strains (Huijbers et al. 2015). To my knowledge, 
there are no studies on the prevalence of MDR Enterobacteriaceae strains from different 
New Zealand environments. ESBL-producing Enterobacteriaceae have been detected in 
a range of environmental samples elsewhere, including from soil, rivers and lakes in 
Tunisia (Ben Said et al. 2016); from coastal waters in Croatia (Maravić et al. 2015); from 
Banani lake in Bangladesh (Haque et al. 2014); and from wild birds in Canada (Parker et 
al. 2016). All of these are potential sources of transmission to humans (Huijbers et al. 
2015). The presence of AMR bacteria in the natural environment can be the result of 
transfer from human and animal sources, or they may be intrinsically present (Allen et al. 
2010).  
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One of the most important routes for the transfer of ESBL-producing Enterobacteriaceae 
into the natural environment from human sources is through the discharge of waste water, 
particularly into waterways (Huijbers et al. 2015). Overseas, ESBL-producing 
Enterobacteriaceae have been isolated from hospital wastewater, treated sewage and 
storm water. Studies carried out in a number of countries [e.g. Tunisia (Ben Said et al. 
2016), Poland (Korzeniewska and Harnisz 2013) and Brazil (Conte et al. 2017)] show that 
the prevalence of ESBL-producing Enterobacteriaceae in wastewater varies, but as a 
result of different methods being used it is difficult to compare between studies. However, 
there is general agreement that routine waste-water treatment processes do not 
effectively remove ESBL-producing Enterobacteriaceae; for example, in a study carried 
out in Brazil it was found that both antimicrobial residues and AMR bacteria were 
persisting after treatment (Conte et al. 2017). In New Zealand, treated sewage is generally 
discharged into a nearby waterway. Although, counts of E. coli are required to be below a 
specified level in compliance with regional council consenting processes, it is unlikely that 
current New Zealand sewage treatment practices remove all AMR bacteria (Yuan et al. 
2015; Hocquet et al. 2016). 
Animal sources may also play an important role in the transfer of AMR to the natural 
environment. For example, from manure application onto soil and produce, farm run-off 
into waterways and milk containing antimicrobials. AMR may develop in the microbial 
community in the environment as a result of antimicrobials still present in these animal 
sources or from the transfer of AMR bacteria and their genes (Huijbers et al. 2015).  
Thus, the environment has been identified as an important reservoir of AMR but there is 
still little known about the role the environment plays in the transmission of AMR genes 
found in the environment to animals and humans (Allen et al. 2010). The natural 
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environment can contain AMR genes with seemingly little or no selection pressure from 
anthropogenic sources (Segawa et al. 2013). For example, AMR bacteria including 
Enterobacteriaceae-producing ESBL have been isolated from seemingly untouched 
environments such as in soil from the Arctic Fjords (Hatha et al. 2015). This is not 
surprising given most antimicrobials are produced innately by bacteria and fungi that 
reside in the natural environment. Many of the AMR genes identified from natural 
environmental sources remain largely uncharacterised and could potentially be a reservoir 
of novel resistance mechanisms (Hatosy and Martiny 2015; Fitzpatrick and Walsh 2016). 
2.4.2 Human-animal transfer 
The movement of AMR bacteria and/or their genes between humans, animals and their 
environment is a complex and interdependent system (Holmes et al. 2016). Evidence for 
transfer of ESBL-producing E. coli from food animals to people is varied and animal 
classes that routinely receive antimicrobials to prevent disease (pigs, poultry) are the most 
likely sources for food-borne animal-to-human transfer (Lazarus et al. 2015). Such 
transmission could occur through direct contact (e.g. pig farmers or abattoir workers), a 
contaminated environment, or through the food chain. Environmental sampling around 
pig farms and meat processing plants have detected ESBL-producing E. coli; CTX-M type 
ESBL-producing bacteria were cultured from air samples on six of the 35 farms in a 
German study, although no pig-to-human transmission was found on any of those farms 
(Schmithausen et al. 2015). Other studies of farmed pigs in Ireland and Denmark have 
identified that CTX-M-14 and CTX-M-1 were more likely to be present than CTX-M-15; 
these are the ESBL enzyme variants that predominates in human clinical cases 
(Hammerum et al. 2014; Wang et al. 2016). Poultry production is a possible source of 
AMR Enterobacteriaceae, and human-associated strains of ESBL-producing E. coli have 
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been found in commercial meat samples and poultry-associated strains have been found 
in human urinary tract infections in Europe following low-resolution genetic analysis 
(Leverstein-van Hall et al. 2011; van Hoek et al. 2016). However, evidence for the 
contribution of these animal sources of bacteria to human disease is inconclusive and the 
relative risk of different ESBL-producing bacteria is likely to depend upon whether the 
bacteria is a host-adapted strain, as carriage of human-adapted strains in animals may be 
transient (Lazarus et al. 2015; van Hoek et al. 2016).  
Multidrug resistant Enterobacteriaceae isolated from some companion and food animals 
have been shown to share the same sequence types as those isolated from human 
infections (Ewers et al. 2012; Woodford et al. 2014). Isolates from infections in horses and 
companion animals, caused by ESBL-producing Enterobacteriaceae, shared a number of 
characteristics with contemporaneous human isolates (Schmiedel et al. 2014). Those 
authors suggest that their study provided some evidence for a possible pathway or 
reservoir for resistant bacteria. AMR bacteria are also found in animals not recently 
treated with antimicrobials; ESBL and AmpC-producing E. coli were found in the faeces 
of 9/106 (8%) dogs in a quantification prevalence study (Espinosa-Gongora et al. 2015). 
That study did not assess the potential for these bacteria to be direct causes of disease in 
humans, however, like other studies it shows companion animals as a potential reservoir 
for mobile resistant genes (Schmiedel et al. 2014; Rocha-Gracia et al. 2015). 
Animals have the potential to carry and disseminate ESBL-producing E. coli and K. 
pneumoniae (Donati et al. 2014; Ewers et al. 2014a; Ewers et al. 2014b) and there are 
examples of transmission incidents of MDR Enterobacteriaceae between humans and 
animals, however evidence of substantive risk of animals to human health is lacking 
(Ewers et al. 2012; Rubin and Pitout 2014). The modes of development, persistence and 
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transmission of AMR bacteria in human and animal populations are complex, and 
dependant on many factors. Some of these known factors include the misuse and overuse 
of antimicrobials in humans and animals, and hospitalised or healthcare-based 
transmission of resistant bacteria; other drivers include environmental contamination, 
ineffective diagnostic testing and lack of proper vaccination and preventative medicine 
(Holmes et al. 2016). 
2.5 Discussion  
Challenges presented by AMR are complex and best tackled with a One Health approach, 
due to the interconnectedness of humans, animals and the environment. Previously 
somewhat neglected as a One Health issue, AMR is now appearing as a platform within 
One Health institutes, at symposia and in publications. Other key global health and 
welfare issues such as climate change, and Ebola virus disease in West Africa have readied 
us to more fully consider the impact of the environment in infectious disease than we may 
have in the past (McMichael et al. 2006). So too, our consideration of the environment 
has broadened to include the social, cultural and political environment in which clinicians 
make decisions about sample submission for culture and susceptibility, antimicrobial 
prescribing, and adherence to stewardship guidelines (McNulty et al. 2012; Pleydell et al. 
2012). Less compartmentalisation, more widespread engagement and effective 
communication will facilitate shared action plans on surveillance, stewardship and 
research to reduce global threats such as AMR. 
2.5.1 Surveillance of antimicrobial resistant bacteria 
Surveillance of antimicrobial susceptibility is a key component of antimicrobial 
stewardship (Prescott 2014; Weese et al. 2015). An example of a successful One Health 
surveillance programme is the Danish Integrated AMR Monitoring and Research 
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Program (DANMAP), which was established in 1995 (www.danmap.org). The 
surveillance component of this programme has provided data for making policy changes 
and therefore the improved usage of antimicrobials. For example, surveillance data was 
able to show that the use of third and fourth generation cephalosporins increased 
considerably from 2001, and in 2005 the first ESBL-producing Enterobacteriaceae were 
isolated from slaughter pigs (Aarestrup et al. 2006). This resulted in the introduction of a 
voluntary ban on cephalosporins in the Danish pig industry and a significant decrease in 
the prevalence of ESBL-producing Enterobacteriaceae in pigs at slaughter and in pork for 
consumption ensued (Agersø and Aarestrup 2013). In 2012, genome sequencing was 
introduced as a surveillance tool for the programme and has been used for multilocus 
sequence typing as well as for the detection and analysis of resistant genes from ESBL and 
AmpC-producing Enterobacteriaceae isolates. This enabled the detection of the first 
ESBL and AmpC-producing isolates that were also mcr-1 (colistin resistant) outside 
China (Hasman et al. 2015). 
In New Zealand, a human AMR surveillance programme is currently carried out by ESR. 
This includes a two-yearly (previously carried out annually) surveillance report on ESBL-
producing Enterobacteriaceae and Enterobacteriaceae with acquired carbapenemases 
(Anonymous 2017; Heffernan et al. 2018). Both surveys are only undertaken on human 
isolates from diagnostic laboratories, including isolates from both screening and clinical 
samples. Routine surveillance of animals entering the food chain for MDR 
Enterobacteriaceae does not occur; neither is there surveillance of animals under 
treatment by veterinarians, i.e. of clinical samples submitted for culture and susceptibility 
testing. An effective New Zealand surveillance system would require routine surveillance 
at both the national and local level of both human and animal isolates. Dedicated research 
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surveillance programmes to understand the prevalence of AMR in particular 
environments are also important as these facilitate the recognition of unusual phenotypes 
or resistance mechanism that may be missed during routine surveillance. In addition, 
research surveillance programmes may enable extra information to be collected that 
would not otherwise be provided with samples submitted to commercial diagnostic 
laboratories (McDougall et al. 2014). 
2.5.2 Antimicrobial use in New Zealand 
New Zealand was one of the few developed countries to show a per capita increase in 
human antimicrobial consumption in a global study that analysed sales data as a proxy for 
determining human consumption (van Boeckel et al. 2014). Between 2005 and 2012 
community antimicrobial use increased from ~17 to ~25 defined daily doses/1,000 
population/day, unlike in many European countries where there was a decrease (van 
Boeckel et al. 2014). This higher relative use is of concern, and has the opportunity to be 
addressed by stewardship policies (Thomas et al. 2014; Williamson et al. 2016). 
Antimicrobial prescribing habits of New Zealand veterinarians are only partially 
documented. Antimicrobial use by Waikato dairy farms, and prescribing practices of their 
veterinarians were evaluated in 2014 (McDougall et al. 2017). In this study, farmers rated 
veterinary advice as most important; however, they also used their own perception of 
drug efficacy to make antimicrobial choices. Prescribing by veterinarians was 
predominantly based on diagnosis, expected pathogen and spectrum of activity. However 
bacterial culture and susceptibility testing was considered of limited use by farmers and 
was not widely used by veterinarians (McDougall et al. 2017). A survey of prescribing 
practices of companion animal veterinarians was conducted in 2008 (Pleydell et al. 2012). 
Results of that survey highlighted antimicrobial use that potentially provided selection 
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pressure for the development of AMR, such as use of fluoroquinolones and amoxicillin-
clavulanate as first-line therapies (Pleydell et al. 2012). It should be noted that both of 
these treatments are listed as critically important by the WHO (Weese et al. 2015). On a 
broader scale, antimicrobial use in New Zealand animals, by total kg of antimicrobial sold, 
is regularly reported (Anonymous 2013c). 
The use of antimicrobials in food animals in New Zealand for the year 2012 was compared 
with use in a selection of other countries by Hillerton et al. (Hillerton et al. 2017). The 
results showed that, based on mg active ingredient sold per kg biomass; New Zealand has 
a relatively low antimicrobial use in food producing animals. However, this study did not 
determine the use of specific antimicrobials, such as the third generation cephalosporins 
or fluoroquinolones. In New Zealand between 2009 and 2011, total ceftiofur sales 
increased 118% (Anonymous 2013c). It should be noted that ceftiofur is only licensed for 
use in horses, pigs and cattle in New Zealand, and such use could increase selection 
pressure for the development of resistant Enterobacteriaceae in these animals (Weese et 
al. 2015; Holmes et al. 2016). In most countries, including New Zealand, measurement of 
antimicrobial consumption is generally based on sales data, represented as mg of active 
substance, or reported as mg active antimicrobial per kg of biomass in food producing 
animals (Anonymous 2013c; Hillerton et al. 2017). This approach has its limitations as 
sales data may not reflect the actual amount used and there is insufficient data on how a 
specific type of antimicrobial is used for a particular animal species.  
The low total use of antimicrobials in New Zealand food production is likely to reflect the 
predominance of pastoral, and therefore less-intensive, agricultural systems when 
compared to many other countries. However, antimicrobials are still used in healthy 
animals in New Zealand, such as in-feed antimicrobials in some intensive systems like 
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zinc bacitracin in the poultry industry, which comprises the greatest mass of 
antimicrobials used (Anonymous 2013c), and provides an opportunity for reducing 
antimicrobial usage. 
2.5.3 Stewardship of antimicrobials 
Antimicrobial stewardship, alongside infection-control measures (e.g. biosecurity and 
hygiene), is important in the reduction and control of infections caused by MDR bacteria. 
The key elements of antimicrobial stewardship programmes in humans include 
implementation of specific interventions to improve antimicrobial use, education of 
professionals and consumers, tracking and reporting antimicrobial prescribing patterns 
and resistance, and leadership commitment. Education of New Zealand medical 
prescribers on the appropriate use of antimicrobials, along with selective reporting of 
susceptibility by laboratories to prescribers, is likely to have caused a reduction in 
fluoroquinolone use in humans from 2010–2014 (Williamson et al. 2016). After the 
introduction of DANMAP, and a voluntary ban of cephalosporin use in pig farming in 
2010, the use of third and fourth generation cephalosporins in pigs across Denmark 
dropped from ~130 kg in 2008 to <1 kg active in 2011 (Andersen et al. 2015). This resulted 
in a significant decrease in the prevalence of ESBL-producing Enterobacteriaceae in pigs 
at slaughter, from 11.8 % (48/407) in 2010  to 0 % (0/78) in 2011 (Agersø and Aarestrup 
2013). 
Education is a cornerstone of antimicrobial stewardship (Weese et al. 2015); animal and 
human healthcare professionals need to have access to continuing professional 
development, as well as be motivated to educate patients and clients (McNulty et al. 2012; 
McDougall et al. 2017). Knowledge of prescribing practice before implementation of 
stewardship interventions can be useful to benchmark changes in clinician behaviour 
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(Pleydell et al. 2012; Williamson et al. 2016). However, considerable and concerted effort 
is still needed in order to achieve and maintain optimal prescribing practice in a consistent 
manner across the country. Linked to education, another method of stewardship is to 
place requirements upon research and publication. For example, the Equine Veterinary 
Journal’s policy requires declarations and justifications from authors on the use of 
antimicrobials, similar to requirements for ethical approvals (Bowen 2013). 
Veterinary student training is also critical and an area that deserves investment (Castro-
Sánchez et al. 2016). A review of AMR and stewardship teaching in the veterinary 
curriculum at Massey University (Palmerston North, NZ) was conducted in 2016. 
Although there were multiple exposures to these topics during the Bachelor of Veterinary 
Science degree course, there was little vertical integration through the curriculum 
(unpublished data by the author). An antimicrobial working group has been formed to 
start to address these deficits. 
2.5.4 Research needs 
Retrospective studies of veterinary clinical isolates from New Zealand equine and 
companion animals have demonstrated an increasing amount of resistance to the 
antimicrobials used to treat infections in young New Zealand horses and in urinary tract 
infections in New Zealand dogs (Toombs-Ruane et al. 2016; McMeekin et al. 2017). 
Although important groundwork, a key limitation of these studies is that cases submitted 
to the laboratory are unlikely to have come from uncomplicated conditions. Submissions 
are more likely to occur when first line empirical treatment had failed (Pleydell et al. 
2012), thus culture results may reflect a more resistant population of bacteria. To date, 
research on MDR bacteria of veterinary importance has focussed on phenotype, whereas 
genomic analysis facilitates a greater understanding of transmission and epidemiology, 
34 
 
and better understanding of the virulence and AMR traits of bacteria (Holt et al. 2015). 
The genotypic characteristics of MDR Enterobacteriaceae from infection sites in 
companion animals between 2012 and 2013 in New Zealand was reported by Karkaba et 
al. and generally reflected the findings of studies conducted in other countries (Karkaba 
et al. 2017b).  
There is a deficit of published observational studies in New Zealand addressing the risk 
factors for the development and carriage of AMR bacteria in animal populations. The 
evidence base for AMR in animals as a causative agent for AMR in humans is variable, 
with findings ranging from no association to a strong causal association (Marshall and 
Levy 2011; Holmes et al. 2016). This deficit will be addressed further in Chapter 3.  
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2.6 Conclusions 
This review has described the mechanisms and potential transmission pathways of 
multidrug resistance in Enterobacteriaceae, especially ESBL-producing bacteria. The 
challenges associated with AMR, including transfer between animals, humans and the 
environment have been identified, and a One-Health approach for controlling AMR 
proposed that includes surveillance of resistant bacteria, monitoring antimicrobial use 
and antimicrobial stewardship. Future research needs include prospective observational 
studies, as well as understanding risk factors for AMR in New Zealand.  In addition to 
scientific studies, we suggest the veterinary community needs to maintain an on-going 
commitment to AMR including engagement in a multi-stakeholder One Health oversight 
committee on AMR, and for this committee to provide advice and guidance at a national 
level. There also needs to be improved surveillance and centralised reporting of 
antimicrobial use and resistance of clinical and post-slaughter isolates in animals, 
coordinated and aligned with similar surveillance of human isolates. Alongside this 
integrated surveillance, we also suggest that there be requirements for routine screening 
of Enterobacteriaceae for ESBL and carbapenemase-producing bacteria in veterinary 
microbiology and pathology laboratories, using methods aligned with the screening of 
human isolates. Finally, we suggest the development and support for antimicrobial 
stewardship and improved infection prevention and control guidelines for New Zealand 
veterinarians. This should include education and extension for both veterinarians and 
clients. 
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3  Companion animals as a risk for community-
acquired extended-spectrum beta-lactamase 
and AmpC beta-lactamase producing 
Enterobacteriaceae infections: a prospective 
case-control study 
3.1 Abstract 
Companion animals in the home are a potential source of plasmid-associated multidrug 
resistant bacteria. With 60% of New Zealand households having at least one pet, the role 
that pets play in human AMR infections warrants investigation. The objective of this 
study was to examine risk factors for community-acquired infections, including those 
associated with having a pet in the home.  
A prospective unmatched case-control study was conducted between August 2015 and 
September 2017. Cases were people with community-acquired urinary tract infection 
(UTI) caused by newly acquired extended spectrum beta-lactamase (ESBL)- or AmpC 
beta-lactamase (ACBL)- producing Enterobacteriaceae. Controls (n=525) were people 
recruited from the community via landline telephone and not matched to cases. A 
telephone questionnaire was administered and putative risk factors were assessed using 
regression analyses on two datasets, one with case-reported antimicrobial use (n=141), 
and the other with independently confirmed antimicrobial use (n=99). A combination of 
logistic regression, LASSO logistic regression and random forest regression was use to 
analyse the data.  
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Pet ownership did not constitute a risk for human urinary tract infections caused by 
ESBL- or ACBL-producing Enterobacteriaceae in any modelling modality used. Risk 
factors estimated using multivariate logistic regression on the full dataset included recent 
antimicrobial treatment (previous 3-months) [adjusted OR = 15.3 (95% CI 6.0 - 43.1)], 
travel to Asia in the previous year [adjusted OR = 9.9 (95% CI 4.0 - 26.8)], and contact 
with healthcare in the previous six-months [adjusted OR = 25.0 (7.4 - 107.1)]. Cases were 
more likely to be female [adjusted OR = 24.7 (95% CI 7.9 - 97.8)] and 65-years or older 
[adjusted OR = 14.0 (95% CI 4.5 - 49.4)] than the control population. 
The whole genomes of ESBL- or ACBL-producing isolates collected from urine were 
sequenced, and assessed through a bioinformatics pipeline. Isolates with an ESBL-
/ACBL-producing phenotype from 132 case people’s UTI were available for analysis. Of 
all isolates, 126/132 (95%) were E. coli, 5/132 (4%) were Klebsiella pneumoniae, and 1/132 
(1%) was Morganella morganii. The blaCTX-M-15 or blaCTX-M-27 genes were found in 90/132 
(68%) of ESBL- and/or ACBL-producing isolates from all case people, blaCTX-M-27 was 
found in 48/115 (42%) and blaCTX-M-15 was found in 42/115 (37%) of ESBL-producing 
isolates. For those ESBL-/ACBL-producing isolates identified as E. coli, 65/126 (52%) 
were phylogroup B2, 35/126 (28%) were phylogroup D; 47/126 (37%) were ST-131, and 
16/126 (13%) were ST-38.  
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3.2 Introduction 
Extended-spectrum beta-lactamase-producing and AmpC beta-lactamase-producing 
Enterobacteriaceae (ESBL-E and ACBL-E respectively) are common antimicrobial 
resistant (AMR) bacteria of importance to people in hospital and healthcare 
environments, and the community at large (Pitout et al. 2005; Heffernan et al. 2018; 
Torres et al. 2018). Historically, these bacteria were acquired through hospital exposures, 
and have since become associated with community-acquired infections (Freeman et al. 
2008; Heffernan et al. 2009; Rogers et al. 2015). These ESBL or ACBL enzymes are often 
expressed from genes on mobile elements (i.e. plasmids), and increasingly are found in 
bacteria with virulence traits that make the bacteria likely to cause disease (Kaper et al. 
2004; Nicolas-Chanoine et al. 2014). These bacteria are also pathogens of animals, being 
isolated from clinical samples in companion and production animals around the world 
(Ewers et al. 2012; Hammerum et al. 2014; Schmiedel et al. 2014; Dohmen et al. 2017), 
including in New Zealand (Karkaba et al. 2017b). 
As multidrug resistant (MDR) infections become more common in a community, the risk 
factors for acquisition of bacteria and subsequent infection (via intestinal carriage) are 
likely to change (Rogers et al. 2014; Karanika et al. 2016). Travel to high-prevalence areas 
(such as the Indian subcontinent) was found to be associated with ESBL-E infection in 
early reports from community-acquired New Zealand infections [e.g. the analysis of 
isolates from 2004 to 2006 by Freeman et al. (2008)]. In 2012, many people infected with 
an E. coli infection resistant to third-generation cephalosporins had not travelled outside 
of New Zealand, however travel still increased the odds of having a resistant infection 
(Rogers et al. 2014). These findings are consistent with other studies where travel was an 
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important risk factor for carriage or infection-with multidrug resistant gram-negative 
infections (Kuenzli et al. 2014; Karanika et al. 2016; Arcilla et al. 2017). 
Person-level risk factors for ESBL-E carriage or infection include high healthcare input 
or contact, recent antimicrobial use, older age, and travel to higher-prevalence countries 
(Karanika et al. 2016; Chatterjee et al. 2018). Risk factors for community-level prevalence 
are predominated by human antimicrobial use, although many countries deemed “high 
risk” have poor or unreliable recording of community prescriptions of antimicrobials 
(Woerther et al. 2013). High community prescribing of antimicrobials has been associated 
with an increased risk of bloodstream infections have been identified as risk factors 
(Lishman et al. 2018). Antimicrobial use may therefore be an important risk factor in New 
Zealand, as community prescribing of antimicrobials is reported to be higher than many 
other OECD countries (Thomas et al. 2014; Williamson et al. 2016).  
Antimicrobial treatment of companion animals has been identified as a risk factor for 
AMR in companion animals (Schmidt et al. 2018). There are also instances of people 
becoming ill after coming into contact with companion animals carrying or infected by 
multidrug resistant pathogens (Pomba et al. 2017), or companion animals carrying and/or 
transmitting MDR bacteria within homes (Johnson et al. 2016). Companion animals in 
New Zealand visiting veterinary clinics may carry human-associated strains of ESBL-E, 
as well as strains of mecA-containing Staphylococcus species (Karkaba et al. 2017a; Karkaba 
et al. 2017b).  
In Europe, human-associated ESBL-E (E. coli and Klebsiella species) are found in clinical 
bacterial isolates from companion animals (Dierikx et al. 2012; Schmiedel et al. 2014; 
Belas et al. 2018). These bacteria may contain plasmid-encoded ESBL genes commonly 
43 
 
associated with human community infections (such as blaCTX-M-14, blaCTX-M-27 or blaCTX-M-
15); the bacteria may also be from human associated MLST types (such as ST-131). In 
some cases, studies have found isolates from companion animals are more likely to be 
ACBL-producers in contrast to other studies where more isolates are ESBL-producers 
(Rubin and Pitout 2014). The choice of phenotypic screening and confirmatory tests will 
also have an impact on the relative proportion of isolates detected in these instances. 
Companion animals living in residential care homes (rest homes or elder care facilities) 
can carry multidrug resistant bacteria (Ewers et al. 2014b; Schaufler et al. 2015; Pomba et 
al. 2017). In a healthcare environment, this scenario is more likely, especially where 
nosocomial infections in humans are prevalent (Rogers et al. 2014). In the community 
however, multidrug resistant bacteria are likely to be less prevalent. In New Zealand, pets 
live in approximately 64% of homes, where 44% of homes have at least one cat and 28% of 
homes have at least one dog (Anonymous 2016a). Where pet ownership is high, risks 
associated with this ownership are worth investigating (Meyer et al. 2012). However, pet 
ownership has not been found to be associated with increased risk for infection or carriage 
of multidrug resistant bacteria in recent studies (Rogers et al. 2014; Leonard et al. 2018). 
While the true or supposed prevalence of intestinal carriage of ESBL-E is not known for 
New Zealand, the rates are likely to be highest in the Auckland region (Heffernan et al. 
2018). This is a concentrated population in relation to the rest of the country, with 
approximately one-third of the population living in the region. The population is more 
diverse with higher proportions of Asian and Pacifica ethnicities than rest of the country. 
The Auckland region is also associated with rates of ESBL-producing infections greater 
than the New Zealand national rate (Dyet et al. 2014; Heffernan et al. 2018). 
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The objective of the study presented in this chapter was to determine the risk of 
companion animals for community-acquired ESBL- and ACBL-producing infections in 
people. Other risk factors for these community-acquired infections were also assessed. 
This study also aimed to describe Enterobacteriaceae cultured from these community-
acquired ESBL- and ACBL-producing urinary tract infections. 
3.3 Materials and methods 
3.3.1 Case and control recruitment and sampling 
Case and control definitions 
A case was defined as a person aged 16-years or older, from whom a urine sample was 
submitted to the recruiting community laboratory (Labtests Auckland, Healthscope) 
from which an ESBL-E or ACBL-E was cultured. Participants consented to release of the 
bacterial isolate for further testing, and to participate in a 20-minute telephone 
questionnaire. Case participants were ineligible if they had been admitted overnight to 
hospital for any reason in the 12-months prior to the urine sample collection, or if they 
lived in a residential care facility such as a rest home. A control participant was eligible to 
be part of the study if they had not been a patient overnight in hospital in the previous 12-
months, did not live in a residential care (rest) home, and were 16-years of age or older.  
Sample size 
In this study a low prevalence of ESBL-/ACBL-producing bacteria in eligible case people 
was anticipated, and therefore a high control-to-case ratio was selected. Based on a target 
of 175 cases (where an estimate of three to four cases per week would be recruited over 
50 weeks), 525 controls were recruited. This sample size was considered to be sufficient 
to detect an odds ratio of >2 for pet-related exposures (assuming approximately 50% of 
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controls had a pet in the home). Based on the Fleiss case-control sample size calculation, 
with an a of 0.05 (assuming 60% of controls have a pet) to detect an OR of 2 (pets in the 
home) with 95% power, 175 cases would need to be recruited (1:3 case-to-control ratio) 
(Fleiss et al. 2013). 
Case and control recruitment 
Case participants were recruited by a clinical microbiologist through submissions to 
Labtests Auckland (Healthscope), a community microbiology laboratory serving the 
Auckland and Northland regional communities. These case participants were recruited 
between September 2015 and September 2017.  
Control recruitment was managed by a research company (UMR Research, Wellington, 
https://umr.co.nz/) performed via telephone (landline) using a combination of random 
digit dialling and verified phone numbers in UMR’s polling database. Controls were 
drawn from the Auckland/Northland regions and otherwise unmatched. Control 
recruitment began in August 2015, with 44 controls recruited each month for the first 6 
months of the study (40 from Auckland, 4 from Northland). Due to slow 
contemporaneous case participant recruitment, control participant recruitment was 
reduced to 18 participants per month. All control participants were recruited between 
August 2015 and March 2017.  
Questionnaire development and delivery 
A 52-question telephone questionnaire was developed to assess risk factor exposures 
during the six months preceding the multidrug resistant urinary tract infection for cases 
or the previous six-months for controls. Demographic factors such as age, gender, 
ethnicity, location (nearest primary school to residence), occupational factors and 
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household factors such as garden and the number bedrooms/cohabiting people residing 
were included1. The full case questionnaire can be found in Appendix IV. 
Participants were asked to recall recent antimicrobial treatment; for case participants this 
was intended to be any treatments prior to their current (i.e. recruited) infection. Other 
healthcare-related questions included any recent day surgery, and any known chronic 
disease co-morbidities. Pet related question included exposure, including food, hygiene 
and contact with pets, vet visits (including any antimicrobial treatment). International 
travel in the previous year was also assessed. 
The questionnaire was pretested by interview (face-to-face) by UMR. This pretesting was 
done on a cross-section of 10 individuals of varying ages and both male and female, living 
in Wellington, New Zealand. After pretesting, a pilot of 15 telephone questionnaires was 
performed on non-cases by a small team at UMR. Language of the questionnaire was 
modified subsequent to recommendations from UMR.  
An optional part of this study was the access to government health data [through the 
National Health Index (NHI) number] for community prescriptions of antimicrobials and 
hospitalisations for multidrug resistant infection. This information was requested but not 
essential for participation in the study. 
 
1 See https://esblfamilypet.wordpress.com/ for chapter 3 supporting documents including case and control 
questionnaires 
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3.3.2 Microbiology 
Bacterial culture and selection of isolates 
Urine samples were submitted to Labtests Auckland microbiology laboratories and the 
ESBL-production phenotype ascertained according to EUCAST guidelines using Kirby-
Bauer disk diffusion assays (Bauer et al. 1966; EUCAST 2018). Mueller-Hinton 
antimicrobial susceptibility plates from the isolates of people meeting the case definition 
were sent from Auckland to the mEpiLab. Once received into the mEpiLab, bacterial 
isolates were subcultured onto Colombia horse blood agar (Fort Richard Laboratories, 
Auckland, New Zealand), and two colonies were subcultured after 24 hours at 35 (+/- 1) 
°C (labelled ‘a’ and ‘b’). Purified isolates were stored at -80°C in a nutrient/glycerol 
suspension [25mg/mL Nutrient broth no. 2 (Oxoid, Basingstoke, U.K.), 15% glycerol (in 
purified and deionised water)]. Bacterial species identification was performed using 
matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) mass 
spectrometry (biotyper, Bruker, Billerica MA, U.S.A) according to manufacturers’ 
instructions and using the Bruker human pathogen database. 
Additional antimicrobial susceptibility testing 
Clinical bacterial isolates were re-tested at mEpiLab for an ESBL-producing phenotype 
using three paired Mastdiscs® [D62C ESBL cefotaxime Paired ID Disks (Mast Group 
Ltd., Liverpool, U.K. ), and D64C ESBL ceftazidime Paired ID Disks (Mast Group 
Ltd.)], and these isolates were also tested for an ACBL-producing phenotype using a 
three-disk comparison assay [D69C AmpC disk test (Mast Group Ltd.)]. If the ‘a’ isolate 
was not positive for an ESBL- and/or ACBL-producing phenotype, the ‘b’ isolates was 
tested likewise. Both isolates were individually suspended in nutrient/glycerol 
suspension and stored at -80°C. Antimicrobial susceptibility testing using the Kirby-
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Bauer disk diffusion assay was performed on isolates included in this study, using 
EUCAST clinical breakpoints (Kirby & Bauer 1967; EUCAST 2018). Antimicrobials 
tested against are shown in Table 3.1 (Mast Group Ltd). Multidrug resistance was 
defined as resistance to more than two of the following antimicrobial classes: beta-lactam 
(AMP10, CFX30, CPD10, CRO30, MEC10, ETP10, AUG30, FOX30), aminoglycoside 
(AK30, GM10), fosfomycin (FOT200), trimethoprim (TM5), nitrofurantoin (NI100), 
and norfloxacin (NOR10). 'Moderate' or ‘intermediate’ susceptibilities were defined as 
those that fell between susceptible and resistance diameters for the following disks: 
CRO30, GM10, AK30, NOR10, TM5, i.e. they did not meet the definition of 
‘susceptible’ or ‘resistant’ as given by the EUCAST clinical breakpoints .  
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Table 3.1 Antimicrobial zone diameters used in Kirby-Bauer disk diffusion phenotypic assays 
(EUCAST 2018) 
Antimicrobial (disk dose)  
Susceptible 
zone size 
(mm) ≥ 
Resistant 
zone size 
(mm) < 
Ampicillin (10ug) AMP10 14 14 
Cephalexin (30ug) CFX30 14* 14* 
Cefpodoxime (10ug) CPD10 21* 21* 
Ceftriaxone (30ug) CRO30 25 22 
Mecillinam (10æg) MEC10 15 15 
Ertapenem (10ug) ETP10 25 22 
Augmentin (amoxicillin 20ug + clavulanic acid 
10ug) AUG30 16* 16* 
Cefoxitin (30ug) FOX30 19† 19† 
Gentamicin (10ug) GM10 17 14 
Amikacin (30ug) AK30 18 15 
Norfloxacillin (10ug) NOR10 22 19 
Trimethoprim (5ug) TM5 18* 15* 
Nitrofurantoin (100ug) NI100 11*‡ 11*‡ 
Fosfomycin (200ug) FOT200 24*‡ 24*‡ 
* Clinical breakpoint for uncomplicated UTI 
† Screening breakpoint for ACBL production 
‡ E. coli only 
 
3.3.3 Extraction and preparation of genomic DNA for sequencing 
Where available, one clinical UTI isolate was sequenced from each case participant. 
Bacterial isolates were re-cultured from frozen (stored at -80°C) and a single colony 
subcultured and incubated for 20-24 hours at 35°C (+/- 1°C) , after an initial revival on 
Colombia horse blood agar (Fort Richard). Extraction of genomic DNA was done using a 
QIAamp DNA mini kit (Qiagen, Hilden, Germany) according to a modified and 
optimised version (for protocol see Appendix II) of the tissue/bacterial colony protocol. 
A PCR-grade water eluate was used, and this was stored at -20°C prior to library 
preparation. Fluorescent spectrometry (Qubit 2.0, Invitrogen, Carlsbad CA, U.S.A.) was 
used to assess quality of the extraction, and DNA was normalised to a concentration of 
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0.16ug/mL prior to preparation of libraries (Nextera XT DNA library preparation kits, 
Illumina Inc.). Libraries were prepared by Massey Genome service (when sequenced on 
the Illumina MiSeq platform, by Massey Genome Service), or by the mEpiLab (when 
sequenced on the Illumina HiSeq platform at the Otago Genomic and Bioinformatics 
facility). Assessment of library quality and fragment size distribution was performed by 
an automated gel fragment analyser prior to pooling of libraries [Labchip GX Touch HT 
(PerkinElmer, Waltham, U.S.A.); or 2100 BioAnalyzer (Agilent Genomics, Santa Clara, 
U.S.A.)].)]. Additional information on the protocol used for DNA extraction and library 
preparation can be found in Appendix III. 
3.3.4 Next generation sequencing and bioinformatics analyses 
Raw pair ended read files were used as the input into the Nullarbor pipeline using ‘careful 
mode’ for the de novo assembly of genomes via SPAdes (version 3.0) (Bankevich et al. 
2012; Seemann et al. 2016). 
Ribosomal multi-locus sequence typing (rMLST) was performed using the outputs from 
Prokka 3.0 (Seemann 2014), with an in-house perl script and an rMLST database for the 
analysis. Assembled contiguous nucleotide sequences of genomes (i.e. the output the 
Nullarbor pipeline) were used for ad hoc whole genome MLST of E. coli and Klebsiella 
pneumoniae clinical isolates [Fast-GeP, (Zhang et al. 2018)]. Whole genome MLST was 
run using default settings.  
The distance matrix tree outputs from whole genome MLST was presented as neighbour-
joining trees in SplitsTree (Huson 1998), and subsequently converted to Newick format 
to allow upload to Evolview (http://www.evolgenius.info/evolview/) for annotating and 
labelling (He et al. 2016).  
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3.3.5 Data management and statistical analyses 
Questionnaire, sample submission, and isolate data were stored in a MySQL (Oracle, 
Redwood City CA, U.S.A.) database, using Access (Microsoft Corporation, Redmond 
WA, U.S.A.) as a data entry interface. Statistical analysis of questionnaire data was 
performed in R-Studio (R version 3.4.3 https://www.r-project.org) and Excel (Microsoft 
corporation, Redmond WA, U.S.A). Missing variables in this study were not imputed. 
Outputs from the case and control questionnaires were used as inputs into a MySQL 
database and managed through MySQL Workbench (Oracle and Microsoft Access). 
These data were analysed using Rstudio (rstudio.com), with an open database 
connectivity (OBC) interface to the data stored remotely and securely on the Massey 
University Social Sciences server.  
R packages “RODBC” (https://cran.r-project.org/web/packages/RODBC/index.html) 
and “sqldf” (https://cran.r-project.org/web/packages/sqldf/index.html) were used for 
extraction and manipulation of data from this database through queries in the database 
programming language SQL, and recoding free-text answers though look-up tables. In 
this form, data were then recoded to reduce the number of variables. Variables were 
limited to those with a specific research question (from the questionnaire) and some (such 
as age) were recoded to ensure factors had non-zero entries and/or were split into groups 
that made biological sense. Manual recoding of free text answer to “other” answers in 
the questionnaire included the variables of ethnicity, nearest school, and travel. Where 
participants answered “unsure” to questions, the answers were coded as “NA” (or 
missing) for the purposes of analysis.  
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Within the questionnaire, participants were asked to identify the nearest primary school 
to their home. The answers to this question were cross-matched to the New Zealand 
Schools database (http://www.educationcounts.govt.nz/data-services/directories/list-
of-nz-schools; accessed 21/2/18) and school latitude and longitude, school decile, NZ 
2013 census mesh block with urban area designation extracted and added to the 
questionnaire dataset.  
3.3.6 Regression Modelling 
Subset analysis with NHI prescription data 
Community prescription data [accessed through National Health Index (NHI)] for the 
six months preceding the submission of the urine sample of the incident case was available 
for some case participants (n=99). This included systemic antimicrobial prescriptions, 
with drug formulation, date and length of course included. For the purposes of using this 
data in multivariate modelling, the most recent prescription was used if there were 
multiple recorded prescriptions. This subset was used with the full control dataset for 
repeated regression modelling as described in the next sections. Sensitivity and specificity 
of the questionnaire was assessed using NHI prescription data as the true exposure status 
of cases participants, where the test result was the answer provided in the questionnaire.  
Univariate screening of variables 
Variables were described first by one-way (count) tables. As no variables in the dataset 
were continuous (i.e. all were factors, either ordinal, categorical or binary), they were 
subsequently screened in relation to case and controls using two-way tables. Chi-squared 
tests and p-values from univariate regressions for odds ratios were used to assess 
statistical significance of variables in two-way tables. Demographic factors [including 
decile of nearest primary school, whether that school was in an urban or rural area, region 
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(Auckland, Northland or Waikato), gender, ethnicity, whether they lived alone, whether 
they worked in healthcare, and whether they had been a visitor to a hospital or rest-home 
in the previous six-months] were assessed.  
Multivariate regression models 
Logistic regression was used to assess the relationship between the outcome variable (case 
or control) and each variable of interest. All 85 variables were analysed in this way, 
including variables where more than one method of recoding was used (such as chronic 
disease). Potential confounders for the exposure of interest (pet ownership) include age, 
gender, and ethnicity. For healthcare associated exposures, possible confounders include 
age, chronic disease (i.e. diabetes) and recurrent/multiple urinary tract infections. For 
travel-associated exposures, possible confounders include age and ethnicity. 
Hypothesised confounders affecting a model with healthcare, pet, and travel-associated 
exposures included were age, gender, previous urinary tract infection, and diabetes. A 
preliminary multivariate model was constructed from variables where at least one factor 
(or level) in the variable had a p-value £0.2.  
In moving to a final multivariate logistic regression model, variables were excluded from 
the model using a stepwise approach. Variables were excluded when the covariate did not 
reach significance of p<0.05, provided they were not a confounder or the exposure of 
interest. 
Model fit was assessed using likelihood ratio tests, area-under ROC (c-statistic), and 
pseudo R-squared (Nagelkerke R-squared) with the R package ‘rms’ [https://CRAN.R-
project.org/package=rms (Miller et al. 1991)]. These tests, in addition to p-values, 
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residual deviance and Akaike information criterion (AIC) were used to describe and 
assess multivariate model(s) [calculated with the R function ‘glm’]. 
A Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression model 
was also used. This modelling tool is applied to datasets with a large number of variables 
of interest, where the effects of multi-collinearity can result in inflated estimates of 
regression coefficients (and hence odds ratios). Using this approach many variables are 
reduced to coefficients of zero by the LASSO (Tibshirani 1996), thus, the coefficients 
from a LASSO logistic regression model tend to be lower than a multivariate logistic 
regression model, but from these coefficients more conservative estimates of odds ratios 
can be determined for the variables that emerge (between the range for optimal least 
absolute shrinkage). This regression modelling was performed in R using the package 
“glmnet” (https://cran.r-project.org/package=glmnet). Two datasets were analysed 
using a penalised model, with constraints placed upon the LASSO regression given by a 
lambda at the minimum (min) and minimum plus one standard error (min + 1 standard 
error) (Friedman et al. 2010). Supplementary information for LASSO model can be found 
in Figure 6.2 in Appendix V.  
Population attributable fractions 
Attributable fractions give an estimation of the population-level effect of exposures on the 
outcome, accounting for rarity of exposures. Attributable fractions were calculated for 
variables included in the final multivariate logistic regression model using the R package 
“AF” (https://CRAN.R-project.org/package=AF), which used adjusted variable odds 
for the AF analysis. The was done using binary risk factors recoded for the following 
variables: antimicrobial treatment (reported for <3 month=1, >3months=0), age (>64 
years=1, <65years=0), healthcare work (yes=1, or no=0) (Dahlqwist et al. 2016). 
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Random forest regression 
Random forest classification is a method of analysing a large number of variables (or large-
scale datasets) using machine learning. This method, in comparison to the more 
commonly used methods of regression in epidemiologic research, does not provide a 
measure of risk (i.e. odds ratio). However, it does provide robust information on the 
importance of a variable to the outcome (i.e. case versus control) and further 
complemented the multivariate logistic regression and LASSO models. Random forest 
classification also automatically assess potential interactions, as a variable might appear 
only on one side of a split and it automatically handles missing data through the use of 
surrogate splits in each of the trees. 
Random forest regression was performed in R using the package “randomForest” 
(https://CRAN.R-project.org/package=randomForest). The same 85 variables screened 
for use in the multivariate regression model were used in the random forest regression. 
This was run initially with 2000 trees, and subsequently repeated with 10000 trees. Class 
weight was changed to reduce class confusion (1000 cases:1 control). The results of the 
random forest regression are described by the mean decrease in accuracy and the mean 
decrease in the Gini index. These values are ways of assessing how accurately the trees 
assign cases and controls at each variable.  
3.3.7 Ethics 
This case-control study, with a cross-sectional stool-sampling component, was approved 
by the New Zealand Health and Disability Ethics Committee (HDEC) - central 
committee (reference 15/CEN/47). Locality agreements were made with the Auckland, 
Northland, Waitemata, and Counties Manukau district health boards in compliance with 
HDEC approval.  
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3.4 Results 
3.4.1 Results of questionnaire  
Overview of cases and controls 
A total of 141 cases and 525 controls were recruited between 1 August 2015 and 30 
September 2017. Both cases and controls were predominantly European, 74.1% of 
controls and 74.5% of cases identified as European or New Zealand European ethnicity. 
There was a disparity in gender between cases and controls; 94.3% of cases were female 
compared to 52.2% of controls. The age distribution was also markedly different between 
cases and controls: for cases 22.0% were 16 to 44 years-old, 37.6% were 45 to 64 years-old, 
40.4% were 65-years-or-over. For controls 52.4% were 16 to 44 years-old, 30.7% were 45 
to 64 years-old, and 17.0% were 65-years-or-over. Most participants lived with other 
people, 89.3% and 85.6% of control and case participants respectively. Over 80% of cases 
and controls lived in main urban or secondary urban areas compared to rural area or minor 
urban areas (NZ census definitions, 2013 school data), 90.0% and 85.0% of cases and 
controls lived in urban areas respectively. Further descriptions of the characteristics of 
cases and controls are described more fully in Table 3.2. The distribution of other 
questionnaire-assessed risk factors are described in Tables 3.3, and 3.4.
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Table 3.2 Summary of demographic and heath variables of 141 case and 525 control participants 
Variable Risk factor Controls (n/N) 
Case 
(n/N) 
Crude OR 
(95%CI) 
p-
value 
Home Lives alone 56/524 20/139 Ref 
 
 
Lives with others 468/524 119/139 0.7 (0.4 - 1.3) >0.2 
Gender Male 251/525 8/141 Ref 
 
 
Female 274/525 133/141 15.2 (7.8 - 34.4) <0.001 
Age Age: 16 to 44 years 275/525 31/141 Ref 
 
 
Age: 45 to 64 years 161/525 53/141 2.9 (1.8 - 4.8) <0.001  
Age: 65+ years 89/525 57/141 5.7 (3.5 - 9.4) <0.001 
Ethnicity a Maori 39/525 8/141 0.7 (0.3 - 1.6) >0.2  
Asian 37/525 12/141 1.2 (0.6 - 2.4) >0.2  
Pacifica 10/525 2/141 0.7 (0.1 - 2.9) >0.2  
European 389/525 105/141 1.0 (0.7 - 1.6) >0.2  
MELAA 22/525 5/141 0.8 (0.3 - 2.1) >0.2 
Healthcare work No 468/525 109/136 Ref  
 Yes: no patients 15/525 15/136 4.3 (2.0 - 9.1) <0.001 
 Yes: patient contact 42/525 12/136 1.2 (0.6 - 2.3) >0.2 
School decile 1 to 3 115/486 18/119 Ref  
 4 to 7 160/486 44/119 1.8 (1.0 - 3.3) 0.065 
 8 to 10 211/486 57/119 1.7 (1.0 - 3.1) 0.064 
Urban No 74/486 12/119 Ref  
 Yes 413/486 107/119 1.6 (0.9 - 3.2) 0.16 
Overall health Good to excellent 487/525 113/140 Ref  
 Fair to poor 38/525 27/140 3.1 (1.8 - 5.2) <0.001 
Any chronic disease No 394/524 60/136 Ref  
 Yes 130/524 76/136 3.8 (2.6 - 5.7) <0.001 
Asthma None reported 495/524 126/136 Ref  
 Yes 29/524 10/136 1.4 (0.6 – 2.8) >0.2 
Cardiac disease None reported 506/524 127/136 Ref  
 Yes 18/524 10/136 2.2 (1.0 - 4.8) 0.051 
Diabetes None reported 514/524 126/136 Ref  
 Yes 10/524 10/136 4.1 (1.6 - 10.1) 0.0022 
Other chronic disease None reported 445/524 75/136 Ref  
 Yes 79/524 61/136 4.6 (3.0 - 6.9) <0.001 
Chronic disease score None reported 394/523 59/136 Ref  
 1 (of 4) 116/523 59/136 3.4 (2.2 - 5.2) <0.001 
 2 (of 4) 10/523 15/136 10 (4.3 - 24) <0.001 
 3 + 3/523 3/136 6.7 (1.2 - 36.8) 0.022 
>1 UTI last 6-months None reported 509/524 64/134 Ref  
 Yes 15/524 70/134 37.1 (20.6 - 71) <0.001 
Doctor visit last 6-months None reported 260/525 10/138 Ref  
 Yes 265/525 128/138 12.6 (6.8 - 26) <0.001 
Antibiotics last 6-months >6 months or never 385/521 28/129 Ref  
 3-6 months 72/521 19/129 3.6 (1.9 - 6.8) <0.001 
 <3 months 64/521 82/129 17.6 (10.8 - 29.6) <0.001 
Visitor to hospital last 6-months None reported 290/523 60/139 Ref  
 Yes 233/523 79/139 1.6 (1.1 - 2.4) 0.01 
Visitor to hospital last 6-months:  Lives alone 56/516 19/129 Ref  
- other person None reported 269/516 74/129 0.8 (0.5 - 1.5) >0.2 
Antibiotics: other person Lives alone 56/506 19/117 Ref  
 None reported 284/506 48/117 0.5 (0.3 - 0.9) 0.024 
 Yes 166/506 50/117 0.9 (0.5 - 1.7) >0.2 
MDR: other person Lives alone 56/514 19/119 Ref  
 None reported 444/514 96/119 0.6 (0.4 - 1.1) 0.12 
 Yes 14/514 4/119 0.8 (0.2 - 2.7) >0.2 
a Ethnicity was reported with multiple answers allowed, ethnicities were compared to “not ethnicity” for 
the purposes of odds ratio screening; MELAA – Middle Eastern, Latin American, and African  
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Table 3.3 Summary of travel, home, hygiene and food related variables from 141 case and 525 
control participants 
Variable Risk factor Control (n/N) 
Case 
(n/N) 
Crude OR 
 (95% CI) 
p- 
value 
All travel last year None reported 271/524 51/140 Ref 
 
 
Yes 253/524 89/140 1.9 (1.3 - 2.8) 0.001 
Travel to Africa None reported 519/524 133/140 Ref 
 
 
Yes 6/524 7/140 4.6 (1.5 - 14.4) 0.007 
Travel to EU None reported 488/524 121/140 Ref 
 
 
Yes 37/524 19/140 2.1 (1.1 - 3.7) 0.016 
Travel to Asia None reported 463/524 97/140 Ref 
 
 
Yes 62/524 43/140 3.3 (2.1 - 5.1) <0.001 
All travel last year:  Lives alone 56/523 19/137 Ref 
 
- other person None reported 221/523 48/137 0.6 (0.4 - 1.2) 0.15  
Yes 246/523 70/137 0.8 (0.5 - 1.5) >0.2 
Diet: vegetarian Yes 20/525 10/139 Ref 
 
 
No 505/525 129/139 0.5 (0.2 - 1.2) 0.093 
Diet: meat type None 20/525 10/139 Ref 
 
 
No homekill or hunted 375/525 99/139 0.5 (0.2 - 1.2) 0.11  
Homekill or hunted 130/525 30/139 0.5 (0.2 - 1.1) 0.077 
Diet: raw milk No 481/525 134/141 Ref 
 
 
Yes 44/525 7/141 0.6 (0.2 - 1.2) 0.18 
Diet: vegetables from  None reported 296/525 70/141 Ref 
 
garden or family/friends Yes 229/525 71/141 1.3 (0.9 - 1.9) 0.154 
Handwashing:  Always 259/525 46/141 Ref 
 
- before eating Often 104/525 47/141 2.5 (1.6 - 4.1) <0.001  
Sometimes 137/525 39/141 1.6 (1 - 2.6) 0.051  
Never 25/525 9/141 2 (0.8 - 4.5) 0.093 
Handwashing:  Always 142/523 38/140 Ref 
 
- after sneezing or blowing nose Often 145/523 26/140 0.7 (0.4 - 1.2) 0.154  
Sometimes 183/523 50/140 1.0 (0.6 - 1.6) >0.2  
Never 53/523 26/140 1.8 (1.0 - 3.3) 0.044 
Garden at home No 56/525 8/137 Ref 
 
 
Yes 469/525 129/137 1.9 (0.9 - 4.5) 0.094 
Garden: compost No garden 56/520 7/138 Ref 
 
 
No compost 184/520 78/138 3.4 (1.6 - 8.5) <0.001  
Yes 280/520 53/138 1.5 (0.7 - 3.8) >0.2 
Garden: cat/dog faeces seen  No garden 56/522 7/140 Ref 
 
 
No 217/522 50/140 1.8 (0.8 - 4.7) 0.155  
Yes 249/522 83/140 2.7 (1.2 - 6.6) 0.020 
Garden: feeds wild birds No 322/522 74/136 Ref 
 
 
Yes 200/522 62/136 1.3 (0.9 - 2.0) 0.12 
Garden: bird bath No 427/525 85/122 Ref 
 
 
Yes 98/525 37/122 1.9 (1.2 - 2.9) 0.005 
  
59 
 
Table 3.4 Summary of animal-related variables from 141 case and 525 control participants 
Variable Risk factor Controls (n/N) 
Case 
(n/N) 
Crude OR 
(95%CI) 
p-
value 
Pet in homea None 267/525 71/139 Ref 
 
 
Yes 258/525 68/139 1.0 (0.7 - 1.4) >0.2 
Pet type None 267/525 71/137 Ref 
 
 
Cat(s) only 95/525 26/137 1.0 (0.6 - 1.7) >0.2  
Dog(s) only 51/525 16/137 1.2 (0.6 - 2.2) >0.2  
Cat(s) and dog(s) 44/525 15/137 1.3 (0.7 - 2.4) >0.2  
Other pets included 68/525 9/137 0.5 (0.2 - 1.0) 0.066 
Diet: cat No cat 386/510 96/135 Ref 
 
 
Commercial diet only 65/510 15/135 0.9 (0.5 - 1.7) >0.2  
Some raw meat 59/510 24/135 1.6 (1.0 - 2.7) 0.066 
Diet: cat hunts No cat 386/481 96/126 Ref 
 
 
No 26/481 1/126 0.2 (0 - 0.7) 0.069  
Yes 69/481 29/126 1.7 (1.0 - 2.7) 0.035 
Person handles pet faeces No pet 267/497 71/134 Ref 
 
 
No 90/497 14/134 0.6 (0.3 - 1.1) 0.091  
Yes 140/497 49/134 1.3 (0.9 - 2.0) 0.20 
Handwashing:  Not applicable† 267/521 74/139 Ref 
 
- before feeding pet Always 46/521 7/139 0.5 (0.2 - 1.2) 0.16  
Often 33/521 5/139 0.5 (0.2 - 1.3) >0.2  
Sometimes 61/521 22/139 1.3 (0.7 - 2.2) >0.2  
Never 114/521 31/139 1.0 (0.6 - 1.6) >0.2 
Handwashing:  Not applicable† 267/521 74/139 Ref 
 
- after feeding pet Always 146/521 26/139 0.6 (0.4 - 1.0) 0.077  
Often 29/521 12/139 1.5 (0.7 - 3) >0.2  
Sometimes 47/521 18/139 1.4 (0.7 - 2.5) >0.2  
Never 32/521 9/139 1.0 (0.4 - 2.1) >0.2 
Handwashing:  Not applicable† 267/518 72/139 Ref 
 
- after petting/stroking pet Always 72/518 7/139 0.4 (0.1 - 0.8) 0.015  
Often 32/518 17/139 2.0 (1 - 3.7) 0.039  
Sometimes 91/518 21/139 0.9 (0.5 - 1.4) >0.2  
Never 56/518 22/139 1.5 (0.8 - 2.5) 0.19 
Handwashing:  Not applicable† 267/467 75/129 Ref 
 
- after picking up pet faeces Always 180/467 47/129 0.9 (0.6 - 1.4) >0.2  
Often 5/467 4/129 2.8 (0.7 - 11) 0.13  
Sometimes 8/467 2/129 0.9 (0.1 - 3.6) >0.2  
Never 7/467 1/129 0.5 (0 - 2.9) >0.2 
Type of vet visit  No pet 267/517 71/129 Ref 
 
- last 6-months None 111/517 26/129 0.9 (0.5 - 1.4) >0.2  
Short: GP 88/517 23/129 1.0 (0.6 - 1.6) >0.2  
Short: ER or surgery 38/517 5/129 0.5 (0.2 - 1.2) 0.15  
Long: any 13/517 4/129 1.2 (0.3 - 3.4) >0.2 
Any treatment at vet  No pet 267/513 71/133 Ref 
 
- last 6-months No vet 111/513 24/133 0.8 (0.5 - 1.3) >0.2  
No treatment‡  47/513 3/133 0.2 (0.1 - 0.7) 0.019  
Yes treatment‡ 88/513 35/133 1.5 (0.9 - 2.4) 0.094 
Animal contact:  None reported 455/525 130/141 Ref 
 
- farm Yes 70/525 11/141 0.6 (0.3 - 1.0) 0.078 
Animal contact:  None reported 506/525 129/141 Ref 
 
- wild or other Yes 19/525 12/141 2.5 (1.1 - 5.2) 0.018 
a Included due to research question;† Not applicable included if there was no pet in the home, or if the 
person answering the questionnaire did not engage in activity; ‡ Treatment non-specified medication 
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3.4.2 Modelling and risk factor analysis 
Regression modelling was used to estimate the odds ratios (ORs) for exposure variables. 
Adjusted ORs for variables included in the multivariate models are shown using the two 
case datasets where antimicrobial use was self-reported (n=141 cases, Table 3.5) and from 
a subset of this dataset (n=99 cases) where community prescriptions were accessed from 
the NZ government database (Table 3.7). Having a pet in the home was not found to be 
a significant risk factor in either dataset [adjusted OR: 0.8 (95% CI 0.4 – 1.9)]. Other 
exposures of interest were found to be associated with an increased risk, such as travel to 
Asia [adjusted OR: 9.9 (95% CI 4.0 – 26.8)], and antimicrobial treatment in the previous 
3-months [adjusted OR: 15.3 (95% CI 6.0 – 43.1)].  
Eight animal-related variables not related to having a family pet were examined, and two 
were associated with significant ORs and remained in the final adjusted questionnaire-
only model. These were contact with livestock (farm animals) with a protective OR and 
contact with wild animals (or other animals not listed) as an increased risk. For contact 
with wild animals or ‘other’ animals in the previous six-months, an adjusted OR was 3.4 
(95% CI 0.8 – 13.6), and for contact with farm livestock the previous six-months, an 
adjusted was OR 0.2 (95% CI 0 – 0.8). Other animal-related risks associated with the 
garden (univariate ORs in Table 3.3) were associated with increased risk. These risk 
factors were: seeing cat/dog faeces in the garden, feeding wild birds in the garden and 
having a birdbath. While none of the garden-related variables were included in the 
multivariate logistic regression model(s), cat/dog faeces seen in the garden was one of 
variable which remained in the LASSO regression model (OR = 1.1) when constrained to 
λmin + 1 SE (Table 3.12) 
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In univariate screening of 21 pet-associated variables in this study, 10 were associated with 
the outcome variable with a p-value of ≤0.2 (Table 3.4). Protective odds were associated 
with: having non cat/dog pets (e.g. rodents, fish, birds, livestock), not handling pet faeces, 
“always” washing hands before feeding pets, “always” washing hands after feeding pets, 
“always” washing hands after petting cat/dog, pet having a short visit at the vet (surgery 
or emergency), and a pet visiting the vet but not receiving treatment. Associated with 
increased odds were including some raw food in cat’s diet, cat hunting wildlife, handling 
of pet faeces, “often” or “never” washing hands after petting cat/dog, “often” washing 
hands after handling of pet faeces, and a pet visiting the vet and receiving treatment. 
From univariate screening of variables, 12 personal healthcare variables were significant 
to a p-value of ≤0.2. Six of these variables were associated with chronic disease (Table 
3.2), however only two variables were included in the final model [diabetes (adjusted 
OR=4.3; 95% CI 0.8 – 24.8) and ‘other’ chronic disease (adjusted OR=3.0; 95% CI 1.3 – 
6.9)]. 
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When adjusted for in the final model, being older and female were associated with having 
an ESBL-/ACBL-producing UTI [ORage45to65=8.8 (95% CI 3.1 - 28.7) and ORage65+=14.0 
(95% CI 4.5 - 49.4); ORfemale=24.7 (95% CI 7.9 - 97.8)]. Visiting a doctor in the previous 
six-months was associated with an increased risk [adjusted OR=33.6 (95% CI 8.4 - 192.4)], 
as was having more than one urinary tract in the preceding six months before incident 
UTI [adjusted OR=142.7 (95% CI 36.8 - 745.4)]. Handwashing was also associated with 
increased risk (“often” c.f. “always”) in the adjusted model [OR=5.5 (95% CI 2.0 - 15.8)]. 
Five variables were associated with other types of healthcare exposure, including working 
in healthcare [with patient contact (adjusted OR=1.1; 95% CI 0.3 – 4.0) or without patient 
contact (adjusted OR=4.1; 95% CI 0.8 – 19.8)], and visiting a hospital or rest home in the 
previous six-months. Exposures relating to other people in the home that were significant 
to p ≤0.2 on univariate screening, but were not significant in the final model were: being 
a visitor to a hospital or rest home in the previous 6-months, taking antimicrobials in the 
previous 6-months, or having a previous multidrug resistant infection.  
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Multivariate logistic regression of questionnaire results only 
Table 3.5 Odds ratios (OR) for risk factors for urinary tract infections caused by ESBL- or 
ACBL-producing Enterobacteriaceae in the community, based on questionnaire data from 141 
case and 525 control participants 
Variable Risk factor Controls (n/N) 
Case 
(n/N) 
Crude OR 
(95%CI) 
Adjusted OR 
(95% CI) 
Gender Male 251/525 8/141 Ref Ref 
 Female 274/525 133/141 15.2 (7.8 - 34.4) 24.7 (7.9 - 97.8) 
Age Age: 16 to 44 years 275/525 31/141 Ref Ref 
 Age: 45 - 64 years 161/525 53/141 2.9 (1.8 - 4.8) 8.8 (3.1 - 28.7) 
 Age: 65+ years 89/525 57/141 5.7 (3.5 - 9.4) 14.0 (4.5 - 49.4) 
Healthcare work No 468/525 109/136 Ref Ref 
 Yes: no patients 15/525 15/136 4.3 (2.0 - 9.1) 4.1 (0.8 - 19.8) 
 Yes: patients 42/525 12/136 1.2 (0.6 - 2.3) 1.1 (0.3 - 4.0) 
Diabetes None reported 514/524 126/136 Ref Ref 
 Yes 10/524 10/136 4.1 (1.6 - 10.1) 4.3 (0.8 - 24.8) 
Other chronic 
disease 
None reported 445/524 75/136 Ref Ref 
 Yes 79/524 61/136 4.6 (3.0 - 6.9) 3.0 (1.3 - 6.9) 
>1 UTI last 6-
months 
None reported 509/524 64/134 Ref Ref 
 Yes 15/524 70/134 37.1 (20.6 - 71) 38.7 (12.0 - 150) 
Doctor visit <6-
months 
None reported 260/525 10/138 Ref Ref 
 Yes 265/525 128/138 12.6 (6.8 - 26) 25.0 (7.4 - 107) 
Antibiotics <6-
months 
>6 months or never 385/521 28/129 Ref Ref 
 3 to 6 months 72/521 19/129 3.6 (1.9 - 6.8) 2.6 (0.8 - 7.9) 
 <3 months† 64/521 82/129 17.6 (10.8 - 29.6) 15.3 (6.0 - 43.1) 
Travel to Asia No 463/524 98/140 Ref Ref 
 Yes 62/525 43/140 3.3 (2.1 - 5.1) 9.9 (4.0 - 26.8) 
Travel to Africa No 519/524 133/140 Ref Ref 
 Yes 6/525 7/140 4.6 (1.5 - 14.4) 23.2 (0.6 - 520) 
Handwashing:  Always 259/525 46/141 Ref Ref 
- before eating Often 104/525 47/141 2.5 (1.6 - 4.1) 4.6 (1.7 - 12.6) 
 Sometimes 137/525 39/141 1.6 (1.0 - 2.6) 2.9 (1.1 - 7.8) 
 Never 25/525 9/141 2.0 (0.8 - 4.5) 1.4 (0.3 - 6.8) 
Pet in home No 267/525 71/139 Ref Ref 
 Yes 258/525 68/139 1.0 (0.7 - 1.4) 0.8 (0.4 - 1.9) 
Animal contact: 
farm 
No 455/525 130/141 Ref Ref 
 Yes 70/525 11/141 0.6 (0.3 -1.0) 0.2 (0 - 0.8) 
Animal contact:  
wild 
No 506/525 129/141 Ref Ref 
 Yes 19/525 12/141 2.5 (1.1 - 5.2) 3.4 (0.8 - 13.6) 
  
64 
 
Table 3.6 Descriptions and tests for the multivariate regression model in Table 3.5 
Model property Index or score 
Nagelkerke R-squared index 0.745 
Area under ROC curve 0.966 
Likelihood ratio chi-squared (14 d.f.; p-value <0.001) 377.94 
AIC 232.19 
Null deviance (629 d.f.) 586.62 
Residual deviance (611 d.f.) 194.19 
Missing observations 36 
 
Multivariate logistic regression of subset where case prescription data was known 
Additional prescription information from the national database (through case participant 
NHI number) was available for a subset of 99 clinical case participants. When reclassified 
with antibiotic prescriptions in previous 6 months as a binary variable, results for 88 
individuals were used (both questionnaire and community prescription data was 
available). The questionnaire test sensitivity for this question was estimated to be 87%, 
while the specificity was 44% (i.e. >50% false positives where people reported 
antimicrobial use but no prescriptions were recorded in NZ government database). 
Results of this subset of data is summarised in Tables 3.7, 3.8, 3.9, 3.11 and 3.12.  
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Adjusted OR for risk factors of interest (as described for the questionnaire-only dataset) 
in this model were: having a pet in the home [adjusted OR: 1.3 (95% CI 0.6 – 3.1)], travel 
to Asia [adjusted OR: 6.9 (95% CI 2.6 – 19.4)], and antimicrobial treatment in the previous 
3-months [adjusted OR: 2.8 (95% CI 1.1 – 7.3)]. Of these, antimicrobial treatment in the 
previous 3-months was the most different to the OR given for the questionnaire-only 
dataset. 
Table 3.7 Self-reporting vs government data (NHI) for systemic antimicrobial community 
prescriptions (n=99 cases) 
Most recent antimicrobial 
treatment 
Reported in questionnaire 
n/N           % (95% CI) 
Reported though NHI 
n/N          % (95% CI) 
None or >6months 27/88 31 (21 - 40) 57/99† 58 (48 - 67) 
3 to 6 months 11/88 13 (6 - 19) 9/99 9 (3 - 15) 
<3 months 50/88 57 (46 - 67) 33/99 33 (24 - 43) 
† Including prescriptions in government database the week of clinical urinary sample submission 
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Table 3.8 Summary of characteristics of case-control subset where antimicrobial prescription 
history was known. Odds ratios (OR) are results of univariate and multivariate analysis. 
Variable Risk factor Controls (n/N) 
Case 
(n/N) 
Crude OR 
(95%CI) 
Adjusted OR 
(95% CI) 
Gender Male 251/525 8/99 Ref  
 Female 274/525 91/99 10.4 (5.3 - 23.7) 13.3 (4.5 - 48.9) 
Age Age: 16 to 44 years 275/525 16/99 Ref  
 Age: 45 - 64 years 161/525 37/99 3.9 (2.2 - 7.5) 9.2 (2.8 - 35.9) 
 Age: 65+ years 89/525 46/99 8.9 (4.9 - 16.9) 17.9 (5.1 - 77.4) 
Healthcare work No 468/525 74/95 Ref  
 Yes: no patients 15/525 13/95 5.5 (2.5 -12.0) 2.8 (0.5 - 15) 
 Yes: patients 42/525 8/95 1.2 (0.5 -2.5) 0.4 (0.1 - 1.9) 
Diabetes None reported 514/524 92/97 Ref  
 Yes 10/524 5/97 2.8 (0.9 -8.1) 3.4 (0.5 - 22.7) 
Other chronic disease None reported 445/524 56/97 Ref  
 Yes 79/524 41/97 4.1 (2.6 -6.6) 1.5 (0.6 - 3.6) 
>1 UTI last 6-months None reported 509/524 45/95 Ref  
 Yes 15/524 50/95 37.7 (20.1 - 74.6) 143 (37 - 745) 
Doctor visit <6-months None reported 260/525 7/96 Ref  
 Yes 265/525 89/96 12.5 (6.1 - 30.1) 33.6 (8.4 - 192) 
Antibiotics <6-months >6 months or never 385/521 57/99 Ref  
 3 to 6 months 72/521 9/99 0.8 (0.4 - 1.7) 0.3 (0.1 - 1.2) 
 <3 months† 64/521 33/99 3.5 (2.1 - 5.8) 2.8 (1.1 - 7.3) 
Travel to Asia No 463/524 69/98 Ref  
 Yes 62/525 29/98 3.1 (1.9 - 5.2) 6.9 (2.6 - 19.4) 
Travel to Africa No 519/524 92/98 Ref  
 Yes 6/525 6/98 5.6 (1.7 - 18.4) 43.6 (2.8 - 493) 
Handwashing:  Always 259/525 29/99 Ref  
- before eating Often 104/525 37/99 3.2 (1.9 - 5.5) 5.5 (2.0 - 15.8) 
 Sometimes 137/525 27/99 1.8 (1.0 - 3.1) 2.2 (0.8 - 6.5) 
 Never 25/525 6/99 2.1 (0.7 - 5.4) 1.2 (0.2 - 5.5) 
Pet in home No 267/525 51/97 Ref  
 Yes 258/525 46/97 0.9 (0.6 - 1.4) 1.3 (0.6 - 3.1) 
Animal contact: farm No 455/525 90/99 Ref  
 Yes 70/525 9/99 0.7 (0.3 -1.3) 0.6 (0.2 - 2.2) 
Animal contact:  wild No 506/525 89/99 Ref  
 Yes 19/525 10/99 3.0 (1.3 -6.5) 2.0 (0.5 - 8.7) 
†For cases, this time-period is defined as prescriptions between 1 week and 3 months prior to 
collection of urine sample from which the ESBL/ACBL isolate was cultured. This was to exclude 
antimicrobials prescribed for incident case infection. 
  
67 
 
 
Table 3.9 Descriptions and tests for multivariate regression model in Table 3.8 
Model property Index or score 
Nagelkerke R-squared index 0.676 
Area under ROC curve 0.957 
Likelihood ratio chi-squared (14 d.f.; p-value <0.001) 281.08 
AIC 216.96 
Null deviance (608 d.f.) 482.91 
Residual deviance (595 d.f.) 176.96 
Missing observations 22 
 
Population attributable fractions 
Attributable fractions give an estimation of the population-level effect of exposures on the 
outcome, accounting for rarity of exposures. Risk factor variables were expressed as 
binary variable levels in Tables 3.10 and 3. 11. 
Table 3.10 Population attributable fractions (AF) for binary outcomes [final model risk factor 
odds ratios (OR) recoded] from questionnaire data 
Risk factor OR AF model 
AF 
(95% CI) 
AF 
Pr(>|z|) 
Pet in home 1.2 0.02 (-0.08 - 0.13) >0.5 
>1 UTI last 6-months 32.2 0.26 (0.18 - 0.35) <0.001 
Female 17.0 0.55 (0.38 - 0.72) <0.001 
Age 65+ 3.0 0.11 (0.03 - 0.19) 0.007 
Diabetes 6.3 0.03 (-0.01 - 0.06) 0.103 
Other chronic disease 3.4 0.13 (0.05 - 0.22) 0.002 
Doctor visit last 6-months 17.4 0.53 (0.37 - 0.68) <0.001 
Antibiotics last 3-months 6.4 0.2 (0.11 - 0.3) <0.001 
Healthcare worker 1.6 0.02 (-0.03 - 0.07) 0.406 
Travelled to Asia 8.1 0.14 (0.07 - 0.21) <0.001 
Travelled to Africa 7.6 0.01 (-0.01 - 0.02) 0.281 
Sometimes/never wash hands before eating 1.1 0.01 (-0.07 - 0.08) >0.5 
No contact with farm animals reported 5.7 0.38 (0.15 - 0.61) <0.001 
Contact with wild or other animals reported 3.8 0.03 (0 - 0.07) 0.066 
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Table 3.11 Population attributable fractions (AF) for binary outcomes [final model risk factor 
odds ratios (OR) recoded] from case-control subset where antimicrobial prescription data was 
known 
Risk factor OR AF model AF (95% CI) 
AF 
Pr(>|z|) 
Pet in home 1.4 0.05 (-0.09 - 0.2) 0.464 
>1 UTI last 6-months 43.0 0.35 (0.24 - 0.46) <0.001 
Female 10.4 0.53 (0.33 - 0.73) <0.001 
Age 65+ 4.1 0.18 (0.07 - 0.29) 0.002 
Diabetes 3.6 0.02 (-0.01 - 0.05) 0.282 
Other chronic disease 1.9 0.08 (-0.02 - 0.17) 0.112 
Doctor visit last 6-months 15.4 0.58 (0.39 - 0.78) <0.001 
Antibiotics last 3-months† 2.4 0.08 (0 - 0.16) 0.048 
Healthcare worker 1.3 0.01 (-0.05 - 0.07) >0.5 
Travelled to Asia 6.1 0.14 (0.06 - 0.22) <0.001 
Travelled to Africa 19.8 0.02 (-0.01 - 0.05) 0.111 
Sometimes/never wash hands before eating 0.9 -0.01 (-0.11 - 0.08) >0.5 
No contact with farm animals reported 2.6 0.26 (0.01 - 0.52) 0.045 
Contact with wild or other animals reported 3.3 0.04 (-0.01 - 0.08) 0.092 
†For case participants, this time-period was defined as prescriptions between 1 week and 3 
months prior to collection of urine sample from which the ESBL/ACBL isolate was cultured. This 
was to exclude antimicrobials prescribed for incident case infection. 
 
LASSO regression modelling 
Results of LASSO regression models are described below in Table 3.12. The ORs 
described here are based on coefficients from these regression models with more 
conservative constraints (min+1SE) or less conservative constraints (min). As noted in 
Table 3.12, recent antimicrobial use does not appear as a risk factor variable in the 
conservative prescription dataset model. 
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Table 3.12 LASSO/elastic net regression model outputs where coefficients for the logistic model 
were used to calculate odds ratios (OR) for risk factors at the minimum lambda (min) and at 
minimum lambda plus one standard error (min + 1SE) 
Risk factor variable 
OR 
λmin 
Questionnaire 
dataset 
OR 
λmin 
Prescription 
dataset 
OR 
λmin + 1SE 
Questionnaire 
dataset 
OR 
λmin + 1SE 
Prescription 
dataset 
>1 UTI last 6-months 28.3 21.4 10.8 12.7 
Doctor visit last 6-months 33.0 13.0 2.4 2.4 
Travel to Asia 22.0 6.7 2.3 1.7 
Other chronic disease 4.4 3.4 2.2 2.2 
Antibiotics last 3-monthsa 8.8 1.9† 2.0 None† 
Female 14.8 5.7 1.8 1.5 
Contact with wild or other animals 
reported 
1.2 1.8 1.3 1.4 
Cat/dog faeces seen in garden 6.2 2.3 1.1 None 
Often washes hands before 
eating 
2.3 2.3 1.1 1.1 
Travel to Africa 19.4 13.0 None 1.8 
a Variable different in questionnaire and prescription datasets; †For cases in this prescription 
dataset, this time-period was defined as prescriptions between 1 week and 3 months prior to 
collection of urine sample from which the ESBL/ACBL isolate was cultured. This was to exclude 
antimicrobials prescribed for incident case infection. 
 
Random forest regression 
Random forest regression was carried out on all 85 examined variables. The top 15 
variables from the questionnaire dataset that have the greatest decrease in either accuracy 
and/or Gini are described in Table 3.13. When these variables were examined for the 
prescription-only dataset, the most important variables for accurately predicting 
outcomes were: >1 UTI last 6-months, age, chronic disease score, and any chronic 
disease. The values for the decreases in accuracy were of the same order of magnitude as 
those shown in Table 3.13.  
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Table 3.13 Random forest regression of questionnaire dataset 
Variable Mean Decrease in Accuracy (x10-2) 
Mean Decrease 
in Gini (x10-2) 
>1 UTI last 6-months 4.63 7.17 
Antibiotics last 3-months 2.09 4.04 
Chronic disease score  1.62 3.83 
Handwashing: after feeding pet 0.39 3.64 
Handwashing: after petting/stroking pet 0.30 3.41 
Age 0.84 3.27 
Type of vet visit: last 6-months 0.50 2.75 
Pet type 0.29 2.62 
Travel to Asia 0.51 2.41 
Any treatment at vet: last 6-months 0.32 1.62 
Other chronic disease 0.62 1.39 
Doctor visit last 6-months 1.23 1.27 
Gender 1.42 1.17 
Any chronic disease 1.28 0.99 
Handwashing: before eating 0.10 4.52 
Handwashing: after sneezing or blowing nose 0.00 4.11 
Handwashing: after pet licks hands† 0.16 3.07 
Healthcare work 0.15 3.00 
Type of animal contact (non-pet)† 0.08 2.95 
Handwashing: before handling food†  0.00 2.53 
† Not significant (p ≤0.2) on univariate screening of variables 
 
Both the mean decrease in accuracy and the mean decrease in Gini described by the 
outputs of the random forest regression are measures of variable importance (Archer and 
Kimes 2008). An interpretation of the mean decrease in accuracy from Table 3.13 is: 
when the variable “>1 UTI last 6-months” was removed from the model, the model was 
less accurate at prediction. For example in Table 3.13, having >1 urinary tract had the 
highest mean decrease in accuracy (4.63 x 10-2) and was therefore the most important in 
assigning case vs control status. Random forest models for this dataset were consistently 
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better at assigning control status when compared to case, and this was described as class 
error. Class error was 0.38 for cases and 0.03 for controls.  
3.4.3 Clinical bacterial isolates 
From 141 clinical cases, clinical isolates were available from 132 people. The isolates from 
nine case people that were not available were reported as E. coli with an ESBL-producing 
phenotype based on results from the clinical microbiology laboratory (Labtests 
Auckland). Of the isolates that were available for sequencing, 126/132 were E. coli, 5/132 
were Klebsiella pneumoniae, and 1/132 was Morganella morganii; 113/132 were ESBL-
producing, and 12/132 had plasmid associated ACBL genes (excluding 4/131 ESBL-
producing E. coli or Klebsiella pneumoniae isolates that were also co-producers of ACBL). 
Species identification reported here are from results of both MALDI-TOF and whole 
genome sequencing. Seven isolates (all E. coli) had non-plasmid associated ACBL genes 
only [found using CARD (Jia et al. 2017)]. Genes for two ESBL enzymes (blaCTX-M-15 or 
blaCTX-M-27) were found in 68% (90/132) of all clinical bacterial isolates, and 87/106 (82%) 
of ESBL-containing E. coli isolates.  
E. coli isolates 
A summary of 103/126 (82%) E. coli isolates is found in Table 3.14, and phylogenies of 
these bacteria described by ribosomal MLST and whole genome MLST in Figures 3.1 
and 3.2 respectively. Fifteen sequence types had more than one bacterial isolate with that 
type, and the isolates from these sequence types are described in Table 3.14. Clermont 
extended MLST phylogenetic groupings (A to F) were assigned by Warwick MLST 
seven-gene scheme for E. coli (Clermont et al. 2014; Clermont et al. 2015). Group B2 
accounted for 65/126 (52%) of all E. coli isolates, group D accounted for 35/126 (28%) 
isolates, group B1 accounted for 10/126 (8%) isolates, group A accounted for 7/126 (6%), 
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and the remaining isolates were E, F, or not assigned. In phylogenetic group B2, there 
were eleven STs, with ST-12, ST-80, ST-131, ST-998, and ST-1193 all assigned to more 
than one isolate. In phylogenetic group D, there were seven STs, including ST38 and 
ST69. Bacterial isolate types not included in Table 3.14 accounted for 22 MLST (n=23 
isolates), and included an un-typed E. coli strain.  
In silico serotyping of O- :H-antigens and fimH adhesion typing was done through the 
CGE pipeline (Thomsen et al. 2016). Two O:H types were found in E. coli ST-131 isolates 
(n=47 isolates), with O25:H4 accounting for 31/47 (66%) of isolates, and O16:H5 
accounted for 16/47 (34%) of isolates. For ST-131 O25:H4 isolates, 30/31 (97%) were 
associated with fimH-30. For ST131 O16:H5, 15/16 (94%) were associated with fimH-41.  
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Table 3.14 Fifteen MLST types of E. coli from community acquired urinary tract infections in 
New Zealand (2015-2017) 
Phylogenetic 
group† 
Warwick 
MLST 
Proportion  
% (95% CI) 
  
E. coli isolates  
n (total =126) 
Associated ESBL 
genes 
(n isolates) 
Associated ACBL 
genes 
(n isolates) 
A 744 1.6 (0 - 3.8) 2 blaCTX-M-8 (n=1)      
blaCTX-M-14 (n=1)  
B1 410 1.6 (0 - 3.8) 2 blaCTX-M-15 (n=1)      
blaCTX-M-55 (n=1)  
B1 648 2.4 (0 – 5.0) 3 blaCTX-M-15 (n=2)      
blaCTX-M-55 (n=1)  
B1 345 1.6 (0 - 3.8) 2 blaCTX-M-14 (n=1) Chromosomal 
AmpC (n=1) 
B1 58 1.6 (0 - 3.8) 2 blaCTX-M-14 (n=1)      
blaCTX-M-55 (n=1)  
B2 12 2.4 (0 - 5) 3 blaCTX-M-15 (n=1) Chromosomal 
AmpC (n=2) 
B2 80 1.6 (0 - 3.8) 2  Chromosomal 
AmpC (n=2) 
B2 131 37.3 (28.9 - 45.7) 47 blaCTX-M-14 (n=2) blaCMY-2 (n=1)     
blaCTX-M-15 (n=21) blaCMY-60 (n=1)     
blaCTX-M-27 (n=24)  
B2 998 1.6 (0 - 3.8) 2 blaCTX-M-15 (n=2)  
B2 1193 4.0 (0.6 - 7.4) 5 blaCTX-M-15 (n=2) blaCMY-2 (n=2) 
Chromosomal 
AmpC (n=1) 
D 38 12.7 (6.9 - 18.5) 16 blaCTX-M-14 (n=1)  
    blaCTX-M-15 (n=7)  
    blaCTX-M-24 (n=1)  
    blaCTX-M-27 (n=6)  
D 69 6.3 (2.1 - 10.6) 8 blaCTX-M-14 (n=1) blaCMY-2 (n=1) 
    blaCTX-M-15 (n=2)  
    blaCTX-M-27 (n=3)  
    blaCTX-M-55 (n=1)  
D 349 1.6 (0 - 3.8) 2  blaCMY-2 (n=1) 
     blaDHA-1 (n=1) 
D 405 2.4 (0 – 5.0) 3 blaCTX-M-14 (n=1) Chromosomal 
AmpC (n=1) 
    blaCTX-M-15 (n=1)  
D 963 3.2 (0.1 - 6.2) 4  blaCMY-2 (n=4) 
    blaCTX-M-27 (n=2)  
†As in Clermont et al. (2015)  
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Non-E. coli isolates 
Four unique MLST were found in K. pneumoniae, with ST-562 isolated from more than 
one individual’s sample (n=2). Of all the K. pneumoniae isolates, 3/5 (60%) had a blaCTX-
M-15 gene; 1/5 (20%) was found to have a blaCTX-M-14 gene; and 1/5 (20%) was found to have 
a blaSHV-27 gene. An ACBL gene (blaDHA-1) was found in 1/5 (20%) of Klebsiella isolates. 
One community-acquired UTI included in this study had an isolate of Morganella 
morganii cultured from a urine sample. This isolate contained both ESBL and ACBL 
genes, blaVEB-1 and blaDHA-5 respectively, however blaDHA-5 is not considered plasmid 
associated in Morganella as blaDHA genes originate from Morganella species (Jacoby 2009). 
Antimicrobial susceptibility testing 
Combined disk tests (CDT) using cefotaxime and ceftazidime were used for phenotype 
confirmation of ESBL-production (Anonymous 2013a). ESBL phenotypic CDT assay 
results for E. coli isolates were positive with the ceftazidime (CAZ) test for 87/126 (69%) 
of isolates, and 103/125 (82%) of isolates were positive with the cefotaxime (CTX) test 
(one ACBL-producing isolate not tested against CTX). When ACBL isolates were not 
included, these proportions were 87/106 (82%) and 103/106 (97%) respectively, with three 
isolates positive on the CAZ test, but not on the CTX test. For Klebsiella pneumoniae 
isolates, all were positive with the CTX test, and 3/5 (60%) were positive with the CAZ 
test. The Morganella morganii isolate was positive with the CAZ test, but not the CTX 
test.  
Cefoxitin is used as a screening test (Table 3.1) for ACBL-producing isolates; however, 
in this study eligible isolates were tested for an ACBL-producing phenotype prior to 
screening against the panel of antimicrobials, which included cefoxitin. Of E. coli isolates 
resistant to cefoxitin, 22/33 (67%) phenotypically positive for ACBL using the D69C disk 
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assay (Halstead et al. 2012); 2/93 (2%) of E. coli isolates that were susceptible to cefoxitin 
were also were phenotypically positive for ACBL. When an isolate each of Klebsiella 
pneumoniae and M. morganii were included, 26/132 of clinical bacterial isolates were 
phenotypically positive for ACBL. Of these, 17/26 (65%) of isolates were found to have 
blaCMY or blaDHA genes. 
An MDR phenotype was observed in 76/132 (60%) of all clinical isolates. For E. coli, 
51/126 (40%) of isolates were resistant to beta-lactam, trimethoprim, and fluoroquinolone 
antimicrobials; 23/126 (18%) of isolates were resistant to beta-lactam, aminoglycoside, 
trimethoprim, and fluoroquinolone antimicrobials. Individual antimicrobial resistance 
rates for E. coli isolates are shown in Table 3.15.  
Table 3.15 Antimicrobial susceptibility test results from 126 clinical urinary E. coli isolates 
with an ESBL- and/or ACBL-producing phenotype from the NZ community (EUCAST 
2018) 
Antimicrobial (disk dose) Isolates resistant n 
Proportion resistant 
% (95% CI) 
Augmentin (amoxicillin 20ug + clavulanic acid 10ug) 70 55.6 (46.9 - 64.2%) 
Ampicillin (10ug) 121 96 (92.6 - 99.4%) 
Cephalexin (30ug) 121 96 (92.6 - 99.4%) 
Cefpodoxime (10ug) 125 99.2 (97.7 - 100%) 
Ceftriaxone (30ug) 115 91.3 (86.3 - 96.2%) 
Cefoxitin (30ug) 33 26.2 (18.5 - 33.9%) 
Mecillinam (10æg) 12 9.5 (4.4 - 14.6%) 
Ertapenem (10ug) 13 10.3 (5.0 - 15.6%) 
Amikacin (30ug) 2 1.6 (0 - 3.8%) 
Gentamicin (10ug) 45 35.7 (27.3 - 44.1%) 
Fosfomycin (200ug) 8 6.3 (2.1 - 10.6%) 
Trimethoprim (5ug) 86 68.3 (60.1 - 76.4%) 
Nitrofurantoin (100ug) 4 3.2 (0.1 - 6.2%) 
Norfloxacillin (10ug) 59 46.8 (38.1 - 55.5%) 
 
For E. coli ST131 isolates, 33/47 (70%) of isolates were resistant to norfloxacin, 17/21 
(81%) of those with blaCTX-M-15 genes and 14/24 (58%) of those with blaCTX-M-27 genes were 
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resistant to norfloxacin. Resistance to trimethoprim was found in 40/47 (85%) of these 
isolates, and resistance to gentamicin was found in 22/47 (47%) of ST131 isolates [11/21 
(52%) and 9/24 (38%) resistance for blaCTX-M-15 and blaCTX-M-27 containing isolates 
respectively]. All ST131 isolates were susceptible to nitrofurantoin, and 1/47 (2%) was 
resistant to fosfomycin. Antimicrobial resistance genes for E. coli isolates found through 
ResFinder are shown in the presence-absence matrix in Figure 3.2. All five K. pneumoniae 
isolates were resistant to ampicillin, cephalexin, cefpodoxime, ceftriaxone, and 
trimethoprim. None of these same isolates were resistant to mecillinam or amikacin. 
Antimicrobial resistance genes for K. pneumoniae isolates found through ResFinder are 
shown in a presence-absence matrix in Figure 3.3 (Zankari et al. 2012). 
Virulence genes 
Presence and absence of virulence genes found through VirulenceFinder database is 
shown in the purple presence-absence matrix in Figure 3.2 (Kaper et al. 2004; Joensen et 
al. 2014). An acid resistant genotype (glutamate decarboxylase) conferred by a gad gene 
was found in 125/126 (99%) of E. coli isolates. An increased serum survival genotype 
conferred by an iss gene was found in 78/126 (62%) of E. coli isolates. An adherence protein 
iha gene was found in 69/126 (55%) of E. coli isolates. A serine protease autotransporter 
sat gene was found in 62/126 (49%) of E. coli isolates. A plasmid-associated enterotoxin 
senB gene was found in 61/126 (48%) of E. coli isolates. 
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3.4.4 Phylogenies of clinical bacterial isolates 
Describing the relatedness of clinical bacterial isolates from case participants in this study 
is shown as whole genome MLSTs in Figures 3.2 and 3.3. The relationship between E. 
coli isolates are shown in Figures 3.1 (rMLST) and 3.2, and for Klebsiella pneumoniae in 
Figure 3.3
Figure 3.1 Neighbour joining tree of the ribosomal MLST 
(51 genes) of 126 clinical E. coli isolates with MLST and 
Clermont phylogrouping. 51 ribosomal genes used to 
construct distance matrix from which the tree was 
constructed using the Neighbour Joining method. 
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Figure 3.2 
Neighbour joining 
tree of the whole 
genome MLST of 
126 clinical E. coli 
isolates, from 2654 
shared-loci alleles 
(reference genome 
LT8144a) 
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3.5 Discussion  
Companion animals in the home were not found to be a risk factor for community-
acquired ESBL-/ACBL-producing urinary tract infections in this study. However, 
previous urinary tract infections, healthcare contact, and travel to Asia or Africa were 
associated with increased odds of having a community-acquired ESBL-/ACBL-
producing urinary tract infection. Gender (being female), being older, and having chronic 
disease were also associated with having a community-acquired ESBL-/ACBL-producing 
urinary tract infection. Variables not associated with increased risk included ethnicity, 
nearest school decile (used as a proxy for social deprivation), and whether or not someone 
lived in a rural or urban area. 
In general, the risk factors associated with increased odds of ESBL infection in this study 
have been previously described. There are a number of studies where acquisition of 
antimicrobial resistant bacteria is associated with travel to high-risk global regions, 
antimicrobial treatment while traveling, and/or gastrointestinal disease while traveling 
(Freeman et al. 2008; Rogers et al. 2014; Arcilla et al. 2017). Travel to high-risk global 
regions has been defined in other studies as travel to North Africa, the Indian 
subcontinent, southeast Asia, the Middle East, and China (Kennedy and Collignon 2010; 
Arcilla et al. 2017). These areas are associated with higher rates of gastrointestinal 
colonisation with ESBL-producing Enterobacteriaceae (Karanika et al. 2016), and is 
Figure 3.3 Neighbour joining tree of cgMLST of five clinical Klebsiella pneumoniae 
isolates, from 4254 shared-loci alleles (reference genome LT8007a) 
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associated with carriage in travellers returning from visiting such places (Arcilla et al. 
2017). In the study presented in this chapter, travel to Asia was significantly associated 
with having a UTI caused by ESBL- and/or ACBL-producing bacteria [adjusted OR = 9.9 
(95% CI 4.0 - 26.8); PAF = 0.14 (95% CI 0.07 - 0.21)]. Travel to Africa was only 
significantly associated with risk in the smaller government prescription dataset (Table 
3.8).  
As noted above, there was some internal disagreement noted between the models within 
this chapter when examining travel-associated risk factors. LASSO logistic regression 
modelling found increased odds associated with travel to Asia (all parameters and both 
datasets described in Table 3.12). However, travel to Africa was not associated with 
increased risk in the conservative model (min + 1SE) when using the questionnaire 
dataset. Travel to Asia (but not travel to Africa) was also among the top ten variables (in 
terms of effect on outcome) within the random forest regression. The recurrence of Asian 
travel in all these modelling modalities reinforces the inference of increased risk 
associated with travel to this continent within this study. As this finding reflects findings 
from other low-prevalence countries (Rogers et al. 2014; Karanika et al. 2016; Arcilla et 
al. 2017), it is likely to be widely applicable to the New Zealand population.  
Healthcare exposures, including antimicrobial treatment are well described as risk factors 
for carriage of ESBL-producing bacteria (Karanika et al. 2016). They have also been 
described in a study looking at risks for community-acquired infection, where healthcare 
exposure in the previous six-months, urinary tract infection in the previous year, and 
antimicrobial treatment in the previous six-months were all associated with increased risk 
(Rogers et al. 2014). All these risk factors were also identified by multiple modelling 
methods in the study presented in this chapter. However, antimicrobial treatment in 
81 
 
previous three-months was not found to be a risk factor in the more penalised LASSO 
regression model (λmin + 1 SE), although it was significantly associated with risks in other 
models. In multivariate regression models when prescription data was available (for the 
NHI subset of cases), an adjusted OR of 2.8 (95% CI 1.1 - 7.3) was observed for the risk 
factor of antimicrobial prescription in the previous three-months. This is less than the 
adjusted OR of 15.3 (95% CI 6.0 - 43.1) for the same risk factor when case participants self-
reported this exposure. This difference shows the importance of validating self-reporting 
of medication data, especially when it is considered an exposure of interest.  
The outputs from random forest regression and LASSO regression, where no differential 
weighting of variables to test specific hypotheses were imposed upon the models as 
compared to multivariate regression, varied slightly in the order of the most important 
variables for predicting the outcome. However, there were areas of crossover between 
these two model outputs, and the results of the multivariate logistic regression. The 
consistency of these findings indicates that they are likely non-spurious. The variables 
important to multivariate logistic regression, LASSO regression, and random forest 
regression were: (1) being over 65-years old; (2) being female; (3) having more than one 
urinary tract infection in the previous six-months; (4) travel to Africa and/or Asia in the 
previous 12-months; (5) contact with healthcare (as a patient) in the previous six-months; 
(6) contact with wild animals in the previous six-months; (7) having an “other” chronic 
disease (not asthma, diabetes, COPD, or cardiac disease); (8) not “always” washing 
hands before eating.  
Some variables identified in the random forest regression as important were not detected 
as significant in either the multivariate or the LASSO regressions. Some of these variables 
were related to companion animal contact (handwashing behaviour) and animal contact 
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with veterinary care (Table 3.13 for results of random forest and 3.4 for animal related 
univariate ORs). These findings may be spurious, but they also may indicate some low or 
marginal level of risk associated with animals, or indeed be a result of collinearity or 
interaction in the LASSO regression. Verification of collinearity/interaction may be 
possible but was not attempted here. As with other countries, it is likely that the 
prevalence of these bacteria will increase in both human and animal populations will 
increase in time, and therefore community-wide risk factors will change as a result 
(Nicolas-Chanoine et al. 2013).  
Companion animals were not found to be a risk for ESBL-/ACBL-producing infection. 
Along with the results of the case control study presented here, other studies have also 
not found pets to be a risk factor for non-healthcare associated ESBL carriage or infection 
(Rogers et al. 2014; Leonard et al. 2018). There was no substantial difference between the 
OR for having a pet in the home between the questionnaire dataset and the government 
prescription dataset [OR=0.8 (95% CI 0.4 – 1.9) and OR= 1.3 (95% CI 0.6 - 3.1) 
respectively], and these results are therefore internally consistent. 
Where bacterial isolates from the initial bacterial infection were available, over a third of 
isolates were E. coli ST131 [47/132 (36%) of all isolates and 47/126 (37%) of E. coli isolates]. 
This finding is consistent with previous reports on community-acquired infection in New 
Zealand (Dyet et al. 2014; Drinkovic et al. 2015; Heffernan et al. 2018). ST131 isolates 
were more resistant to norfloxacin and trimethoprim when compared to E. coli isolates as 
a whole (70% c.f. 47% for norfloxacin, and 85% c.f. 68% for trimethoprim). As a whole, the 
E. coli isolates in this study contained between one and 15 virulence genes (Figure 3.2). 
Many of these genes promote intestinal colonisation (e.g. gad found in 99% of isolates), 
and allow the bacteria to live commensally prior to invasion/colonisation/infection in the 
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lower urinary tract (Kaper et al. 2004; Schmidt et al. 2015). The bacterial factors enabling 
infection may be related to those contributing to subsequent infection (such as the 
virulence gene sat for an autotransporter toxin that was found in 49% of E. coli isolates) 
(Kaper et al. 2004). The findings presented in this chapter show that while there is 
substantial diversity among E. coli isolates causing UTI in the New Zealand community, 
these bacteria generally contain multiple AMR and virulence genes.  
There were a number of limitations within this study. Sources of bias in this study 
included known information (and possibly recall) biases associated with the 
questionnaire, non-response bias for cases, and the fact that missing data from the 
questionnaire was not imputed in this study. The most tangible of these biases was 
inaccurate reporting of antimicrobial use found for the subset of 70% (99/141) of case 
participants. Self-reporting of antimicrobial use in case participants provided an over-
estimate of the number of antimicrobial treatments in the six-months before their urinary 
tract infection [44% specificity of this question in questionnaire (Table 3.7)]. A 
comparable test was not performed for control participants, as the same prescription data 
was not available. Discrepancies in reporting prescription data have been reported 
elsewhere (West et al. 1995). However, the inverse of what was found in this study (i.e. 
under-reporting of prescriptions) was reported in West et al. (1995). This finding is likely 
due to both the wording of the questions within the questionnaire, and to other factors 
such as some uncertainty by participants about when their infection occurred (and this 
information was not available to help prompt them at the time of questionnaire delivery). 
The questionnaire used in this study asked case recipients to answer questions relating to 
time prior to their index case infection. However, it can be assumed that the majority of 
this over-reporting is related to people thinking of the prescription they received for the 
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index infection. In order to remove these prescriptions for contemporaneous UTI from 
the NHI prescription dataset, those filled within the seven-days prior to laboratory 
submission of urine were not included in the regression models. The assumption here was 
that people would be likely prescribed antimicrobials for symptomatic UTI (or after 
results of urine dipstick analysis) at the same time, and therefore start treatment before, 
the lab received a sample.  
Another limitation of this study is around the selection of controls. All controls were 
assumed to be non-carriers of ESBL/ACBL-E, although it is possible that up to 10% had 
faecal carriage of ESBL-E. coli (Woerther et al. 2013). In general, reports of carriage of 
ESBL-E varies between regions (4 - 46%), with a pooled prevalence from 66 studies of 14% 
(Karanika et al. 2016). However, the community carriage prevalence of ESBL/ACBL-E 
in New Zealand was not known at the time of this research, and too few control 
participants volunteered to give faecal samples to assess this in the cross-sectional part of 
the study (described further in Chapter 4). The general results of this study indicate that 
future work with a focus on community-level prevalence of ESBL-ACBL-producing 
bacteria is needed. 
In some studies, length of colonisation of ESBL-producing E. coli has been reported up to 
(or exceeding a year), resulting in a longer window for extra-intestinal colonisation and/or 
infection (Bar-Yoseph et al. 2016). In a study looking at acquisition associated with travel, 
11% of people who acquired an ESBL-producing E. coli were still carrying the same strain 
12-months later (Arcilla et al. 2017). The knowledge of time between travel and infection 
with ESBL-E is valuable information; however, this was not recorded in this study. 
Additionally, gathering exact details of travel, and any illness or treatments while 
travelling, would have been valuable in quantifying risk but were not collected as part of 
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this study but would have been valuable. Recent/prior gastrointestinal distress or 
medication with proton-pump inhibitors was not investigated in the study presented here, 
however should be included in future studies investigating community-acquired ESBL-
producing infections as they are well-described risk factors (Kuenzli et al. 2014; Arcilla et 
al. 2017). Alongside general carriage of these bacteria, an important contributor to 
multidrug resistance in a population of bacteria are the transferrable elements that allow 
for horizontal transmission of resistance genes. In the case of ESBL-/ACBL-producing 
Enterobacteriaceae, plasmids that carry blaESBL genes. Plasmids were not closely 
evaluated in this study, and no discrete plasmid isolation and/or sequencing was 
performed. This should be considered as a priority for future work in this area. 
3.6 Conclusions 
Although no pet-related factors were found to be significantly associated with ESBL- 
and/or ACBL-producing UTI in people, some of these factors may be part of a more 
complex dynamic where domestic animals are part of risk for human infection and/or 
carriage. It is also possible that pets in the home are a protective factor and their presence 
dilutes the resistant bacterial population in the home by acting as a source of non-resistant 
bacteria. The benefits of pet ownership can be immense, especially in older or vulnerable 
populations, and while zoonotic disease in general should be considered when having 
close contact with animals, the risk of transmission of ESBL-/ACBL-producing 
Enterobacteriaceae is low. 
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4  Transmission of extended spectrum beta-
lactamase- and AmpC beta-lactamase-producing 
Escherichia coli between people with a 
community-acquired urinary infection, their 
family, and pets in the household: The “resist-
home” 
4.1 Abstract 
The objective of this study was to evaluate transmission of extended spectrum beta-
lactamase Escherichia coli (ESBL-EC) or AmpC beta-lactamase E. coli (ACBL-EC) within 
households recruited in Chapter 3. From cases from these households, a bacterial culture 
of urine was performed as part of routine diagnostic work-up. In addition, faecal samples 
from people and pets in the household were collected and screened for ESBL- and/or 
ACBL-producing Enterobacteriaceae. E. coli isolate DNA from these households were 
sequenced on the Illumina HiSeq and MiSeq platforms. Comparative genomic analysis of 
E. coli genomes from households was conducted using nucleotide, whole genome, and 
pan-genome analyses. 
Twenty-three households were recruited for cross-sectional faecal sampling between 
December 2015 and January 2017. Twenty of these households submitted samples from 
pets, and 11 households submitted faecal samples from other people (non-case people) 
living in the home. Of these, seven households had family members and four had pets’ 
positive for ESBL-EC and/or ACBL-EC. Whole genome sequencing of 125 E. coli isolates 
from these 11 households (7-28 isolates per household) showed eight households (35%) 
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where more than one person or pet was positive for the same strain of ESBL- and/or 
ACBL-EC; two of these households included a pet sharing the same strain. In three 
households, different strains of ESBL- and/or ACBL-EC were cultured from each person 
or pet.  
In a third of households where a person acquired an ESBL-EC or ACBL-EC infection 
from the community, co-habiting people or pets also had genetically similar E. coli in their 
faeces. This suggests that the AMR bacteria circulate through homes, and contribute to 
community transmission of ESBL- or ACBL-producing E. coli. 
4.2 Introduction 
The home environment is a place of comfort and security. However, it is also a place for 
communities of potentially life-threatening microbes to be shared between human and 
(human or pet) family members. Antimicrobial resistant (AMR) bacteria are one such 
threat. The known promiscuity of some AMR-containing plasmids means they are found 
in a variety of bacterial strains, and therefore, may be carried in turn by diverse hosts 
(Mathers et al. 2015). 
Escherichia coli is a commensal organism, found both inside and outside the mammalian 
large intestine. It is commonly used as an indicator of faecal contamination (Edberg et al. 
2000); however, E. coli is also observed (along with other Enterobacteriaceae) as an 
oropharyngeal coloniser (Sokurenko et al. 1998; Lemon et al. 2010). Bacterial resistance 
to antimicrobials, namely resistance to extended spectrum cephalosporins by 
Enterobacteriaceae, results in infections that are difficult to treat (Levy and Marshall 
2004; Livermore et al. 2007). Since the turn of the 21st century, enzymes such as AmpC 
beta-lactamases (ACBL) and extended spectrum beta-lactamases (ESBL) in disease-
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causing bacteria have increasingly been reported, as discussed in Chapter 2 (Bradford 
2001; Toombs-Ruane et al. 2017). These bacteria are often resistant to multiple classes of 
antimicrobials, in addition to beta-lactams, and are therefore considered multidrug 
resistant (MDR) (Magiorakos et al. 2012).  
ESBL- and AmpC- producing Enterobacteriaceae, predominantly E. coli and to a lesser 
extent Klebsiella pneumoniae, are the most common cause of MDR urinary tract infections 
(UTI) in the New Zealand community (Heffernan et al. 2009; Drinkovic et al. 2015). 
Surveillance of these bacterial infections from 2011 to 2014 showed an increasing rate of 
these infections in New Zealand, especially in the Auckland regional district health board 
areas (Heffernan et al. 2013; Heffernan et al. 2018). In comparison to human infections, 
antimicrobial resistance surveillance data is lacking for clinical isolates from animals in 
New Zealand, although cephalosporin resistance (including ESBL-and AmpC-
production) has been found in bacterial isolates from companion animals (Karkaba et al. 
2017b; McMeekin et al. 2017).  
Animal to human transmission and human to animal transmission of AMR bacteria, mean 
that interventions such as therapeutic antimicrobial use (and therefore selective or altered 
colonisation of the individual’s microbiota) in either a pet or a person may affect the 
microbiome of those they live with. Sharing of genetically similar Staphylococcus aureus 
between pets and people in homes was observed in an MRSA study; carriage of clonal S. 
aureus at the same time was observed in 57% of positive humans and pets (van Balen et al. 
2017). The association had been also found with Staphylococcus species in other studies 
(Weese et al. 2006; Hanselman et al. 2009; Walther et al. 2012). Reverse zoonotic transfer 
has also been implicated in MRSA transfer events (van Duijkeren et al. 2004; Weese et 
al. 2006). 
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Human to human transmission within the household is also an important pathway for 
spread of AMR bacterial spread within the community. Family members can share faecal 
and oral bacteria (Shaffer and Lozupone 2018), and the likelihood of sharing means that 
potentially pathogenic bacteria harboured quiescently by one individual could be shared 
with (and consequently cause disease in) a person (or pet) that they live with (Löhr et al. 
2013; Holmes et al. 2016). In a country with relatively low prevalence of carriage of 
extended-spectrum beta-lactamase producing E. coli such as New Zealand (Rogers et al. 
2014; Rogers et al. 2015), the family may be an important reservoir of antimicrobial 
resistant bacteria (Karkaba et al. 2017b). Isolation of closely related AMR bacteria from 
co-habiting people has been demonstrated with methicillin resistant S. aureus (Miller et 
al. 2012; Knox et al. 2015). Transmission of ESBL-producing ST131 E. coli within 
households has also been observed (Johnson et al. 2016), in addition to pathogenic urinary 
tract infection-causing E. coli being shared between sexual partners (Ulleryd et al. 2015). 
4.2.1 Study objective 
This study aimed to evaluate transmission of ESBL- or ACBL-producing 
Enterobacteriaceae, and more specifically E. coli, between individuals within households. 
The particular focus of the extended molecular work presented here is around the 
genomic relatedness of bacterial isolates from within households where E. coli was 
cultured from multiple individuals (people and/or pets) including an index person with 
an ESBL- or ACBL-producing urinary tract infection.  
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4.3 Materials and methods 
4.3.1 Study population 
Ethics 
Human ethics for this study was granted by the New Zealand Health and Disability Ethics 
Committee (HDEC) under the reference 15/CEN/47; this study was part of a larger 
prospective case control study looking at risks for community-acquired UTI (Chapter 3). 
Animal ethics for sampling via rectal swab from cats was granted by Massey University 
Animal Ethics Committee under the reference 15/35.  
Study participants 
Case participants were recruited into this study from laboratory results submitted to 
Labtests Auckland (Healthscope) between 28 September 2015 and 5 September 2017 in 
the Auckland and Northland regions of New Zealand. Prospective case participants were 
eligible if this was a new infection with an ESBL- or AmpC-producing 
Enterobacteriaceae, they had no record of being hospitalised overnight in the previous 12-
months, and they did not have a residential address in a residential elder care facility or 
rest home. Case participants were invited to submit faecal samples from themselves, as 
well as any cat, dogs, or birds that lived with them in the home. Invitations were also given 
to other members of the household to submit a faecal sample at the same time as case 
participants, and their pets. Information on age, gender/sex, recent antimicrobial 
treatment, and recent hospitalisation/veterinary care was also requested with submission 
of faecal samples. 
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4.3.2 Microbiologic methods 
Bacterial culture and identification  
Bacterial isolates from index case people’s urine samples were collected as part of 
Chapter 3 (see Section 3.3.3 for methodology). Faecal samples were collected either by 
direct sampling with a rectal swab (cats only, where litter trays were not used) using an 
agar transport swab (Copan Diagnostics, Mantua, Italy), and by collection of faecal 
samples by the participant with instructions provided on how they could do this cleanly. 
Some direction on using cling-film and a sterile faecal collection bottle was provided to 
participants for sample collection. Only one faecal sample was accepted for each 
individual; where more than one was provided, the most recent sample was used. Once 
collected, these samples were stored between approximately 4 and 15 °C for up to 48 
hours before being plated onto culture media as described in Appendix I. These culture 
media were: plain MacConkey (BD Difco™ supplied by Fort Richard, Auckland, New 
Zealand); MacConkey with 1mg/L cefotaxime sodium (Sigma-Aldrich, St. Louis, 
U.S.A); MacConkey with 1mg/L ceftazidime pentahydrate (Sigma-Aldrich); 
chromogenic ESBL CHROMagar (CAC, Becton Dickinson, Heidelberg, Germany; 
supplied by Fort Richard). Rectal swabs taken from cats, and faecal samples from pet 
birds were enriched in buffered peptone water for approximately 16 hours at 35 (+/- 1) °C 
before being plated onto culture media. Agar was incubated overnight at 35 (+/-1) °C for 
20 to 24 hours and single colonies were selected for subculture onto Columbia horse blood 
agar (Fort Richard). These colonies were chosen if they were lactose fermenting on 
MacConkey agar, or pink/purple/blue on ESBL CHROMagar. Up to eight colonies were 
chosen for subculture from each faecal sample, two from each plate, and labelled ‘a’ to 
‘g’. Identification of bacterial species from both urine and faeces was done using matrix 
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assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry 
[faecal isolates (bioMérieux, Marcy-l'Étoile, France), urine isolates (Bruker, Billerica, 
U.S.A.)]. Both faecal and urinary isolates were subsequently stored as pure cultures in 
glycerol broth suspensions (in-house formulation, mEpiLab) at -80°C prior to subsequent 
phenotypic tests (where appropriate) and genomic DNA extraction.  
Antimicrobial susceptibility tests 
Faecal isolates were tested for an ESBL-producing phenotype using three paired disk 
tests [D62C ESBL cefotaxime Paired ID disks (Mast group, Bootle, U.K.; supplied by 
Fort Richard, Auckland, New Zealand); D63C ESBL cefepime Paired ID disks (Mast 
group); D64C ESBL ceftazidime Paired ID disks (Mast group)]. Urine isolates were 
tested for ESBL-producing phenotype using two paired disk tests [D62C ESBL 
cefotaxime Paired ID disks (Mast group); D64C ESBL ceftazidime Paired ID disks (Mast 
group)]. All isolates were also tested for an AmpC-producing phenotype using a three-
disk comparison assay [D69C AmpC disk test (Mast group)]. Subsequent antimicrobial 
susceptibility testing of both urine and faecal isolates was performed using the panel and 
as described in section 3.3.2. 
4.3.3 Extraction and preparation of genomic DNA for sequencing 
Isolates were selected for whole genome sequencing where multiple individuals in a 
household had at least one ESBL- or AmpC- producing Enterobacteriaceae isolate 
(Figure 4.1). Bacterial isolates were cultured from frozen (stored at -80°C in 
nutrient/glycerol broth) and a single colony subcultured and incubated for 20-24 hours at 
35 (+/- 1) °C, after an initial revival on Colombia horse blood agar. Extraction of genomic 
DNA was done using a QIAamp DNA mini kit (Qiagen, Hilden, Germany) according to 
a modified and optimised version of the tissue/bacterial colony protocol as described in 
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Appendix II. A PCR-grade water eluate was used as part of the final step in DNA 
extraction, and this was stored at -20 °C prior to library preparation. Fluorescent 
spectrometry (Qubit 2.0 Fluorometer, Thermo Fisher Scientific, Waltham, U.S.A) was 
used to assess the quality of the extraction, and DNA was normalised to a concentration 
of 0.16ug/mL prior to preparation of libraries (Nextera library preparation kits, Illumina 
Inc., San Diego, U.S.A.). Libraries were prepared at Massey Genome service (when 
sequenced on Illumina MiSeq, by Massey Genome Service), or at mEpiLab (when 
sequenced on Illumina HiSeq at Otago Genomic and Bioinformatics facility). Assessment 
of library quality and fragment size distribution was performed by an automated gel 
fragment analyser [Labchip GX Touch HT (PerkinElmer, PerkinElmer, Waltham, 
U.S.A.); or 2100 BioAnalyzer (Agilent, Santa Clara, U.S.A.)]. 
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Figure 4.1 Bacterial genome outputs workflow: selection of households and processing of isolates 
after sequencing  
 
4.3.4 Next generation sequencing  
Sequencing of genomic DNA was performed by Massey Genome Services (New Zealand 
Genomics Limited, Massey University, New Zealand) for Illumina MiSeq; Illumina 
HiSeq was performed by Otago Genomic and Bioinformatics facility (New Zealand 
Genomics Limited, Otago University, New Zealand). 
4.3.5 Data analysis 
Sample and isolate metadata was stored on a MySQL database (Oracle Corporation, CA, 
USA), and Microsoft Access used for input interface and query management (Microsoft 
Corporation, WA, USA); data were manipulated in R-Studio, (Boston MA, USA; R 
version 3.4.3 https://www.r-project.org) and Excel (Microsoft corporation, WA, USA). 
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4.3.6 Bioinformatics 
Raw sequence reads were assessed for quality, and processed [using QCtool: Solexxa, 
PhiX adapter removal (Truglio 2016)] prior to going into the Nullarbor bioinformatics 
pipeline (Seemann et al. 2016). Assembly of genomes in this pipeline (“careful” mode in 
Nullarbor) was done using SPAdes assembler (Bankevich et al. 2012) and single 
nucleotide polymorphism (SNP) analysis executed by Snippy (Seemann 2015). All 
assembled genomes were checked for quality of assembly using the outputs from 
Nullarbor, and Quast software (Gurevich et al. 2013). These assembled genomes were 
uploaded to the Centre for Genomic Epidemiology pipeline, from which 
resistance/virulence/plasmid-associated genes were found, and O:H/fim-antigen typing 
was done [http://www.genomicepidemiology.org (Thomsen et al. 2016)]. The flow of 
isolates described here is shown in Figure 4.1. A summary of sequencing and assembly of 
genomes in this chapter can be found in Appendix III (Table 6.2). 
4.3.6.1 SNP and whole genome trees 
Initially, SNP analysis of E. coli isolates included in this study was performed using 
reference genome JJ1886 for E. coli isolates (Andersen et al. 2013). Individual SNP 
alignments were subsequently repeated for households, and internal references chosen 
from the clade with isolates from more than one individual person (see Table 4.1 for each 
household’s isolates). This isolate was chosen based upon having a low number of 
contiguous DNA consensus regions (contigs) and a high number of coding sequences 
(CDS). Whole genome multi-locus sequence typing (wgMLST) was executed using Fast-
GeP, gene prediction and comparison software (Zhang et al. 2018). A nexus tree output 
was constructed using Splitstree, then transformed in a Neighbour Joining nexus tree 
(Huson 1998; Rambaut 2007) for upload to EvolView for annotation and presentation 
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(He et al. 2016). An E. coli isolate (LT1090b) was removed from SNP and wgMLST 
analysis from household HH0039 due to no blaESBL or blaAmpC beta-lactamase gene 
detected in ResFinder. 
4.3.6.2  Phylogenetic analysis of E. coli ST131 isolates 
For ST131 isolates from four households (HH0024, HH0039, HH0040 and HH0086), 
the reference genome JJ1886 was used for SNP alignment and subsequent BEAST 
phylogeny; this reference is an E. coli isolate originating from a urinary tract infection, and 
a contains a blaCTX-M-15 gene conferring an ESBL- producing phenotype (Andersen et al. 
2013). 
Using the output of Snippy, a core SNP alignment of E. coli from three households 
(HH0024, HH0039 and HH0040) was prepared using BEAUTi 2, with exact collection 
dates known for these isolates (Bouckaert et al. 2014). Different combinations of 
substitution models [general time reversible model (GTR), Hasegawa, Kishino and Yano 
model (HKY)], molecular clocks (strict, relaxed lognormal), and population models 
(constant coalescent, coalescent extended-Bayesian skyline) were run. The models were 
compared using Tracer [version 1.6 (Rambaut et al. 2018)]. A strict molecular clock, with 
a general time reversible (GTR) substitution model and coalescent constant population 
was used for the final BEAST model (Bouckaert et al. 2014). Gubbins was used to 
estimate the effect of recombination that might have occurred between these isolates 
(Croucher et al. 2015). Posterior support, effective sample size (ESS), and model trace 
stability were used to assess model performance. An ESS of less than 200 for the posterior 
was considered minimum criteria for model fitness. 
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Table 4.1 Summary of reference genomes used for intra-household core SNP comparison of isolates [using Snippy 3.0 (Seemann 2015)] 
Household 
Reference 
Isolate ID 
Read 
depth 
GC 
content 
(%) 
Assembled 
genome size 
(bp) 
Assembled 
contigs 
(n) 
CDS 
(n) 
Pair-wise 
core-SNP distance 
(reads to 
reference) 
HH0008 LT1003c 94 50.7 5434577 553 5001 8 
HH0015 LT1030h2 61 50.0 5168471 249 4749 2 
HH0016 LT1029f 133 49.9 5245042 312 4904 4 
HH0024 LT8179a 81 51.1 5160657 178 4808 41 
HH0026 LT1044g 118 50.3 4985966 219 4653 7 
HH0039 LT1090f 113 50.8 5188047 305 4888 3 
HH0040 LT1082f 107 50.3 5164692 181 4840 3 
HH0048 LT1097g 129 51.1 5151025 339 4709 1 
HH0064 LT8371a 120 50.2 5153473 338 4694 2 
HH0065 LT1132e 122 50.0 5118820 288 4715 2 
HH0086 LT1173e 199 50.1 5141055 298 4744 8 
bp: base pairs 
CDS: coding sequences 
Read depth expressed as fold-coverage: each base sequenced on average the depth number of times
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4.4 Results 
4.4.1 Summary 
Sixty-eight of the case households in Chapter 3 owned a pet (68/141; 48%) and 117 had 
other family members (117/141; 83%). Faecal samples from 23 of these households were 
collected between December 2015 and January 2017, and were collected between 31 and 
180 days after the case UTI sample was collected (median time = 63 days, mean time = 77 
days). Twenty of these 23 households submitted samples from pets, and 11 of the 23 
households submitted faecal samples from other people (non-case people) living in the 
home.  
In 15 households, at least one cat was sampled and in 11 households, at least one dog was 
sampled. Of the 11 households with in-contact people sampled, 1/11 had three in-contact 
people, and 10/11 had one in-contact person sampled. Fourteen households had more 
than one individual with an Enterobacteriaceae isolate(s) with ESBL-/ ACBL-producing 
phenotype collected from them, and there were 11 households where ESBL- / ACBL-
producing E. coli was cultured from more than one individual. An overview of samples 
submitted from pets and people in these fourteen households is described in Table 4.3, 
with 11 households where E. coli was cultured from more than one individual as indicated 
in the table footnotes. In the14 households described in Table 4.3, 13/14 index case 
persons did not live alone. However, in-contact people were only sampled from 10/14 
households. In the 11 households positive for ESBL- / ACBL-producing E. coli, no-one 
lived alone, and in-contact people were sampled from 10/11 (91%) of households.  
The index case person (from whom an ESBL- / ACBL-producing bacteria was cultured) 
in all households were predominantly female (21/23; 91%), and 10/23 (43%) were over 65-
years-old. In the households where more than one person/pet was positive for an ESBL- 
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/ ACBL-producing E. coli, 9/11 (82%) of the incident case people were female and 7/11 
(64%) were over 65-years-old. The ages of all (n=13) in-contact people sampled ranged (in 
groups) from 10-to-19 years-old to 70-to-79 years-old; the same age range was observed 
in ESBL- / ACBL-producing E. coli positive in-contact people. Sampled pet ages from all 
households ranged from 1-to-11 years old for dogs, and 1-to-17 years old for cats; an age 
range of 1-to-8 years-old was observed for dogs positive for ESBL- / ACBL-producing E. 
coli (no cats were positive).  
Table 4.2 Summary of sources of samples from fourteen households  
Household 
People 
sampled in 
household‡  
Total ESBL- or 
AmpC-producing 
Enterobacteriaceae 
Isolates 
People with 
ESBL or AmpC 
phenotype 
isolates 
Pets 
sampled in 
household 
Pets with 
ESBL or 
AmpC 
phenotype 
isolates 
Total 
individuals 
with ESBL 
or AmpC 
phenotype 
isolates 
HH0008 2 7 2 3
a 0 2* 
HH0015 2 7 2 None NA 2* 
HH0016 2 14 2 None NA 2* 
HH0024 2 14 2 2
ab 0 2* 
HH0026 1 12 1 1
b 1b 2* 
HH0039 2 10 2 1
a 0 2* 
HH0040 4 28 4 3
ab 0 4* 
HH0048 2 9 1 2
b 1b 2* 
HH0053 1 11 1 2
ab 1a† 2 
HH0064 2 10 1 2
ab 2a†, b 3* 
HH0065 2 13 1 1
b 1b 2* 
HH0071 1 12 1
† 1a 1a 2 
HH0077 1 9 1 1
b 1b† 2 
HH0086 2 8 1 2
b 1b 2* 
‡ Faecal and/or urine sample; each person counted once; † Not E. coli; * Samples cultured ESBL-
ACBL- E. coli and included in further genomic analysis; a cat; b dog 
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From 23 households, 17 case participants submitted a faecal sample (17/23; 74%), and 
16/17 reported receiving antimicrobial treatment in the prior six-months including any 
treatment for index UTI. In all 23 households, 30 people submitted faecal samples; in the 
14 households outlined in Table 4.3, faecal samples were obtained from 26 people.  
Of these people from households summarised in Table 4.3, 12/26 (46%) were in-contact 
people, and the remainder were incident case people (n=14). Antimicrobial treatment was 
reported in two in-contact people, both from households where more than one person/pet 
was positive for ESBL- / ACBL-producing E. coli, however only one of these people were 
positive for ESBL- / ACBL-producing E. coli. Twenty of 23 households (87%) submitted 
at least one sample from a pet, 7/23 (30%) submitted samples from both cats and dogs, 
8/23 (35%) submitted from only cats and 5/23 (16%) submitted from only dogs. 
Antimicrobial treatment prior to faecal sampling was reported in pets from 14/23 (61%) 
households; eight individual pets from 7/11 (64%) households where more than one 
person/pet was positive for ESBL- / ACBL-producing E. coli.  
Antimicrobial treatment was also reported in households as part of the Chapter 3 
questionnaire. As reported by the incident case person, someone other than the case 
person was treated with antimicrobials in the six-months prior to the case infection in 
5/20 (25%) households. Two of these households were included in the 11 households 
where more than one person/pet was positive for ESBL- / ACBL-producing E. coli. In 
these same 20 households, no in-contact people (as reported by the case person) had a 
multidrug resistant infection. Hospitalisation of an in-contact person in the previous year 
was reported in 6/20 (30%) households, while 4/11 (36%) households where more than 
one person/pet was positive for ESBL- / ACBL-producing E. coli reported the same.  
102 
 
4.4.2 Bacterial isolate descriptions 
Eleven households had more than one individual with at least one E. coli isolate containing 
the beta-lactamase genes: blaESBL, blaCMY or blaDHA, as determined by whole genome 
sequencing. A description of the genomics of those isolates (n=125) is found in Figures 
4.2, 4.3, and 4.4. Resistance genes present in the isolates from the 14 households 
described in Table 4.3 are summarised in Table 4.4. A more complete overview of all 
resistance genes in the 11 households’ E. coli isolates is given in Table 4.6. Antimicrobial 
resistance genes are described in Figure 4.2, 4.3, and 4.4 and Table 4.4 and 4.6). The 
multilocus sequence types (determined via Nullarbor) ST-131 and ST-69 were found in 
more than one household; ST-131 was found in four households and accounted for 47/125 
(46%) of isolates described here. Characterisation of E. coli isolates is described further in 
Tables 4.5.  
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Table 4.3 ESBL, ACBL and plasmid-mediated quinolone resistance (PMQR) genes from 
Enterobacteriaceae in 14 households  
Household 
Total 
isolates 
N 
Bacterial 
isolates 
(n/N) 
ESBL gene(s) 
(n/N) 
ACBL gene(s) 
(n/N) 
PMQR gene(s)  
(n/N) 
Number of people 
or pets sampled 
where E .coli had 
ESBL/ACBL 
genes (n) 
HH0008 7 E. coli (7/7) blaCTX-M-15 (7/7) none (7/7) QnrS1 (7/7) 2 
HH0015 7 E. coli (7/7) none (7/7) blaCMY-2 (7/7) none (7/7) 2 
HH0016 14 E. coli (14/14) blaCTX-M-15 (14/14) none (14/14) none (14/14) 2 
HH0024 14 E. coli (14/14) blaCTX-M-14 (2/14); 
blaCTX-M-27 (12/14)  
none (14/14) none (14/14) 2 
HH0026 12 E. coli (11/12); 
Citrobacter spp 
(1/12) 
blaCTX-M-15 (8/12); 
blaCTX-M-27 (3/12); 
none (1/12)  
blaCMY-83 
(1/12);  
none (11/12) 
QnrB10 (1/12); 
none (11/12) 
2 
HH0039 10 E. coli (10/10) blaCTX-M-27 (9/10); 
none (1/10)  
none (10/10) none (10/10) 2 
HH0040 28 E. coli (28/28) blaCTX-M-15 (28/28) none (28/28) none (28/28) 4 
HH0048 9 E. coli (9/9) blaCTX-M-14 (7/9); 
blaCTX-M-15 (1/9);  
none (1/9)  
blaDHA-1 (1/9); 
none (8/9) 
QnrB4 (1/9); 
none (8/9) 
2 
HH0053 11 E. coli (11/11) blaCTX-M-15 (4/11); 
none (7/11)  
none (11/11) QnrB4 (2/11); 
QnrS1 (4/11); 
none (5/11) 
1 
HH0064 10 E. coli (5/10); 
Enterobacter 
spp (5/10) 
none (10/10) blaCMY-2 (5/10); 
none (5/10)  
none (10/10) 2 
HH0065 13 E. coli (13/13) blaCTX-M-15 (3/13); 
blaCTX-M-27 (8/13); 
none (2/13)  
blaCMY-2 (2/13); 
none (11/13) 
none (13/13) 2 
HH0071 12 E. coli (8/12); 
Escherichia spp 
(4/12) 
blaCTX-M-15 (1/12); 
blaCTX-M-27 (7/12); 
none (4/12)  
blaCMY-2 (4/12); 
none (8/12) 
none (12/12) 1 
HH0077 9 E. coli (2/9); 
Citrobacter spp 
(7/9) 
blaCTX-M-15 (1/9);  
none (8/9)  
blaCMY-71 (1/9); 
none (8/9) 
QnrB6 (1/9); 
none (8/9) 
1 
HH0086 8 E. coli (8/8) blaCTX-M-27 
(8/8) 
none (8/8) none (8/8) 2 
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Table 4.4 A summary of multi-locus sequence type (MLST) and serotying (O- and H- antigen) 
of 125 E. coli isolates from 11 households 
Household 
Total 
E. coli isolates 
N 
MLST 
(n/N) 
Serotype  
(O-antigen) 
Serotype (H-
antigen) 
HH0008 7 ST-69(6/7); 
ST-58 (1/7)  
O15 (6/7); 
O8 (1/7) 
H18 (6/7); 
H25 (1/7) 
HH0015 7 ST-963 (7/7) NT (7/7) H18 (7/7) 
HH0016 14 ST-500 (14/14) O8 (14/14) H5 (14/14) 
HH0024 14 ST-131 (12/14); 
ST-648(2/14)  
O25 (12/14); 
O1 (2/14) 
H4 (12/14); 
H6 (2/14) 
HH0026 11 ST-617(8/11); 
ST-1193 (3/11)  
O89 (8/11); 
O75 (3/11) 
H10 (8/11); 
H5 (3/11) 
HH0039 9 ST-131 (9/9) O25 (9/9) H4 (9/9) 
HH0040 28 ST-131 (28/28) O25 (28/28) H4 (28/28) 
HH0048 9 ST-38 (7/9); 
ST-4553 (1/9); 
ST-538(1/9)  
O2 (7/9); 
O83 (1/9); 
O13 (1/9) 
H30 (7/9); 
H42 (1/9); 
H4 (1/9) 
HH0064 5 ST-2541 (4/5); 
ST-963 (1/5)  
NT (5/5) H7 (4/5); 
H18 (1/5) 
HH0065 13 ST-69 (8/13); 
ST-746 (3/13); 
ST-10 (1/13); 
ST-2541 (1/13)  
O15 (8/13); 
NT (5/13) 
H2 (8/13); 
H37 (3/13); 
H40 (1/13); 
H7 (1/13) 
HH0086 8 ST-131 (8/8) O16 (8/8) H5 (8/8) 
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Figure 4.2 Whole genome MLST 
of 125 E. coli isolates from 11 
households; 3022 alleles used to 
construct distance matrix in Fast-
GeP genome profiler (Zhang et al. 
2018).  
 
Reference genome LT1099f. A 
black circle to the left of the tip 
label indicates that the isolate was 
from the index case urine sample. 
The colour strip in the tip label 
(isolate ID) denotes household. 
Presence and absence of plasmid, 
resistance, and virulence genes as 
found in PlasmidFinder 
(green/yellow matrix), ResFinder 
(orange/yellow matrix), and 
VirulenceFinder (purple/yellow 
matrix) respectively (Zankari et 
al. 2012; Carattoli et al. 2014; 
Joensen et al. 2014) 
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Table 4.5 Antimicrobial resistance genes in 125 E. coli isolates from 11 households 
  Isolates with resistance genes  
Resistance gene type Antimicrobial resistance class  n/Total isolates Proportion (95%CI) 
aac-type Aminoglycoside 
and/or 
fluoroquinolone 
 
67/125 53.6% (45 - 62%) 
aad-type Aminoglycoside 86/125 68.8% (61 - 77%) 
str-type Aminoglycoside 57/125 45.6% (37 - 54%) 
blaESBL-type Beta-lactam  
(incl. 3rd & 4th 
generation 
cephalosporins) 
 
109/125 87.2% (81 - 93%) 
blaAmpC-type Beta-lactam  
(incl. 3rd & 4th 
generation 
cephalosporins) 
 
18/125 14.4% (8 - 21%) 
blaOXA-type  
(non-ESBL)  
Beta-lactam  49/125 39.2% (31 - 48%) 
blaTEM-type  
(non-ESBL)  
Beta-lactam  38/125 30.4% (22 - 38%) 
dfrA-type Trimethoprim 97/125 77.6% (70 - 85%) 
sul-type Sulphonamide 104/125 83.2% (77 - 90%) 
Qnr-type Fluoroquinolone 8/125 6.4% (2 - 11%) 
mph-type Macrolide 92/125 73.6% (66 - 81%) 
tet-type Tetracycline 76/125 60.8% (52 - 69%) 
catB-type Phenicol 43/125 34.4% (26 - 43%) 
 
No colistin or carbapenem resistance genes were found in this dataset. A multidrug 
resistance genotype was observed in the majority of isolates with 106/125 isolates [84.8%; 
95% CI (79 – 91%)] having more than two classes of resistance genes. 
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Table 4.6 Results of antimicrobial susceptibility testing of 125 E. coli isolates from 11 
households 
Antimicrobial  Number of isolates (n/Total isolates) 
Proportion  
 (95%CI) 
Ampicillin R 122/125 97.6% (95 - 100%) 
Cephalexin R 117/125 93.6% (89 - 98%) 
Cefpodoxime R 125/125 100% (100 - 100%) 
Ceftriaxone M 1/125 0.8% (0 - 2%) 
 R 123/125 98.4% (96 - 100%) 
Mecillinam R 4/125 3.2% (0 - 6%) 
Ertapenem M 18/125 14.4% (8 - 21%) 
 R 0/125 0% (0 – 0%) 
Augmentin R 42/125 33.6% (25 - 42%) 
Cefoxitin R 32/125 25.6% (18 - 33%) 
Gentamicin R 38/125 30.4% (22 - 38%) 
Amikacin R 0/125 0% (0 – 0%) 
Norfloxacillin M 5/125 4.0% (1 - 7%) 
 R 76/125 60.8% (52 - 69%) 
Trimethoprim M 1/125 0.8% (0 - 2%) 
 R 96/125 76.8% (69 - 84%) 
Nitrofurantoin R 14/125 11.2% (6 - 17%) 
Fosfomycin R 6/125 4.8% (1 - 9%) 
M: moderate susceptibility; R: resistant (see Table 4.1 for respective zone diameters and disk 
concentrations) 
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A multidrug resistant phenotype was observed in 87/125 isolates [69.6%; 95% CI (62 – 
78%)]. The overviews given for resistance genotype (Table 4.6) and phenotype (Table 
4.7) do not illustrate the household-level patterns. See Figure 4.2 for associations of 
resistance and virulence genotypes for households. This figure also shows the whole 
genome MLST for all 125 E. coli isolates made using 3022 alleles. 
 
Table 4.7 Virulence genes in 125 E. coli isolates from 11 households 
Virulence gene Gene description† Isolates with gene N 
Proportion 
(95%CI) 
gad Glutamate decarboxylase 121 96.8% (94 - 100%) 
iss Increased serum survival 82 65.6% (57 - 74%) 
sat Secreted autotransporter toxin 67 53.6% (45 - 62%) 
iha Adherence protein 65 52.0% (43 - 61%) 
senB Plasmid associated enterotoxin 41 32.8% (25 - 41%) 
lpfA Long polar fimbriae 37 29.6% (22 - 38%) 
eilA HilA–like regulator 32 25.6% (18 - 33%) 
†References: (Shin et al. 2001; Kaper et al. 2004; Sheikh et al. 2006; Wiles et al. 2008; Joensen 
et al. 2014) 
 
Virulence genes were identified by VirulenceFinder and the seven most common genes 
are shown in Table 4.8; genes air, astA, capU, eatA, cnf1, iroN, nfaE, ireA, vat and celb 
were also present in isolates at frequencies of less than 25% of isolates. These genes were 
not investigated in detail, and here serve to provide non-AMR gene similarity between 
isolates, and as shown in Figure 4.2 clonal faecal and urinary isolates had a similar 
virulence gene profile. 
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Pair ended sequence reads from each E. coli isolate in these 11 households was compared 
to a reference selected from that household (Table 4.1). These comparisons were made 
using SNPs, and the resultant trees are presented in Figure 4.3 for individual households, 
and Figure 4.4 for E. coli ST-131 isolates from these households. As shown in Figure 4.3, 
clonal isolates were cultured from more than one person in six households [6/11; 55% (95% 
CI 25-84%)], and from a person and a pet in two households [2/20; 10% (95% CI 0-23%)].  
4.4.3 Phylogenetic analysis of ST-131 isolates 
Using isolates from three households’ E. coli ST-131 isolates, a BEAST analysis on the 
SNP alignment (with and without recombinant sections removed) was performed using a 
GTR substitution model. This model identified intra-cluster common ancestors within 
the year preceding, with an inter-cluster shared common ancestor eight years preceding 
(95% CI 2.9-13.6 years). A mean posterior for this model was -722.401 (ESS = 71). The 
resultant tree is not presented here, due to overall low ESS (<200) for all parameters in 
all tested models. Evolutionary phylogenies were also attempted for each individual 
household, however as no model was able converge on tree height or posterior trace 
values, the results are not presented here. 
.
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Figure 4.3 Household Neighbour-Joining SNP trees for 125 ESBL- and/or ACBL-producing E. coli isolates from 11 households (range 5-28 per household). Reference genomes 
for core SNP alignments given in Table 4.2 and full SNP distances for these figures are in Appendix VI. 
Household HH0008, scale 0.1 = 2 SNPs;  
Household HH0015, scale 0.1 = 20 SNPs;  
Household HH0016, scale 0.1 = 2 SNPs;  
Household HH0024, scale 0.1 = 1 x 104 SNPs;  
Household HH0026, scale 0.1 =1 x 104 SNPs;  
Household HH0039, scale 1 = 2 SNPs; 
Household HH0040, scale 1 = 10 SNPs,  
Household HH0048, scale 0.1 = 1 x 104 SNPs;  
Household HH0064, scale 0.1 = 1 x 104 SNPs; 
Household HH0065, scale 0.1 = 2 x 104 SNPs;  
Household HH0086, scale 0.1 = 10 SNPs  
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Figure 4.4 Neighbour Joining tree of core SNP phylogeny of E. coli ST-131 isolates from four households. Core SNP alignment using 12,454 SNPs  
Scale 0.1 = 1.2 x 103 reference genome JJ1886; SNP distance matrix and tree generated using Snippy (Seemann 2015). 
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4.5 Discussion 
This study is an important first step in examining household in-contacts of people with 
clinical ESBL-/ACBL-producing infections in New Zealand. Transmission of ESBL-
/ACBL- producing bacteria is likely to have occurred in 8/23 (35%) investigated 
households. However, this varies whether looking at households where in-contact people 
were sampled, or where in-contact pets were sampled. In 55% (6/11) of the former, the 
same strain of ESBL-/ACBL- producing E. coli was cultured from more than one person 
in the household, while this was only true for 10% (2/20) of households where pets were 
sampled. 
The results of this study are comparable to other studies, where carriage of similar AMR 
genes/bacteria have been found in family members or couples (Alam et al. 2015; Johnson 
et al. 2016). However, in a study examining travel-associated acquisition of ESBL-
producing Enterobacteriaceae, transmission of bacteria on to other people was found in 
8% (13/168) of households (Arcilla et al. 2017). Long-term transmission risk was also 
observed in an outbreak of ESBL-producing Klebsiella pneumoniae, where carriage of these 
bacteria by one individual in a home was a source for the rest of the family (Löhr et al. 
2013).  
Intestinal carriage of MDR Enterobacteriaceae has been described as a significant risk for 
subsequent infection with MDR bacteria (Woerther et al. 2013; Giannella et al. 2014). It 
is very likely that the proportion of New Zealanders who carry ESBL-E coli in their faecal 
microbiota will continue to rise in the coming years, as it has in other countries (Karanika 
et al. 2016). Benchmarking prevalence of ESBL-producing bacteria in the community 
could be a useful first step for ongoing surveillance. This was not assessed in the current 
study, although it could be noted that at least 11% (2/17) of in-contact people carried an 
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ESBL-producing E. coli un-related to the index UTI in this study. However, the actual 
prevalence rate is likely to be lower, as prevalence less than 6% has been reported in 
Europe and the Americas (Karanika et al. 2016).  
Pets have been described in previous studies as carrying clonal ESBL-E. coli along with 
humans in their house, and in some cases being affected by clinical UTI (Johnson et al. 
2016). A better understanding of AMR transmission dynamics between people and pets 
may have been possible if the study design had allowed for sampling at sequential time-
points. The dogs that were positive for faecal ESBL-producing E. coli may have picked up 
these bacteria from the environment, or they may have picked it up from their owners. 
The results presented here show that they are at least a reservoir for infectious AMR 
pathogens. It is of note that none of the animals positive for the same bacteria as the 
humans in the household were cats, although more households had a cat sampled (15 
households with at least one cat in comparison to 11 households with at least one dog 
sampled). 
Hygiene around the home, between partners, parents and children, and between pets and 
their owners is likely a factor in the transmission of the MDR bacteria isolated in this 
study (Ulleryd et al. 2015; Johnson et al. 2016). In New Zealand, clinical infections with 
multidrug resistant E. coli occur in pets, but at unknown and assumed low rates (Karkaba 
et al. 2017b; McMeekin et al. 2017). Isolates of E. coli collected from dog faecal samples 
in two different households were a different MLST from the clinical case, and both dogs 
carried multiple unique AMR bacteria in their faeces. While the MLST types isolated 
from the faecal samples of these dogs were not commonly associated with community-
acquired infection in New Zealand, the enzyme-coding genes (blaCTX-M-15; blaCTX-M-14) 
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were those also found predominantly in human infection in New Zealand (Heffernan et 
al. 2013; Heffernan et al. 2018). 
Genomic similarities between isolates within households are reflected in the allelic profile 
of the isolates clustered using whole genome MLST, and in the SNP differences when 
compared to a reference. For example, in household HH0040, less than five SNPs were 
found between isolates from different individuals, and 12 SNPs were found between all 
28 isolates cultured from this household. Other studies examining similar datasets of 
closely related or clonal ESBL-EC isolates within households have found high similarity 
between isolates from individuals (Johnson et al. 2016; Torres et al. 2018). It is of note 
that four households (where more than one individual was positive for ESBL-/ACBL-
producing E. coli) were positive for ST-131. Adaptations to support human gut carriage 
(such as virulence genes like gad that improve survival in an acidic stomach) may be a 
contributor to the global success of certain bacteria (especially epidemic clades such as 
ST-131), however these may also reflect the relative proportion of these isolates in the 
clinical case population described in Chapter 3 (Nicolas-Chanoine et al. 2014).  
A superficial analysis of the genomics presented here suggests that horizontal gene 
transfer (via plasmids) between bacteria has occurred in some individuals. This was not 
explored experimentally within this study, although there is potential for this to have 
occurred with the ACBL gene blaCMY-2 in household HH0064 (see Figure 4.3). This also 
highlights the value of collecting and sequencing multiple isolates from faecal samples. 
Discrete plasmids were not assembled through the bioinformatics pipeline; however, 
large plasmid genes (and related plasmid types) were identified and reported. Long read 
sequencing of plasmids would be required to confirm and compare plasmids isolated from 
different bacteria to make any inferences regarding horizontal gene transfer. Evidence of 
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transmissibility of plasmids from cultured bacteria to a donor organism (via conjugation) 
would also be required for any assertions around intra-person (and therefore inter-
person) transmission of resistance genetics to be made.  
A limitation to the study presented here is that transmission within households cannot be 
examined by a cross-sectional methodology. Consequently, this is often assessed through 
mathematical modelling in addition to observational studies (Arcilla et al. 2017; 
Haverkate et al. 2017). Within a longitudinal study of post-acquisition carriage of ESBL-
producing Enterobacteriaceae, results were used for a transmission model that calculated 
a 12% probability of household transmission of ESBL-producing Enterobacteriaceae from 
a positive person to a negative person in the home (Arcilla et al. 2017).  
The results presented in this chapter identify that some “sharing” of ESBL-/ACBL-
producing bacteria within households is likely, even though transmission dynamics 
cannot be inferred from the cross-sectional design used here. However, evolutionary 
evidence from three ST-131-containing households suggests a common ancestor for 
introduction of ESBL-/ACBL- producing E. coli into the home within the year before 
faecal sampling period, and this date does not appear to pre-date the index urinary tract 
infection by more than three to six months. However, the poor posterior support for this 
model means that any inference taken from this should be made with caution. Although 
estimations of common ancestor dates were also attempted for clonal isolates within each 
household individually, the models were also not sufficiently robust to make inferences. 
Within a different study design (e.g. longitudinal case study, or cohort study), sampling 
over a longer time-period may make such inference possible. 
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Another important limitation to this study is around sample collection. As study 
participants collected their own faecal samples, it is possible that they unintentionally 
spiked samples with other people’s E. coli during collection. This would mean that the 
results reported here over-represent the proportion of households where individuals 
carried the same ESBL-/ACBL-producing bacteria. Cases recruited into this study were 
also likely to have self-selected for submission of faecal samples and may have been 
specifically concerned about the possibility of pets being a carrier of AMR bacteria. As 
this cross-sectional study was nested within a larger case control study, some of the 
limitations affecting that study (see Chapter 3) also apply here. This includes a lack of 
medical histories for participants in this study, with limited oral accounts were only 
available for case participants. 
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4.6 Conclusions 
In a home environment where one person has a sample positive for ESBL- or ACBL-
producing E. coli (be it carriage or a clinical infection), other members of the family may 
also harbour the AMR bacteria. The results presented here suggest that companion 
animals (specifically dogs) are potential vectors of ESBL-producing E. coli, but pets are 
likely to be less important vectors than other people living in the home. Longitudinal 
studies are required to examine the relationship between pets and the carriage rates of 
these bacteria in household environments. Two pets were shown to carry the same 
bacterial strain as that which caused a UTI in a person living with that pet. However, 
potential human-to-human spread appears more common in this study, where in 2/20 
(10%) of homes, pets carried the same strain as the case person compared with 6/11 (55%) 
of households were another person (other than index case) carried the same strain. The 
results of this study suggest that transmission occurs through contact between people (or 
people and pets) after an introduction event or through exposure to the same source of 
AMR bacterial isolate, although this does not preclude the presence of other 
strains/species of AMR bacteria in a person or household. As the prevalence of individual 
carriage increases, perhaps the household level is the basal unit from which preventative 
or AMR bacterial depopulation interventions should be targeted.   
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5  New Zealand community-acquired extended 
spectrum beta-lactamase-producing Escherichia 
coli ST-131 in a global context 
5.1 Abstract 
E. coli ST-131 has facilitated the rise and perpetuation of extended spectrum beta-
lactamase enzymes (ESBL) around the globe. It has become the predominant ESBL-
producing strain in human clinical infections in New Zealand, as it has in many other 
countries. This study describes community-acquired clinical isolates (n=48) from New 
Zealand in the context of isolates from around the world. The other isolates examined in 
this chapter (i.e. not from New Zealand community-acquired urinary-tract infections 
collected as part of Chapter 3) were all E. coli ST-131 (n=188) and collected from human 
and animal sources between 2004 and 2015. The New Zealand community-acquired 
isolates were collected between 2015 and 2017. Core and accessory genome and core 
nucleotide alignments were described and analysed using multiple methods including 
evolutionary phylogenetic analyses. Of isolates from community-acquired UTIs in New 
Zealand included in this study, 63% were ST-131 serotype O25:H4 (fimH-30 clade C). 
Isolates clustered in clade A (O16:H5-fimH-41) were predominantly from New Zealand 
community sources [Chapter 3 (64%)], and these isolates were estimated to share a 
common ancestor between 2003 and 2004. E. coli ST-131 appears to have come into New 
Zealand in multiple introductions and both clade A and clade C appear to be dominant 
within the New Zealand community. 
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5.2 Introduction 
Escherichia coli ST-131 is an important, dominant, and pervasive pathogenic strain 
(Nicolas-Chanoine et al. 2014; Petty et al. 2014). It is a substantial cause of antimicrobial 
resistant extra-intestinal infections, and often harbours mobile genetic elements with 
genes encoding extended-spectrum beta-lactamase (ESBL) or AmpC beta-lactamase 
(ACBL), along with other resistance genes such as those for fluoroquinolone resistance 
(Petty et al. 2014; Kakkanat et al. 2017). Since the early 21st century, pathogenic strains of 
ESBL-producing E. coli have risen in prevalence around the globe (Livermore et al. 2007; 
Johnson et al. 2010). ST-131 has also been recognised as the cause of more than 50% of the 
ESBL-producing infections in New Zealand (Heffernan et al. 2013; Heffernan et al. 2018), 
and represented 37% of the E. coli cultured from clinical urinary tract infections (UTI) 
from case participants recruited for the case control study described in Chapter 3. Along 
with associations with community-acquired UTIs, this strain is also associated with 
serious infections such as sepsis (Harris et al. 2018). 
E. coli ST-131 is classified within the Clermont phylogroup B2, and ST-131 fits within the 
Warwick MLST scheme (Clermont et al. 2015). Isolate types within phylogroup B2 (also 
called ribotype B2) are often associated with extraintestinal infections such as UTIs 
(Johnson et al. 2001; Bidet et al. 2007; Clermont et al. 2015). ST-131 can be further 
subdivided into three clades (A, B and C), and these are defined by different fimH pili 
adhesin and chromosomal quinolone resistance genes alongside phylogenetic clustering 
(Petty et al. 2014). Fluoroquinolone use in the 1980s may have been a driver of the 
dominance and spread of pathogenic ST-131 around the world, as this appears to have 
coincided with an increase in point mutations relating to fluoroquinolone resistance 
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(Petty et al. 2014). A common ancestor for all clades of ST-131 is estimated to have been 
in the late 19th century (Stoesser et al. 2016). 
In animal populations, ST-131 has been cultured from both clinical and non-clinical 
samples in companion animals (Johnson et al. 2009; Ewers et al. 2010; Karkaba et al. 2013; 
Haenni et al. 2014; Belas et al. 2018). This ST was also cultured from the faecal sample of 
a dog living in the home of a person who had a community-acquired UTI caused by ST-
131 E. coli as described in Chapter 4 of this thesis. More recently, ST-131 has also been 
found in the poultry supply chain, including in meat (Johnson et al. 2017; Liu et al. 2018). 
It has, however, been less commonly cultured from other food-producing animals (Ewers 
et al. 2012; Afema et al. 2018). Its importance is therefore largely in human populations, 
and the ability of the bacteria to be passively carried in the gastrointestinal tract as well as 
being a pathogen outside the gastrointestinal tract (Woerther et al. 2013). 
The objective of this study was to describe the genetics of E. coli ST-131 from community-
acquired infections in New Zealand and to give a global context for these isolates. 
5.3 Materials and methods 
5.3.1 New Zealand community isolates 
Forty-eight New Zealand clinical isolates were selected after multi-locus sequence typing 
as part of the Nullarbor bioinformatics pipeline (Seemann et al. 2016). These isolates were 
from clinical urinary tract infections and collected as part of a case control study in 
Chapter 3 (including metadata) and the ethical approval for that study was granted by 
the Health and Disability Ethics Committee of New Zealand under the approval number 
15/CEN/47.  
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5.3.2 Search strategy for other isolates 
Searches of the NCBI sequence read archive (SRA) database were made between 6-11th 
December 2017 and 8-11th June 2018 (https://trace.ncbi.nlm.nih.gov/Traces/sra/). 
Search terms included “O25:H4”, “E. coli ST131”, “ST 131”, “ST-131”, and “ST131”. 
5.3.3 Inclusion criteria 
Pre-processing criteria 
Isolates were considered eligible for download from the SRA database if they were from 
projects registered with NCBI where multiple isolates were potentially eligible for 
inclusion. An attempt was made to sample from across the years available, and to ensure 
as many isolates as possible were collected near the time the isolates collected and 
described in Chapter 3 were collected. For all other isolates, pair-ended sequence reads 
were downloaded via the SRA toolkit at NCBI (SRA toolkit https://github.com/ncbi/sra-
tools). Selection of isolates to download was made in an ad-hoc manner for those from 
reads in BioProject PRJEB4681. Forty isolates were chosen, initially one from each year 
(2002 to 2012), then 16 isolates were selected from 2012, two each year from 2008 to 
2011, and one from each year 2003-2007. 
Post-processing criteria 
Isolates were excluded if they were not E. coli, had low average depth coverage (read 
depth <40 fold), poor assembly (genome size and Kraken database comparison indicative 
of not being E. coli, >1000 contigs), if the isolate was not ST-131 [as either indicated by 
SRA database metadata, or as a result of processing with the Nullarbor pipeline (Seemann 
et al. 2016)], if the isolate did not have an ESBL or plasmid-associated AmpC-beta 
lactamase (Wood and Salzberg 2014). Fifteen isolates were excluded due to poor quality, 
72 downloaded isolates were not ST-131, and the remainder (n=90) were excluded due to 
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absence of AmpC beta-lactamase (ACBL) and/or ESBL gene(s) detected on a ResFinder 
search as part of the Nullarbor pipeline (Zankari et al. 2012; Seemann et al. 2016). From 
the six BioProjects where reads were downloaded from the SRA database (a total of 365 
isolates downloaded), 66 isolates from PRJDB3868 were eligible for inclusion (from Japan 
and Nepal, collected in 2014); 35 isolates from PRJNA297860 were eligible for inclusion 
(from Thailand, Venezuela, France, Taiwan, Spain, Cambodia, Canada, Laos, and UK 
collected between 2008 and 2011); 8 from PRJEB23663 were ST-131 (from Germany 
collected between 2010 and 2014), 13 from PRJEB4681 (from the UK, collected between 
2004 and 2012); 24 from PRJNA327820 (USA collected between 2008 and 2014); 42 
from PRJNA327820 (Singapore, Australia and New Zealand collected between 2014 and 
2015). Forty-eight isolates collected from cases recruited into the case-control study as 
described in Chapter 3 were included in these analyses, and further a description of the 
process from collection to sequencing can be found in Section 3.3.4, Section 4.3.3, and 
Section 4.3.4.  
5.3.4 Bioinformatics 
Assembly and annotation 
All sequenced pair-ended DNA reads (Illumina HiSeq or MiSeq platforms) were 
trimmed [Trimmomatic (Bolger et al. 2014)], and processed within the Nullarbor 
bioinformatics pipeline [version 1.20 (Seemann et al. 2016)]. Reads were assessed for 
quality using genome size, read depth and GC% (along with other measures of sequence 
quality via Nullarbor). Assembly of genomes in this pipeline was done using SPAdes 
assembler [SPAdes version 3.10.0 (Bankevich et al. 2012)] and single nucleotide 
polymorphism (SNP) analysis executed by Snippy [version 3.1 (Seemann 2015)]. Initial 
SNP analysis was performed using the reference genome JJ1886 (Andersen et al. 2013). 
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Assembled genomes were uploaded to the Centre for Genomic Epidemiology pipeline 
(http://www.genomicepidemiology.org, 1 July 2018), from which resistance, virulence, 
and plasmid-associated genes were identified [using ResFinder, VirulenceFinder, and 
PlasmidFinder respectively (Zankari et al. 2012; Carattoli et al. 2014; Joensen et al. 2014)], 
and O:H/fim-antigen typing was also done subsequently within this tool (Thomsen et al. 
2016). Annotation of assembled genomes was done using Prokka [Prokka version 1.11 
(Seemann 2014)]. A summary of Chapter 5 isolates can be found in Appendix III (Table 
6.3). 
Gene-based analysis 
Serotyping, fim-antigen typing, resistance gene identification, virulence gene 
identification, was carried out using the CGE pipeline (Resfinder, PlasmidFinder, and 
VirulenceFinder) (Zankari et al. 2012; Carattoli et al. 2014; Joensen et al. 2014; Thomsen 
et al. 2016). Whole genome MLST (wgMLST) using Fast-GeP genome profiler (Zhang 
et al. 2018), using LT8144a (an ST-131 isolates) as the reference genome, the same 
reference genome as used in whole genome MLST as described in Chapter 3. A pan-
genome was provided by Roary from the Prokka-annotated genomes (using default 
settings), and this provided the gene presence/absence outputs for pan-genome heat 
maps and subsequent trait analysis [Roary version 8.0 and Scoary (Page et al. 2015; 
Brynildsrud et al. 2016)]. 
A Nexus tree output of wgMLST was constructed using SplitsTree, then transformed 
into a Neighbour Joining tree (Huson 1998; Rambaut 2007) for upload to EvolView 
(http://www.evolgenius.info/evolview/) for annotation and presentation (He et al. 
2016).  
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Clades A, B, and C were determined by isolates clustering in the generated SNP 
phylogenetic tree with other isolates previously determined as that clade [in Harris et al. 
(2018)], and by clustering of the fimH-type where the majority of isolates were fimH-41 
(clade A), fimH-22 (clade B), or fimH-30 (clade C) as described in Petty et al. (2014). 
Statistical association between travel and phylogeny of clade A isolates 
Whole genome MLST of clade A isolates from Chapter 3 was performed using Fast-GeP 
(Zhang et al. 2018). The distance matrix (from alleles) was used, along with binary 
metadata on whether or not the person from whom the isolate was collected reported 
travelling outside New Zealand in the previous year (collected as part of the questionnaire 
in Chapter 3). Permutational analysis of variance (PERMANOVA) was performed in 
Rstudio (r-studio.com; R version 3.4.3 https://www.r-project.org) to compute F-
statistics across all groups to compare within group and between group variance 
(Anderson 2001). PERMANOVA was used to assess whether wgMLST allelic profiles 
differed between travel and non-travel groups, implemented in Rstudio, to identify if 
there was a distinct New Zealand community cluster (i.e. a cluster not associated with 
travel) within the clade A isolates. 
Genomics, SNP alignment and evolutionary phylogeny of isolates 
Nucleotide variation (core SNP) between genomes was performed as part of the 
Nullarbor pipeline using the reference genome JJ1886, an ESBL-producing E. coli ST-131 
isolate (Andersen et al. 2013; Seemann et al. 2016). For evolutionary phylogenetic models 
of isolates in clade A, a SNP core alignment to an internal reference (MER102) from this 
dataset was performed using Snippy (Seemann 2015), and this was used for the Bayesian 
models to generate an evolutionary phylogeny [BEAST 2 (Bouckaert et al. 2014)]. This 
isolate was selected based upon having a low number of contiguous DNA consensus 
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regions (contigs) and a high number of coding sequences (CDS). Recombination of 
genomes was estimated using Gubbins on full SNP alignment outputs from Snippy 
(Croucher et al. 2015). Gubbins was run using default parameters, with a GTR 
substitution model and FastML used for maximum likelihood tree; these outputs (e.g. 
variant site estimates) were visualised in Phandango (Ashkenazy et al. 2012; Hadfield et 
al. 2018).  
The output of Gubbins (full SNP alignment with recombinant sections removed) was the 
basis for the BEAST models. Model comparison was made using Tracer (Rambaut et al. 
2018). The models described in Table 5.1 show the parameters used in generating various 
models.   
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Table 5.1 Model parameters for BEAST phylogenetic models for 25 E coli ST-131 clade A 
isolates 
Model  Site model Clock model Priors 
1 GTR Strict Constant coalescent 
2 GTR Relaxed lognormal Constant coalescent 
3 GTR Strict Coalescent extended-Bayesian skyline 
4 HKY Strict Constant coalescent 
5 HKY Relaxed lognormal Constant coalescent 
6 HKY Strict Coalescent extended-Bayesian skyline 
GTR: general time reversible model, HKY: Hasegawa, Kishino and Yano model 
Due to the large number of isolates in clade C (n=201), a selection of 35 isolates were 
chosen based on distribution across the clade as ascertained by wgMLST in order to 
represent the diversity within the clade, and also on the quality of reads. These 35 isolates 
were combined with all isolates collected from New Zealand, and the same methodology 
used for clade A was used for these isolates. BEAST evolutionary models 1 to 4 were 
applied to this dataset (as per Table 5.1). The date of collection for isolates were given to 
the nearest date; if only year was known, the date was estimated to be half-way through 
the given year.  
5.4 Results 
5.4.1 Summary of isolates 
A total of 236 isolates were included in analyses for this study, 24/236 (11%) were from 
the Americas (collected between 2008 and 2014), 109/236 (46%) were from Asia 
(collected between 2006 and 2015), 61/236 (26%) were from Australasia (collected 
between 2014 and 2017), 42/236 (18%) were from Europe (collected between 2004 and 
2014). No isolates were from Africa or the Middle East. Twenty-five isolates were 
collected between the years 2004-2009, 138 isolates were collected between 2010 and 
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2014, and 73 isolates were collected between 2015 and 2017. The majority of isolates were 
from human sources (231/236; 98%), and the remainder were from animal sources (either 
poultry or an unspecified animal). There were 48 isolates included in this study from the 
case control study described in Chapter 3. A brief description of select metadata relating 
to these isolates is given (where available) in Table 5.2.  
Table 5.2 Description of select metadata for 48 NZ community-acquired E. coli ST-131 
isolates 
 Total 
(n/N) 
Proportion 
% (95% CI) 
Female 46/47 98 (94 - 100) 
Age:  
- 16 to 44 years 12/47 26 (13 - 38) 
- 45 to 64 years 16/47 34 (20 - 48) 
- 65 years and over 19/47 40 (26 - 54) 
Any travel in previous year 27/46 59 (47 - 75) 
- Travel to Africa 3/46 7 (0 - 14) 
- Travel to Asia 10/46 22 (10 - 34) 
Antibiotics: 
- Previous 3 to 6 months  4/31† 13 (1 - 25) 
- Previous 3 months 12/31† 39 (22 - 56) 
†Missing data described in Chapter 3 
Travel to Asia or Africa were found to increase the odds of having a urinary tract infection 
in the case control study (Chapter 3), so travel status of the person from whom those 48 
isolates was cultured is described here. This travel status was known for 46/48 of the New 
Zealand community-acquired isolates from Chapter 3. Of these, 19/46 (41%) of isolates 
were from people who had not travelled outside NZ in the previous 12-months. Asian or 
African travel in the previous 12-months was reported from 28% of people (13/46). Where 
people lived with others (40/46; 87%), four individuals had not travelled in the previous 
12-months, although someone else in their house had travelled outside New Zealand. The 
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48 isolates from people in New Zealand are highlighted in Section 5.4.3 with travel 
metadata included in figures in this section. Records were available for antimicrobial 
prescriptions for 31/48 (65%) of the people from whom New Zealand community-
associated isolates originated. Of these, 15/31 (48%) had no record of antimicrobial 
prescription in the previous six months, 12/31 (39%) came from people who had their most 
recent antimicrobial prescription in the previous three months, and 4/31 (13%) had the 
most recent prescription in the previous three to six months. 
5.4.2 Gene based results for E. coli ST-131 isolates 
Shown in Figure 5.1 are descriptions of plasmid, ESBL and virulence genes. In this figure, 
a whole genome MLST (wgMLST) using 3011 genes was used to create a distance matrix 
and subsequent neighbour joining tree for 256 E. coli isolates. In this figure, ESBL and 
ACBL genes are described alongside other acquired resistance genes found in the 
assembled genomes. The most commonly found ESBL gene in these isolates was blaCTX-
M-15 (171/236; 72%). Other ESBL and ACBL genes found in these isolates were blaCTX-M-
14 (12/236; 5%), blaCTX-M-27 (43/236; 18%), blaCMY-2 without a blaESBL gene (7/236; 3%), a 
blaESBL plus blaCMY-2 (4/236; 2%), a blaESBL plus blaDHA-1 (1/236; 0.4%), and a blaESBL plus 
blaCMY-60 (1/236; 0.4%). Of the 48 NZ isolates from Chapter 3, 22/48 (46%) had the 
blaCTX-M-15 ESBL gene. The other two ESBL genes found among these isolates were 
blaCTX-M-27 (24/48; 50%), and blaCTX-M-14 (2/48; 4%). 
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Table 5.3 A description of five virulence genes in 236 E. coli ST-131 isolates 
Gene Description Reference Association 
Isolates with 
gene  
N (%) 
gad Glutamate decarboxylase (Shin et al. 2001; Kaper et 
al. 2004) 
Survival in acid 235 (99.6) 
iha Adherence protein (Joensen et al. 2014)  227 (96.2) 
iss Increased serum survival (Joensen et al. 2014)  211 (89.4) 
sat Secreted autotransporter toxin (Kaper et al. 2004; Wiles et 
al. 2008) 
ExPEC, UPEC 218 (92.4) 
senB Plasmid associated enterotoxin (Joensen et al. 2014)  124 (52.5) 
fimH Type 1 pili (Wiles et al. 2008) ExPEC, UPEC 235 (99.6) 
ExPEC: extra-intestinal pathogenic E. coli, UPEC: urinary pathogenic E. coli 
Three virulence genes (gad, iss, and sat) associated with extraintestinal pathogenicity 
were found in the majority of these isolates, with 213/236 having all three of these genes. 
A description of the function of these genes is found in Table 5.3. Five virulence genes 
(gad, iha, iss, sat and senB) were found in 94/236 isolates. Presence-absence matrices of 
all virulence genes found using VirulenceFinder for the 236 isolates is shown in Figure 
5.1. 
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A neighbour joining tree of the whole genome MLST is given in Figure 5.2 with a pan-
genome of these isolates where 3603 core genes (identified by Roary) and 13713 total 
genes are shown in a heat map based on presence and absence of these genes. The isolates 
cluster into three clades, and these clades (A/B/C) are shown in the colour bar in Figure 
5.2. 
Twenty-five isolates clustered into clade A. The serotypes for this clade were O16:H5 
(21/25) and included New Zealand clinical isolates (Chapter 3), and isolates from 
Cambodia, Spain, and Australia. The remaining 4/25 isolates were serotype O25:H4 and 
all were from Singapore; 20/21 O16:H5 isolates had the fimH-41 antigen, and 2/4 each 
had fimH-41 and fimH-30 in the O25:H4 isolates.  
Clade B and C isolates were initially examined together, then separately for evolutionary 
analysis. In these two groups were 211 isolates, the majority (201/211) were in clade C. 
All ten isolates of group B were an O25:H4 serotype; 7/10 were fimH-22, 2/10 fimH-30 
and 1/10 were fimH-27. In clade C, 195/201 isolates were O25:H4 fimH-30; 3/201 isolates 
were H4 (O-unknown type) and fimH-30; 2/201 isolates were O16:H5 fimH-41; 1/201 
isolates was O25 H-unknown type fimH-30. 
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Figure 5.1 Whole genome 
MLST Neighbour Joining tree 
from 236 E. coli isolates; 3011 
alleles [Genome profiler: Fast 
GeP (Zhang et al. 2018)].  
 
Region/country of origin of 
isolates is given by the colour 
bar. Presence-absence of 
Plasmid replicon genes, 
resistance genes, and virulence 
genes as reported from Centre 
for Genomic Epidemiology 
bacterial analysis pipeline 
(Zankari et al. 2012; 
Carattoli et al. 2014; Joensen 
et al. 2014; Thomsen et al. 
2016). Region of origin: NZ 
(green), Australia (red), USA 
(orange), South East Asia – 
Thailand, Cambodia, Laos, 
Singapore (blue), South and 
East Asia – Japan, Taiwan, 
Nepal (brown), Europe – UK, 
Germany, Spain (purple) 
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Figure 5.2 Pan-genome of 236 ST-131 E. coli isolates using 13713 genes; 3603 core genes, 224 soft-core genes, 1534 
shell genes, 8314 cloud genes. Neighbour-joining tree (unrooted) from whole genome MLST (Figure 5.1 and using 3011 
alleles ), genome output from pan-genome presence-absence matrix [Roary version 8.0 (Page et al. 2015)] 
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5.4.3 SNP analysis and evolutionary phylogeny for E. coli ST-131 isolates 
A core-SNP analysis was generated which clustered isolates into three distinct clades (A, 
B, and C). Within this dataset using the reference genome JJ1886, 14949 SNPs were found 
among the 236 isolates. A NeighborNet tree of the core-SNP alignment output is shown 
in Figure 5.3. Individual Snippy core alignments for each separate clade are shown in 
Figure 5.4 where 6558 SNPs were used for the NeighborNet of 25 clade A isolates, 7940 
SNPs for 10 clade B isolates, and 5505 SNPs for 201 clade C isolates. The same source 
core SNP phylogeny shown in Figure 5.3 is also used for Figure 5.5, and this core-SNP 
analysis was used to compare the phylogenetic relationship of New Zealand isolates with 
other non-New Zealand isolates. However, in Figure 5.5, country of origin and travel 
metadata of the people from whom the isolate was collected (where known) were included 
in the figure. A core-SNP alignment of clade A was performed in preparation for 
evolutionary phylogenetic analysis using an internal reference genome (MER102); 8225 
SNPs made up this core alignment and in each isolate ≥94.63% bases aligned to the 
reference (full alignment used for subsequent BEAST models).  
  
Figure 5.3 NeighborNet trees of Snippy outputs from clades A, B and C combined (using the reference 
genome JJ1886) of 236 isolates of E. coli ST-131 [Snippy version 3.1 (Seemann 2015)] 
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Figure 5.4 NeighbourNet trees of E. coli ST-131 clades A, B and C (using the reference genome JJ1886); 25 
isolates in clade A, 10 isolates in clade B, 201 isolates in clade C. Scale is variable, and shown for each clade 
[Snippy version 3.1 (Seemann 2015)] 
 
6558 SNPs were used for the NeighborNet of 25 clade A isolates, 7940 SNPs for 10 clade B isolates, and 5505 
SNPs for 201 clade C isolates.   
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Figure 5.5 Neighbour Joining tree of core SNP alignment (as in 
Figure 5.4) of 236 isolates of E. coli ST-131 (using reference 
genome JJ1886) using 14949 SNPs.  
 
Clades and region/country of origin are shown as denoted by the 
legend. Isolates from New Zealand community-acquired urinary 
tract infections (UTI) are denoted by a circle to the left of the isolate 
name. A green circle indicates a person who had a UTI but did not 
travel outside New Zealand in the preceding 12-months, a yellow 
circle indicates that this information was unavailable, and a blue 
circle indicates that the person  travelled anywhere outside New 
Zealand in the preceding 12-months. Where people had travelled, 
regions visited in previous 12-months are shown as the charcoal bars 
to the right of the figure. 
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A common ancestor for the isolates in clade A was estimated using a GTR nucleotide 
substitution rate with a strict molecular clock and a constant coalescent population in 
BEAST (Bouckaert et al. 2014). The final model (‘model 1’ in Table 5.1) was identified 
by comparing models using AIC (Akaike information criterion), and measures of 
posterior support [for ‘model 1’: mean posterior=-6770.7 (95% highest posterior density -
6785.3 to -6757.6; ESS=1178, standard deviation=7.4)]. This model estimated a common 
ancestor for NZ isolates in this clade between 1984 and 2001 (95% credibility interval), 
with a common ancestor for 24/25 of all clade A isolates circa 1991 (95% credibility 
interval between 1978 and 1999). The evolutionary phylogeny estimated by this model is 
shown in Figure 5.6. New Zealand community isolates made up the majority of the 
isolates examined in this group (16/25; 64%), and a cluster of 12 appear to have a common 
ancestor around 2008. All model statistics had effective sample size (ESS) support of 
>200. The mean posterior for this model was -6771 (with an ESS of 1178), the estimated 
clock rate (prior to adjustment for non-variant sites) was 5.3 x 10-3 [for 1006 SNPs (a core 
alignment of 8225 SNPs) and MER102 genome size estimate of 5065233 bp] or 1.1 x 10-6 
SNPs per site per year. 
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Figure 5.6 Evolutionary phylogeny for E. coli ST-131 ‘clade A’ isolates. SNP alignment with recombinant 
regions removed used to generate evolutionary trees [BEAST 2.0 TreeAnnotater (Bouckaert et al. 2014); 
Gubbins was used to remove recombinant regions (Croucher et al. 2015)].  
 
Isolates from New Zealand community-acquired urinary tract infections (UTI) are denoted by a circle to 
the left of the isolate name. A green circle indicates person who had UTI did not travel outside New 
Zealand in the preceding 12-months, and a blue circle indicates that they travelled outside New Zealand in 
the previous 12-months. Reference genome used: MER102 (Harris et al. 2018)  
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A distance matrix from the whole genome MLST of 16 New Zealand isolates in clade A 
using the reference genome LT8262a used 3950 alleles. When this was utilised alongside 
travel status (as in Figures 5.5 and 5.6), no statistical association between travel and the 
tree structure was found [p-value = 0.48 (F-statistic = 0.88)]. 
Evolutionary analysis for all 236 E. coli ST-131 isolates did not result in phylogenies that 
met the quality criteria outlined in the methods and therefore the results are not given 
here. Isolates for the smaller clade C group did likewise not meet the quality criteria, and 
all models had low posterior support (ESS <10).  
5.5 Discussion  
There are multiple strains of ESBL-producing E. coli circulating in the New Zealand 
community as demonstrated in Chapter 3. ST-131 was the most commonly found in cases 
of community-acquired ESBL-/ACBL-producing urinary tract infections in that study 
(37% of all E. coli isolates), although the actual proportion may be higher, as 50% (of ESBL-
producing E. coli infections) was reported to be ST-131 in the 2016 national surveillance 
report (Heffernan et al. 2018). The distribution of the isolates from these people shown 
in Figure 5.5 indicates that there are multiple sub-types of ST-131 circulating in the 
Auckland and Northland regions of New Zealand. Some of these strains (as in those in 
ST-131 clade A) appear to be more closely related to other isolates from NZ when 
compared to international isolates, although isolates described here were overrepresented 
in the clade A isolates used in this study. 
Travel from a global region with high ESBL-carriage prevalence to a low-prevalence 
region has become a well-recognised risk factor for carriage of ESBL-producing 
Enterobacteriaceae (Rogers et al. 2014; Karanika et al. 2016; Armand-Lefèvre et al. 2018). 
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Travel to Asia was identified in Chapter 3 as a risk factor that increased the odds of being 
a case in the case control study. In contrast, it appears from Figure 5.4 that isolates 
collected from the New Zealand community (Chapter 3) were overall not associated with 
a particular global region and within clade A, travel was not significantly associated with 
isolate clustering (using wgMLST). However, of people with a UTI caused by ESBL-
producing ST-131 in the case control study described in Chapter 3, 30% reported no one 
in their home had travelled internationally in the previous year (including themselves). It 
is also important to note that this study was not intended to be a systematic representation 
of geographic and temporal ST-131 E. coli, as not all regions were included (notably no 
isolates were from Africa, or from Central and South America), and possibly reflects 
submission patterns to the SRA database as a whole. 
The diversity within all isolates included in this study was represented by Figures 5.2, 
5.3, and 5.5. The presence of a large accessory genome within the isolates in this dataset 
(approximately 10,000 non-core shell/cloud genes identified) indicates substantial 
diversity within this sequence type. This aspect is worth investigating in future work, 
especially around the role of non-AMR aspects of mobile genetic elements. A high 
proportion (99%) of the isolates included in this study had a combination of the large 
plasmids IncFIA/IncFIB/IncFII, as shown in Figure 5.1. These plasmids have been 
found associated with blaESBL carriage in E. coli , particularly blaCTX-M-15, so this is not a 
novel finding (Carattoli 2009). However, it is used here as a proxy for confirmation that 
it is likely that the majority of blaESBL in isolates in this study were associated with large 
plasmids. Long read sequencing of plasmids in these isolates would be needed to confirm 
and identify plasmids, and genetic associations between plasmids (and between plasmid 
and bacterial chromosome) should be the focus of future work.  
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Some differences were noted in this study when compared to similar studies performed 
outside New Zealand. Unlike the isolates in Matsumura et al. (2015), where 46% of 
isolates carried the blaCTX-M-14 gene, only 5% (12/236) of all isolates [4% (2/48) for the New 
Zealand isolates] presented in this chapter had that gene. Like Petty et al (2014) and 
Stoesser et al (2016), blaCTX-M-15 was the predominant blaESBL identified in ST-131 in this 
chapter (Petty et al. 2014; Stoesser et al. 2016). In comparison, for the clinical ST-131 
isolates from Chapter 3, 50% (24/48) of isolates carried the blaCTX-M-27 gene and 46% 
(22/48) carried blaCTX-M-15. These differences suggest that there may be a unique make-
up to the ESBL-containing plasmids circulating in New Zealand when compared to other 
countries (Petty et al. 2014; Matsumura et al. 2015; Stoesser et al. 2016). 
Virulence genes were identified as part of the CGE pipeline from assembled genomes 
(Thomsen et al. 2016). The virulence-associated genes identified in over 50% of ST-131 
isolates in this chapter were sat, iha, gad, and senB (as described in Table 5.3). These 
genes have been identified with pathotypes of E. coli associated with extraintestinal 
infections (e.g. urinary tract infections) and generally are associated with survival (gad), 
adhesion (iha, fimH), and cytotoxicity (sat, senB) (Guyer et al. 2000; Kaper et al. 2004; 
Mao et al. 2012; Barrios-Villa et al. 2018). As ST-131 is associated with extraintestinal 
infection, this finding is unsurprising (Nicolas-Chanoine et al. 2014). 
Lastly and in addition to the descriptive work, evolutionary phylogenies of clade A, B, and 
C isolates were analysed here. In the work of Stoesser et al. (2016) investigating the 
evolution of ST-131, the 215 isolates used by these investigators were found to have 
recombination accounting for two thirds of the core nucleotide variant sites. They 
excluded these regions for subsequent analysis. From their resultant BEAST model, a 
rate of 2.46 x 10-7 SNPs per site per year was estimated for ST-131 isolates (Stoesser et al. 
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2016). This was similar to the rate estimated in Ben Zakour et al. (2016) which was also 
interested in the evolution of ST-131, where a mutation rate of 4.39 × 10−7 SNPs per site 
per year was estimated from BEAST models across clades C and B in their dataset. These 
rates are both lower than that calculated for the clade A isolates presented in this chapter, 
where a mutation rate of 1.1 x 10-6 SNPs per site per year was estimated, however this 
difference may be attributed to these being different clades and the intrinsic variability in 
mutation rate calculation (Sprouffske et al. 2018).  
Limitations 
The isolates included in this chapter do not include any isolates from before 2004, and 
this was identified as a limitation to common ancestor estimation by Petty et al. (2014). 
Those collected as part of Chapter 3 and the isolates with a ‘MER’ prefix were all from 
samples submitted between 2014 and 2017. All other isolates were collected between 
2004 and 2014. Exact dates were also unavailable for many isolates in this dataset, so the 
temporal inputs into the BEAST models were imprecise. For isolates in clade A, these 
two factors were less important, as accurate dates were known for all New Zealand 
isolates (16/25 in this clade), and the sample size was small enough that the full SNP 
alignment was able to be processed for recombinant regions. Attempts at generating 
evolutionary phylogenetic models for all 236 isolates included in this study were largely 
unsuccessful. This may have been attributed to the fact that there was substantial amount 
of recombination, as suggested by other studies (Stoesser et al. 2016), and the available 
computing power was unable to meet the demands to successfully identify these 
recombinant regions. Presence of a molecular clock signal was not investigated in this 
study, however further expansion of this research should look for this (e.g. using 
Bactdating) to ensure validity of evolutionary phylogeny (Yahara et al. 2018). 
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Another important limitation in this study was around the identification of plasmid 
replicon genes for large plasmids. These were detected from assembled genomes using 
PlasmidFinder (Carattoli et al. 2014). The decision not to use raw reads was made due to 
the focus of this study being on the whole genome of E. coli ST-131. However, plasmids 
are an apparatus by which ESBL genes are disseminated between bacteria, and therefore 
a key part of understanding why particular strains have become globally dominant. 
Therefore, an approach which uses both short-read (e.g. Illumina HiSeq) and long-read 
sequencing [e.g. MinION (Oxford Nanopore)] to examine bacteria on a large scale, would 
be optimal for future investigations of the kind presented in this chapter (San Millan 
2018). 
5.6 Conclusions 
Within the study presented in this chapter, 41% of the community-acquired urinary 
infections from NZ were cultured from people who had not left NZ in the previous year. 
All three clades (A, C, and to a lesser extent B) appear to be circulating in the New 
Zealand community in the absence of recent travel history, and a substantial proportion 
of clade A isolates were cultured from these people. In the future, it is likely that endemic 
clones of ST-131, particularly clades A and C, will come to predominate if the prevalence 
of ESBL-producing bacterial carriage increases in the NZ community. 
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6  General discussion 
6.1 Overview 
6.1.1 Summary of findings 
The research presented in this thesis was centred on the prospective case control study 
in Chapter 3 and the research question: is the family pet a risk for multidrug resistant 
infections?  
Companion animals in the home were not found to be risk for community-acquired 
urinary tract infections caused by ESBL-/ACBL-producing Enterobacteriaceae in this 
study. However, I did find pets carrying the same strain of bacteria that caused a person 
to have an ESBL-/ACBL-producing infection in the same household, so pets may have 
some role in transmission of these bacteria in the home (and therefore the community as 
a whole).  
Other well-recognised risk factors for ESBL-/ACBL-producing infections were found to 
increase the odds of infection in the case control study. These factors included healthcare 
contact, recent antimicrobial treatment, and travel to high-risk countries. Other factors 
that increased the odds of being a case included being female, over 65-years-old, and 
having more than one urinary tract infection in the previous six-months. E. coli isolates 
from these index urinary tract infections were compared to isolates collected from people 
and pets in the homes of 23 case people. Faecal samples from 11 of these households 
cultured ESBL-/ACBL-producing E. coli isolates from more than one person or pet, and 
close genomic relatedness between isolates suggested some form of intra-household 
transmission was likely to have occurred in eight households. E. coli ST-131 was cultured 
from multiple individuals in four households and was the most commonly cultured strain 
146 
 
from community-acquired infections in case recruits. This strain was examined further 
for associations with isolates cultured from elsewhere in the globe, and the results 
suggested that multiple strains are circulating within New Zealand. 
In this chapter, I will provide a larger context for the results described in Chapters 3 to 
5, indicate where future work is needed, and provide recommendations based on this 
research. 
6.1.2 Lessons learned 
There were aspects to the research included in this thesis that taught me important 
lessons in research design. These lessons included maintenance of ethical standards, and 
the value in treating research ethics as an on-going conversation with oversight bodies and 
the parties involved in research. Four district health boards were involved in approving 
this study and negotiating the ethical expectations of each locality gave me the 
opportunity to reflect on how this study may affect different (albeit geographically close) 
communities. 
Designed to be a prospective case control study, steady contemporaneous case 
recruitment was an important part of the study design for Chapter 3. Slow case 
recruitment during the initial year of this project resulted in necessary amendments to the 
study protocol. Efforts put into recruiting cases became successively more active: moving 
from a letter of invitation, to a follow-up call and incentives, to reminder letters and with 
multiple follow-up calls to prospective case participants. These changes were vital for the 
success of the case control study, and although fewer cases were recruited than expected 
(and over a longer period than initially planned), the resultant study was an important 
example in how to address challenges in real time.  
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6.2 Antimicrobial resistance as a societal issue 
Antimicrobial resistance is a complex and multifactorial issue. As a clinician, I appreciate 
the desire to want what is best for your patient. As a scientist, I understand that it is the 
cumulative actions of many that will lead to or exacerbate antimicrobial resistance in the 
future. Examining the issues around AMR from “One Health” or “EcoHealth” 
perspectives, or as a “Wicked Problem”, enables one to change perspective and creates 
the possibly for novel solutions (Signal et al. 2013; Roger et al. 2016). Mixed-methods 
approaches to “wicked problems” have been shown to provide a framework for tackling 
issues where complexity is high so this is something that could be incorporated into action 
plans in New Zealand (van Woezik et al. 2016; Waltner-Toews 2017). The high 
complexity for issues surrounding AMR originates not only in the nature of the organisms 
responsible, but also due to the nature of competing interests. Physicians want to use 
appropriate pharmaceuticals to cure disease, pharmaceutical companies want to stay in 
business, farmers want to produce products for sale in an economically efficient way, 
government policy-makers want to preserve market and trade integrity or reduce the 
impact on the economy that sick people pose, and patients want to be treated for disease 
and spared disability. Coupled with these human concerns, there are aspects that at much 
more difficult to control, such as environmental contamination with human waste in both 
the developed and developing world. This environmental contamination, coupled with 
other “wicked problems” such as climate change and increased wealth disparity, may 
lead to the development of hot spots for untreatable human disease. Increased 
competition for freedom from these areas may add pressure to geopolitical tensions in the 
future. At a global level, there is regional inequity in the burden of ESBL-producing 
bacteria (Karanika et al. 2016). Gender and racial inequalities in ESBL-producing E. coli 
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infections have been described, although they were not found to be a risk factor in 
Chapter 3, they are worth looking at in any further work done in this country (Thaden et 
al. 2016).  
Women, especially post-menopausal women, are more likely to be affected by 
uncomplicated urinary tract infections (Grigoryan et al. 2014). While issues like 
prostatitis and acute urinary retention (with sequelae of the requirement for 
catheterisation) will increase the risk for urinary tract infection in men (Emberton and 
Anson 1999), as shown in Chapter 3, women represent a much higher proportion of total 
community-acquired MDR urinary tract infections [these demographics have been 
reflected in general cases of ESBL-producing infections in New Zealand (Heffernan et al. 
2013)].  
The social and emotional impacts of urinary tract infections, especially where it is 
accompanied by incontinence, can be imaginably high (Eriksson et al. 2014). The impacts 
on quality of life for a susceptible urinary tract infection may then be amplified by stigma 
associated with having a multidrug resistant infection. In addition to the personal 
implications for the individual emotional health, persistent carriage is also a public health 
concern. The long-term sequelae of these infections, if carriage status persists or cycling 
within the household allows for re-carriage, could cause complications and increase 
morbidity of other unrelated diseases. A proactive approach to this public health 
challenge is to reduce carriage status at the community level, not only within New 
Zealand but also as part of the global community.  
There are a number of different approaches to reduce the burden of ESBL-E. coli. For 
example, active decolonisation strategies (i.e. using antimicrobial therapies) appear to 
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yield mixed results, and long term or large scale application of these are not practical (Bar-
Yoseph et al. 2016). Another approach is within the frameworks of antimicrobial 
stewardship. Hygiene and biosecurity measures are key to reducing the need for 
antimicrobials through prevention of bacterial infection and reduction in transmission 
(Tacconelli et al. 2014). As described elsewhere in this thesis, there is also substantial 
support for the impact that reducing antimicrobial use community (or population) -wide 
might have on carriage of ESBL-producing bacteria within that population (Agersø and 
Aarestrup 2013; MacFadden et al. 2018). That said, it is important to recognise that this 
still an area of research requiring further work, and it is unlikely that reducing selection 
pressure alone will reverse AMR (Johnsen et al. 2009; Holmes et al. 2016).   
6.3 Antimicrobial resistance ecology 
6.3.1 Pets in the home 
The risk factor of particular interest in the research presented in this thesis was contact 
with companion animals. As no association between having a pet and acquiring a 
multidrug resistant infection was found, I could not investigate pet-associated risk 
mitigation strategies. Despite this negative result, a description of general behaviour 
around pets in this country can be gleaned from control participants. From these 258 
people with a pet in the home, I observed that many people do not wash their hands 
frequently around contact with their pets. While only 4% of controls with pets reported 
“never” washing their hands after contact with pet urine or faeces, 19% and 22% of 
controls did report “never” washing their hands after their pet licks them or after petting 
their pet respectively. For these two variables, 45% and 29% of control respondents 
reported “always” washing their hands after these respective exposures (the rest 
reporting “sometimes” or “often” wash hands). These could be considered as 
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modifiable behaviours to reduce risks of zoonotic disease. In Chapter 4, the bacteria 
cultured from two dogs in separate households cultured bacteria that was clonally related 
to isolates causing infection in the clinical sample submitted from the person recruited as 
a case for the case-control study. This illustrates that transmission events between 
humans and animals (or vice versa) are likely to be occurring within the home 
environment. The genomics work from the bacteria collected from faecal samples as part 
of Chapter 3 and 4 has been the inspiration for modelling the role that antimicrobial 
treatment in pets play in the development of antimicrobial resistance. 
However, human-to-human, or environment-to-human transfer of ESBL-E are likely to 
be the predominant mode of transmission, and reverse-zoonotic transmission of AMR 
bacteria to pets (rather than pets-to-people) may be a more dominant pathway 
(Messenger et al. 2014). 
6.3.2 The environment 
The role the environment plays in the transmission and propagation of MDR bacteria 
warrants further examination (Larsson et al. 2018). In New Zealand, we still know little 
about environmental AMR sources, and how these putative sources contribute to 
transmission pathways. These could be through waterways contaminated by human or 
animal sources of E. coli, by urban environmental transmission, or by contamination of 
food crops, among others. This knowledge gap was identified in the literature review in 
Chapter 2 and has been since followed up by work in the mEpilab in this area. Other 
studies related to this work included a pilot study examining ESBL-E in production 
animals. Future work for exposures should focus on both humans and animals, and the 
roles that wildlife and the environment may play in providing substrate for (or source of) 
horizontal gene transmission elements (Larsson et al. 2018). 
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6.3.3 The microbiome 
Our understanding of microbiomes has matured substantially over the last decade, and 
this has been facilitated by advances in metagenomics and computing (Crofts et al. 2017). 
With both new molecular techniques and the reduction in cost of whole genome 
sequencing, our understanding is likely to increase as the interpretation and utility of the 
results of these techniques become clearer in the future. It is also likely that our 
understanding of the role that complex communities of microflora will change, and our 
ability to manipulate and optimise this population will likewise evolve. Dogs (and to a 
lesser extent cats) have a similarity in digestive tract physiology and diet to humans, 
unlike many other domesticated animals. This similarity in combination with the 
presence of bacteria (such as ESBL-E) in these populations, in addition to evidence 
provided in Chapter 4, means that future work should continue to investigate companion 
animals’ role in community transmission of ESBL-producing E. coli. 
6.4 Antimicrobial resistance and plasmids  
Plasmids are small circular genomes living within a bacterial cell, regulating their own 
replication and manipulating the host into spreading to conjugated bacteria and as such 
they might be regarded as an independent living entity (Carattoli 2009). More 
importantly, plasmids play an integral role in the transmission and dissemination of 
ESBL-production in disease-causing bacteria. It should be noted however, that plasmid-
associated MDR in Enterobacteriaceae includes not only ESBL- and ACBL-producers, 
but also carbapenemase-producers, fluoroquinolone resistance, and colistin resistance.  
Horizontal transmission of antimicrobial resistance is worth investigating further within 
the dataset curated as part of this project. I found evidence of suspected horizontal gene 
transmission from individuals as part of the cross-sectional study (Chapter 4) between 
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different bacterial types (e.g. E. coli ST-44 and ST-405), as well as between species (e.g. 
Klebsiella pneumoniae and E. coli). Low-cost options for obtaining sequences from 
plasmids include the MinION (Oxford Nanopore Technologies), although ideally PacBio 
(Pacific Biosciences) sequencing would be used (Levy and Myers 2016; Orlek et al. 2017). 
Obtaining these high-quality plasmid sequences using a long-read technique would 
therefore be a first step in examining these isolates, and this work is underway in the 
mEpilab and includes plasmids from some isolates included in this body of work. 
Despite the importance of plasmids, the molecular methodologies used in Chapters 3, 4 
and 5 did not directly allow investigation of these plasmids as the bioinformatics 
techniques utilised in those chapters focussed on core genomic differences and found 
large plasmid genes in bacteria presented in these chapters. Others have examined the 
factors that make plasmid promiscuous, advancing techniques to explore these factors 
(Carattoli 2009; Orlek et al. 2017). Nevertheless, components of the accessory genome 
are likely to be key to understanding the implications for horizontal gene transmission 
dynamics and the determinants of successful colonisation of plasmid-bearing MDR 
bacteria in multiple mammalian hosts requires larger population size to study (San Millan 
2018).  
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6.5 Recommendations to reduce and manage the community burden 
of ESBL-producing bacteria 
1. Advice to New Zealanders travelling to high-risk regions (such as Asia and Africa) 
should emphasise hand hygiene and recommend people only use systemic 
antibiotics while traveling if absolutely necessary  
o See Chapter 3 
2. Healthcare professionals should consider in-contact people in homes where 
someone has been positive for ESBL-E or ACBL-E as at risk of carriage of (and 
therefore becoming infected by) these bacteria  
o See Chapter 4 
3. Antimicrobial stewardship in general practice is a target for reducing antimicrobial 
use and thereby reduce AMR selection pressure in the New Zealand community  
o See Chapter 2 
4. Surveillance screening of ESBL-E should be routine in veterinary diagnostic 
laboratories, and monitoring these bacteria long-term should be considered a 
priority  
o See Chapter 2 
5. More work is required using modern molecular techniques to better understand 
the role of plasmids in endemic and epidemic AMR strains, as this may lead to 
modification of risk  
o See Chapters 4 & 5 
6. Future projects in New Zealand should focus on the role that both urban and rural 
environments play in AMR transmission  
o See Chapter 2 & 4  
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6.6 Concluding remarks 
General applicability and conclusions of the research presented here may not extend 
beyond New Zealand, however they provide valuable insights. Pets are important 
companions for many people, including those in vulnerable situations. As companion 
animals were not found to be a risk for ESBL-/ACBL-E infections, they may not be 
considered a focus for intervention or regarded as an intrinsic risk factor. Antimicrobial 
resistance in the New Zealand community warrants further investigation. The results of 
this thesis indicates that there are various risk factors for ESBL-producing 
Enterobacteriaceae causing infection in the New Zealand community. Areas that require 
further research include resistance gene-containing plasmids circulating in the 
community, and the roles that non-human sources or reservoirs play. Future 
observational studies should focus on longitudinal carriage and transmission of ESBL-
producing E. coli within households (including companion animals), utilising whole 
genome sequencing where intra-person/pet genetic diversity is also captured. 
Examination of microbiomes and environmental metagenomics could also provide 
valuable supplemental information, and may shed light on the role that non-disease 
causing bacterial communities may play in supporting antimicrobial resistance. The 
results of such work could then be used to inform models of antimicrobial resistance 
transmission.  
While there is still work to be done, this research provides an overview of what is known 
regarding ESBL-/ACBL-producing Enterobacteriaceae in New Zealand. Methodologies 
and results presented here have subsequently been used to inform genomic epidemiologic 
research into AMR in food animals and the environment, and future developments will 
add to the larger body of work in which the study presented here resides.  
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Appendix I: microbiology 
Culture of ESBL and suspected AmpC isolates from Human Laboratory Samples 
Day 1  
1. Samples (isolates) received from courier (ex-Auckland) 
2. Fill in Clinical Submission data sheet with date and sample ID (and Labtests ID), 
comments as required. If possible, get data entry verified by another laboratory 
member. 
3. Inoculate onto labelled blood agar; and incubate at 37 °C for 16-24 hours. 
4. Keep Labtests travel plate in chiller. Discard in 7 days. 
Day 2  
1. Subculture a single colony to a fresh labelled blood agar and incubate as per above; 
repeat choosing a second colony. Label ‘sampleID+a’ & ‘sampleID+b’ 
respectively. 
2. Incubate at 37 °C for 16-24 hours 
Day 3 
For isolate ‘sampleID+a’:  
1. From blood agar, make a suspension in sterile saline equivalent to a 0.5 McFarland 
standard with a sterile cotton swab following EUCAST guidelines for 
antimicrobial susceptibility testing (AST) (Kahlmeter et al. 2006).  Within 15 
mins, dip a sterile cotton swab into the suspension, remove excess inoculum by 
rotating the swab on the inner wall of the tube and cover a labelled Mueller–
Hinton agar plate, swabbing in three directions. Repeat for a total of TWO plates. 
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2. Plate 1) ESBL confirmatory test: use cefotaxime & ceftazidime +/- clav disks 
(D62C & D64C) as per MAST instructions. 
3. Incubate at 37°C in air for 16-20 h 
4. Plate 2) AmpC phenotypic test: use disks (D69C) from MAST AmpC test (CPD 
+/- inducer +/- inhibitor) as per MAST instructions. AST to be performed on 
isolates (from frozen) at a later date 
5. Incubate at 37°C in air for 16-20 h  
6. From blood agar, suspend bacteria into broth/cryoprotectant, gently scraping the 
surface using a sterile swab and pipette to freezer cryovial. Transfer to -80 °C 
freezer for storage (prior to consent) 
7. Label vial with isolate ID (sample ID + a), and record location in freezer on 
Clinical Submission data sheet  
For isolate ‘sampleID+b’:  
1. From blood agar, suspend bacteria into broth/cryoprotectant, gently scraping the 
surface using a sterile swab and pipette to freezer cryovial. Transfer to -80 °C 
freezer for storage (prior to consent) 
2. Label vial with isolate ID (sample ID + b), and record location in freezer on 
Clinical Submission data sheet  
Day 4 
1. Measure disk diameters for each plate as per EUCAST protocols using a calliper; 
record results on Clinical Submission data sheet with sampleID+a 
2. If AmpC positive (zone difference both ≥5mm), report as AmpC case to be 
recruited to the clinical microbiologist recruiting cases.  
157 
 
3. If ESBL negative or non-positive, put plate in chiller for repeat ESBL testing using 
D62C, D64C, D63C on next week (i.e. Day 5)  
Day 5 
1. Subculture onto blood agar  
Day 6 
2. Repeat Day 3, including a D63C plate 
Day 7 
3. Measure disk diameters for plate  as per EUCAST protocols using a calliper; 
record results on Clinical Submission data sheet with sampleID+a 
4. If ESBL and AmpC negative, repeat Days 2 to 4 with frozen ‘sampleID+b’ the 
following week 
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AmpC/ESBL isolation from faecal samples 
Day 0 (Sunday) 
1. Samples arrive from Auckland (chilled) 
Day 1 
For bird samples:  
1. Fill in Faecal sample data sheet with date and sample ID, comments as required. 
If possible, get data entry verified by another laboratory member 
2. Use a sterile swab to transfer brown/faecal material into 20mL of buffered 
peptone water (BPW). Incubate for 12-20 hours at 37 °C 
For all other samples: 
1. Fill in Faecal sample data sheet with date and sample ID, comments as required. 
If possible, get data entry verified by another laboratory member 
2. Aliquot ~1g portion into a labelled container (eppendorf) and store in -80 °C 
freezer. Record location on Faecal sample data sheet. 
3. From a faecal sample use a sterile cotton swab and swab a MacConkey plate, and 
proceed to streak plate; 
4. Using same swab, repeat labelled antimicrobial CAZ (MacConkey plus 1mg/L 
ceftazidime) plate 
5. Using repeat labelled antimicrobial CTX (MacConkey plus 1mg/L cefotaxime) 
plate 
6. Using same swab, repeat procedure on a labelled ESBL selective chromogenic 
agar plate (CHROMagar™ , Paris France)   
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7. Incubate plates at 37 °C for 16-24 hours. 
Day 2  
For bird samples:  
1. From a BPW sample, use a sterile cotton swab and swab a MacConkey plate, and 
proceed to streak plate; 
2. Using a fresh swab, repeat labelled antimicrobial CAZ (MacConkey plus 1mg/L 
ceftazidime) plate 
3. Using a new sterile swab, repeat procedure on a labelled antimicrobial FOX 
(MacConkey plus 1mg/L cefotaxime) plate 
4. Using a new sterile swab, repeat procedure on a labelled Chromagar ESBL plate 
For all other samples: 
1. From plain MacConkey plate record plate growth description on Faecal sample 
data sheet. Select 2 morphologically distinct Enterobacteriaceae (suspected to be 
E coli or Klebsiella) colonies using a sterile loop and subculture onto blood agar. 
Isolates to be given isolate ID number (sampleID+a/b).  
2. From CAZ-MacConkey plate examine for growth and record on Faecal sample 
data sheet. Using a sterile loop, subculture a maximum of 2 colonies onto labelled 
blood agar purity plates (one colony per plate). Isolates to be given isolate ID 
number (sampleID+c/d). 
3. Incubate plates at 37 °C for 16-24 hours. 
4. From CTX-MacConkey plate examine for growth and record on Faecal sample 
data sheet. Using a sterile loop, subculture a maximum of 2 colonies onto labelled 
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blood agar purity plates (one colony per plate). Isolates to be given isolate ID 
number (sampleID+e/f). 
5. Incubate plates at 37 °C for 16-24 hours. 
6. From Chromagar ESBL plate examine for growth and record on Faecal sample 
data sheet. Using a sterile loop, subculture a maximum of 2 colonies onto labelled 
blood agar purity plates (one colony per plate). Isolates to be given isolate ID 
number (sampleID+g/h). 
7. Incubate plates at 37 °C for 16-24 hours  
Day 3 
For bird samples:  
1. Refer to Day 2 procedure for all other samples 
For EACH isolate from non-bird samples:  
1. From blood agar, make a suspension in sterile saline equivalent to a 0.5 McFarland 
standard with a cotton swab.  Within 15 mins, dip a cotton swab into the 
suspension, remove excess inoculum by rotating the swab on the inner wall of the 
tube and cover a labelled Mueller–Hinton agar plate, swabbing in three directions. 
Repeat for a total of two plates. AST and some Day 3/4 sample analysis 
(ESBL/AmpC testing) to be performed from frozen isolates at a later date. 
a. Plate 1) ESBL confirmatory test: use cefotaxime & ceftazidime +/- clav 
disks (D62C, D63C & D64C) as per MAST instructions. 
b. Plate 2) AmpC phenotypic test: use disks (D69C) from MAST AmpC test 
(CPD +/- inducer +/- inhibitor) as per MAST instructions 
2. Incubate at 37°C in air for 16-20 h 
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FOR ALL isolates (a-h):  
3. From the blood agar purity plate, suspend bacteria into broth/cryoprotectant, 
gently scraping the surface using a sterile swab and pipette to freezer a labelled 
cryovial. Transfer to -80 °C freezer for storage. Record location in freezer on 
Faecal sample data sheet 
Day 4 
For bird isolates  
1. Refer to Day 3 procedures for non-bird isolates  
For non-bird isolates  
1. Examine ESBL and AmpC plate(s), measure using a calliper; record results in mm 
on Faecal sample data sheet. Interpret results. If positive for ESBL and/or ACBL 
phenotype, record as positive, or equivocal on Faecal sample data sheet. Species 
ID to be performed at a later date (i.e. MALDI-TOF) for isolated positive for ESBL- or 
ACBL phenotype 
Day 5 
For bird isolates  
2. Refer to Day 4 procedures for non-bird isolates  
For ESBL equivocal: Measure disk diameters for cefepime plate as per EUCAST 
protocols using a calliper; record results on Faecal sample data sheet with isolateID 
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Figure 6.1 Algorithm for detection of phenotypic ESBLs. EUCAST guidelines, and AmpC 
interpretation from Halstead et al. (2012) 
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Appendix II: DNA extraction 
and library preparation 
Isolation and purification 
Day 1 
1. Thawing procedure: using a sterile loop scrape isolate sample from cryovial, and 
streak onto blood agar. Return vial immediately to freezer 
2. Incubate plate(s) in 37°C for approx. 24 hours. 
3. Record on Clinical Submission data sheet. 
Day 2 
1. Subculture a single colony onto blood agar. Incubate as above. 
Day 3 
2. Examine plates for growth, if pure growth of sufficient colonies, proceed to DNA 
extraction 
3. DNA extraction:  
a. Qiagen kit DNA extraction protocol for plasmid retention 
b. Qubit kit for QA of DNA/RNA/Protein  
c. Label, make and freeze DNA at -20°C. Record location on WGS data 
sheet (ensure isolate ID is recorded) 
d. If DNA is not of sufficient quality, sub colony onto fresh blood agar and 
incubate for 18-24 hours at 37°C and repeat day 2 procedure 
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Extraction of genomic DNA (Modified Qiagen protocol for purification from tissues) 
Follow directions for prior to start of protocol 
1. Dispense 180 uL ATL buffer into Eppendorf vials; remove one loop (i.e. one 
colony) and suspend in buffer 
2. Add 20uL of proteinaseK, mix by vortex and incubate in 37°C overnight and then 
at 56°C on shaking heat-block for 1-2 hours (OR 3 hours at 56 degrees on shaking 
heat-block) 
3. Briefly centrifuge vials to remove condensation 
4. Add 15 uL RNAaseA (100mg/mL) to the vial and incubate at 37°C for 40 minutes 
on the shaking heat-block 
5. Briefly centrifuge to remove condensation 
6. Add 200 uL of AL buffer, mix by pulse vortex and incubate at 70°C for 10 minutes 
on shaking heat-block  
7. Add 200uL of (96-100%) ethanol to the sample and mix using pulse vortex 
8. Transfer sample to spin column, close cap and centrifuge at 6000xg for 1 minute 
9. Add 500 uL of AW1 buffer to spin column and centrifuge at 6000xg for 1 minute 
10. Add 500 uL of AW2 buffer to spin column and centrifuge at 14,000rpm for 3 
minutes 
11. Discard filtrate and centrifuge again at 14,000rpm for 1 minute 
12. Use a clean 1.5 microcentrifuge tube (for later freezing), add 75 uL of PCR grade 
water (37°C) and incubate at room temperature for 5 minutes; then centrifuge at 
6000xg for 1 minute 
13. This sample should then be checked for quality using Qubit fluorimeter, record 
[DNA] for later normalisation and store at -20°C   
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Preparation of libraries from DNA for sequencing 
1. Normalise genomic DNA to 0.16ng/uL 
2. Tagmentation 
a. Follow Nextera Illumina protocol, substitute 10 minutes with PCR 
thermocycler for 12 minutes 
3. Clean up DNA 
a. Follow Nextera Illumina protocol 
b. Store libraries in clean safe-lock tubes at -20°C prior to pooling of libraries  
4. QC of libraries 
a. [DNA] using Qubit 
b. Library fragment analysis using LabChip or Bioanalyzer2100 to determine 
molarity of each library for accurate pooling of DNA for sequencing 
5. If library is of insufficient quality, repeat DNA extraction and library preparation 
steps 
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Appendix III: Isolate summaries 
Table 6.1 Appendix III chapter 3 isolates 
Isolate ID Household Collection date Species MLST 
Genome 
size (bp) GC% 
Read 
depth Contigs N50 
LT8007a HH0001 30/09/2015 Klebsiella 
pneumoniae 
ST-753 5314474 55.8 122 245 188887 
LT8018a HH0005 10/10/2015 Escherichia coli ST-131 5301563 50.4 137 335 180448 
LT8032a HH0022 13/10/2015 Escherichia coli ST-484 4946061 50.2 125 384 94478 
LT8052a HH0015 28/10/2015 Escherichia coli ST-963 5150269 50.5 134 320 115994 
LT8057a HH0003 2/11/2015 Escherichia coli ST-345 4923090 51 155 236 122675 
LT8062a HH0008 9/11/2015 Escherichia coli ST-69 5492481 51.5 48 243 285535 
LT8088a HH0010 24/11/2015 Escherichia coli ST-44 4852736 50.7 139 331 72360 
LT8092a HH0011 23/11/2015 Escherichia coli ST-131 5266448 51.3 66 199 143508 
LT8103a HH0014 30/11/2015 Escherichia coli ST-131 5351299 50.1 121 735 162133 
LT8110a HH0012 4/12/2015 Escherichia coli ST-131 5144652 50.8 117 261 180447 
LT8120a HH0021 15/12/2015 Escherichia coli ST-58 4916347 51.1 146 280 108516 
LT8125a HH0016 15/12/2015 Escherichia coli ST-500 5270376 50.5 56 216 163953 
LT8129a HH0023 13/12/2015 Escherichia coli ST-34 5038369 49.9 153 671 98386 
LT8131a HH0017 22/12/2015 Escherichia coli ST-998 5329330 50.3 100 140 223116 
LT8144a HH0020 26/12/2015 Escherichia coli ST-131 5338622 50.8 59 168 191062 
LT8154a HH0025 12/01/2016 Escherichia coli ST-744 4707466 50 126 470 99952 
LT8171a HH0027 19/01/2016 Escherichia coli ST-410 5163188 50.6 258 310 88409 
LT8179a HH0024 28/01/2016 Escherichia coli ST-131 5160657 51.1 81 178 179969 
LT8198a HH0026 5/02/2016 Escherichia coli ST-1193 5092266 50.3 130 574 162923 
LT8199a HH0035 4/02/2016 Escherichia coli ST-69 5202027 50.7 139 501 134086 
LT8205a HH0038 8/02/2016 Escherichia coli ST-131 5128998 50 104 300 160880 
LT8214a HH0036 22/02/2016 Escherichia coli ST-410 5063940 51 157 648 126665 
LT8230a HH0053 7/03/2016 Escherichia coli ST-73 5029095 50.4 112 227 186707 
LT8231a HH0039 4/03/2016 Escherichia coli ST-131 5206381 50.3 99 444 156192 
LT8242a HH0040 20/03/2016 Escherichia coli ST-131 5215701 51 181 447 170471 
LT8262a HH0052 6/04/2016 Escherichia coli ST-131 5110787 51 112 178 307664 
LT8265a HH0041 31/03/2016 Escherichia coli ST-405 5090574 50.5 139 267 90141 
LT8267a HH0044 1/04/2016 Escherichia coli ST-457 4996121 47.8 78 216 187576 
LT8283b HH0061 20/04/2016 Escherichia coli ST-12 5173501 50.1 150 564 204846 
LT8284a HH0043 20/04/2016 Escherichia coli ST-744 4919565 50.4 98 415 118620 
LT8306a HH0045 27/04/2016 Escherichia coli ST-131 5264432 50.5 110 401 208122 
LT8307a HH0046 30/04/2016 Escherichia coli ST-38 5422420 50.1 74 439 104397 
LT8308a HH0047 3/05/2016 Escherichia coli ST-38 5186779 50.5 71 264 152916 
LT8320a HH0048 9/05/2016 Escherichia coli ST-38 5161032 51 173 381 123639 
LT8335a HH0049 12/05/2016 Escherichia coli ST-393 5097768 50 81 333 129076 
LT8371a HH0064 31/05/2016 Escherichia coli ST-963 5153473 50.2 120 338 92286 
LT8405a HH0057 27/06/2016 Escherichia coli ST-131 4957577 50.7 123 273 178664 
LT8410a HH0059 16/06/2016 Escherichia coli ST-59 5220194 50.1 138 486 55007 
LT8442a HH0063 13/07/2016 Klebsiella 
pneumoniae 
ST-25 5589238 56.2 78 259 172668 
LT8444a HH0060 21/07/2016 Escherichia coli ST-38 5215660 50.3 86 345 133028 
LT8455a HH0065 25/07/2016 Escherichia coli ST-69 5120029 50.2 151 282 164000 
LT8467a HH0066 9/08/2016 Klebsiella 
pneumoniae 
ST-133 5690541 56.6 107 307 165851 
LT8486a HH0068 8/08/2016 Escherichia coli ST-12 5136947 50.4 104 219 225032 
LT8504a HH0072 23/08/2016 Escherichia coli ST-38 5152653 50.5 78 257 123936 
LT8519a HH0071 30/08/2016 Escherichia coli ST-131 5122957 50.9 108 269 166692 
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Isolate ID Household Collection date Species MLST 
Genome 
size (bp) GC% 
Read 
depth Contigs N50 
LT8534a HH0070 5/09/2016 Escherichia coli ST-131 5093878 50.5 129 293 159414 
LT8553a HH0074 21/09/2016 Escherichia coli ST-57 4995515 50.2 69 170 129752 
LT8569a HH0073 25/09/2016 Escherichia coli ST-2345 4596790 50.5 132 662 72910 
LT8578a HH0075 3/10/2016 Escherichia coli ST-131 5292404 50.5 111 346 133277 
LT8604a HH0077 18/10/2016 Klebsiella 
pneumoniae 
ST-405 5668329 56.4 99 362 151889 
LT8610a HH0082 25/10/2016 Escherichia coli ST-38 5321441 50.5 65 410 111559 
LT8662a HH0091 21/11/2016 Escherichia coli ST-38 5304785 50.5 91 367 80948 
LT8679a HH0093 2/12/2016 Escherichia coli ST-131 5290276 50.5 90 257 178374 
LT8685a HH0102 7/12/2016 Escherichia coli ST-349 5267305 50.9 98 301 115398 
LT8691a HH0080 7/11/2016 Escherichia coli Unknown ST 5243293 50.9 162 615 178682 
LT8703a HH0086 29/11/2016 Escherichia coli ST-131 5083072 50.6 131 443 178654 
LT8704a HH0085 13/12/2016 Escherichia coli ST-95 5021005 49.6 110 281 174711 
LT8706a HH0087 13/12/2016 Escherichia coli ST-38 5345003 50.6 72 435 104634 
LT8716a HH0104 16/12/2016 Escherichia coli ST-131 5086836 49.6 135 336 173801 
LT8717a HH0088 21/12/2016 Escherichia coli ST-998 5202978 50.4 137 297 252929 
LT8734a HH0090 17/01/2017 Escherichia coli ST-131 5108706 50.5 91 318 181516 
LT8740a HH0142 18/01/2017 Escherichia coli ST-1193 5157191 50.3 121 285 161155 
LT8744a HH0098 13/01/2017 Escherichia coli ST-131 5211205 51 100 153 255513 
LT8769a HH0097 7/02/2017 Escherichia coli ST-7358 5203953 50.5 124 516 88402 
LT8771a HH0114 7/02/2017 Escherichia coli ST-131 5072572 50.6 139 275 186350 
LT8772a HH0109 8/02/2017 Escherichia coli ST-131 5049815 50.9 124 255 181591 
LT8776a HH0115 9/02/2017 Escherichia coli ST-58 5033666 50.6 168 358 111420 
LT8777a HH0096 7/02/2017 Escherichia coli ST-38 5466893 50.1 93 639 123270 
LT8789a HH0095 21/02/2017 Escherichia coli ST-648 5304063 50.4 126 372 155339 
LT8793a HH0110 21/02/2017 Escherichia coli ST-131 5293870 50.4 115 358 162730 
LT8795a HH0113 20/02/2017 Escherichia coli ST-131 5227381 50.5 118 322 178637 
LT8797a HH0100 17/02/2017 Escherichia coli ST-131 5163199 50.3 111 369 159114 
LT8806a HH0178 2/03/2017 Escherichia coli ST-345 4743293 50.6 81 289 151055 
LT8819a HH0105 17/03/2017 Escherichia coli ST-131 5413553 50.1 167 486 162190 
LT8821a HH0101 28/03/2017 Escherichia coli ST-38 5457864 49.8 79 461 115082 
LT8825a HH0099 24/03/2017 Escherichia coli ST-131 5004821 50.5 103 323 180447 
LT8846a HH0139 9/03/2017 Escherichia coli ST-69 5201815 50.7 135 330 131227 
LT8848a HH0141 4/04/2017 Escherichia coli ST-69 5234166 50.4 149 357 98524 
LT8852a HH0118 6/04/2017 Escherichia coli ST-131 5113467 50.7 114 301 154937 
LT8859a HH0117 11/04/2017 Escherichia coli ST-1193 5062925 50.3 115 196 140191 
LT8862a HH0136 12/04/2017 Escherichia coli ST-14 5351771 50.4 116 297 104857 
LT8863a HH0145 10/04/2017 Escherichia coli ST-131 5147584 50.5 118 231 181672 
LT8866a HH0135 12/04/2017 Escherichia coli ST-131 5208737 50.6 109 243 151001 
LT8868a HH0133 6/04/2017 Escherichia coli ST-131 5391709 50.3 56 318 166898 
LT8875a HH0138 16/04/2017 Escherichia coli ST-12 4989088 50.5 108 170 203071 
LT8876a HH0152 14/04/2017 Klebsiella 
pneumoniae 
ST-562 5515023 53.2 80 327 173893 
LT8877a HH0169 17/04/2017 Escherichia coli ST-131 5200388 49.8 79 377 159114 
LT8880a HH0120 18/04/2017 Escherichia coli ST-38 5244722 50.5 98 390 110346 
LT8883a HH0144 20/04/2017 Escherichia coli ST-131 5064306 50.5 125 263 186549 
LT8887a HH0125 24/04/2017 Escherichia coli ST-131 5140493 50.6 129 270 215233 
LT8888a HH0140 2/05/2017 Escherichia coli ST-295 4702664 50.6 114 268 161944 
LT8897a HH0119 2/05/2017 Escherichia coli ST-80 5183283 50.1 128 341 165660 
LT8899a HH0121 30/04/2017 Escherichia coli ST-131 5293073 50.4 100 349 161706 
LT8910a HH0116 4/05/2017 Klebsiella 
pneumoniae 
ST-562 5544867 52.4 103 442 249057 
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Isolate ID Household Collection date Species MLST 
Genome 
size (bp) GC% 
Read 
depth Contigs N50 
LT8913a HH0132 23/05/2017 Escherichia coli ST-1193 5096054 50.4 132 297 162796 
LT8914a HH0124 24/05/2017 Escherichia coli ST-38 5303500 50.2 115 274 150170 
LT8929a HH0131 10/05/2017 Escherichia coli ST-131 5172032 50.3 140 355 170469 
LT8933a HH0134 15/05/2017 Escherichia coli ST-38 5166554 50.5 121 314 134043 
LT8934a HH0137 13/05/2017 Escherichia coli ST-69 5325629 49.3 71 369 105754 
LT8936a HH0162 6/06/2017 Escherichia coli ST-963 5148386 50.7 62 295 92659 
LT8943a HH0171 4/06/2017 Escherichia coli ST-405 5308992 51.1 70 751 84207 
LT8944a HH0126 30/05/2017 Escherichia coli ST-131 5120691 50.2 136 413 186427 
LT8951a HH0173 1/06/2017 Escherichia coli ST-117 5095165 48.9 70 521 97680 
LT8953a HH0165 10/06/2017 Escherichia coli ST-69 5166376 49.8 72 364 88273 
LT8957a HH0122 10/06/2017 Escherichia coli ST-131 4943026 50.4 135 316 179239 
LT8962a HH0167 13/06/2017 Escherichia coli ST-131 5268001 50.8 73 327 174580 
LT8967a HH0177 14/06/2017 Escherichia coli ST-10 5227291 50.6 69 419 106120 
LT8969a HH0143 13/06/2017 Escherichia coli ST-38 5479616 50.2 150 454 106014 
LT8974a HH0164 21/06/2017 Escherichia coli ST-141 4994712 50.1 77 181 302140 
LT8989a HH0123 23/06/2017 Escherichia coli ST-131 5218304 50.3 124 380 173037 
LT8994a HH0159 2/07/2017 Escherichia coli ST-90 4971338 50.2 81 261 184340 
LT8995a HH0151 1/07/2017 Escherichia coli ST-131 5060282 50.5 88 235 172469 
LT8999a HH0146 6/07/2017 Escherichia coli ST-963 5075554 50.7 81 269 118379 
LT9002a HH0150 10/07/2017 Escherichia coli ST-127 5104681 50.5 83 402 184777 
LT9007a HH0153 8/07/2017 Escherichia coli ST-131 5226954 50.5 79 294 161706 
LT9015a HH0127 12/07/2017 Escherichia coli ST-62 5327794 50 128 395 86846 
LT9021a HH0129 14/07/2017 Escherichia coli ST-131 5140073 50.1 115 409 135107 
LT9024a HH0128 17/07/2017 Morganella 
morganii 
NOT-TYPED 4065243 52.5 129 293 162188 
LT9027a HH0130 17/07/2017 Escherichia coli ST-648 5309875 49.7 128 366 116087 
LT9028a HH0157 17/07/2017 Escherichia coli ST-131 5014608 50.3 74 249 182295 
LT9030a HH0175 19/07/2017 Escherichia coli ST-405 5186899 50.8 83 303 88999 
LT9031a HH0147 19/07/2017 Escherichia coli ST-80 5123063 49 91 309 135186 
LT9034a HH0174 20/07/2017 Escherichia coli ST-131 5391368 50.8 86 348 159143 
LT9039a HH0149 22/07/2017 Escherichia coli ST-131 5377760 51.1 78 394 166801 
LT9040a HH0166 28/07/2017 Escherichia coli ST-69 5336519 50.7 84 314 100522 
LT9041a HH0176 28/07/2017 Escherichia coli ST-131 5047349 50.5 81 220 154568 
LT9046a HH0170 25/07/2017 Escherichia coli ST-38 4945073 50.3 80 224 166225 
LT9050a HH0158 3/08/2017 Escherichia coli ST-349 4878614 50.7 80 135 197221 
LT9067a HH0161 9/08/2017 Escherichia coli ST-648 5322144 50.3 87 298 115632 
LT9074a HH0154 14/08/2017 Escherichia coli ST-2003 5397428 50.3 85 394 121985 
LT9092a HH0179 21/08/2017 Escherichia coli ST-354 5051326 50.5 87 185 173398 
LT9095a HH0160 18/08/2017 Escherichia coli ST-131 5043550 50.6 90 221 180557 
LT9099a HH0163 28/08/2017 Escherichia coli ST-1193 5013936 50.2 83 180 160714 
LT9101a HH0172 27/08/2017 Escherichia coli ST-38 5488417 50.7 93 398 111014 
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Table 6.2 Appendix III chapter 4 isolates 
Isolate ID Source Household Collection date Species MLST 
Genome 
size (bp) GC 
Read 
depth Contigs N50 
LT1003c Human HH0008 13/12/2015 Escherichia coli ST-69 5434577 50.7 94 553 164042 
LT1003d Human HH0008 13/12/2015 Escherichia coli ST-69 5445852 50.6 135 575 158266 
LT1003e Human HH0008 13/12/2015 Escherichia coli ST-69 5436162 49 73 627 121170 
LT1003f Human HH0008 13/12/2015 Escherichia coli ST-58 4864009 50.7 82 248 119956 
LT1003g Human HH0008 13/12/2015 Escherichia coli ST-69 5434782 50.4 107 540 150367 
LT1003h Human HH0008 13/12/2015 Escherichia coli ST-69 5443523 50.5 109 590 158266 
LT1030c Human HH0015 12/02/2016 Escherichia coli ST-963 5174159 50.5 113 288 94030 
LT1030d Human HH0015 12/02/2016 Escherichia coli ST-963 5182980 50.1 125 298 97413 
LT1030e Human HH0015 12/02/2016 Escherichia coli ST-963 5172726 50.1 83 269 94501 
LT1030f Human HH0015 12/02/2016 Escherichia coli ST-963 5176389 50.2 59 279 93422 
LT1030g1 Human HH0015 12/02/2016 Escherichia coli ST-963 5171168 50 71 267 93422 
LT1030h2 Human HH0015 12/02/2016 Escherichia coli ST-963 5168471 50 61 249 117931 
LT1028a Human HH0016 12/02/2016 Escherichia coli ST-500 5221272 49.2 105 402 112357 
LT1028b Human HH0016 12/02/2016 Escherichia coli ST-500 5254279 49.5 89 361 121189 
LT1028c2 Human HH0016 12/02/2016 Escherichia coli ST-500 5215390 49.6 88 367 104399 
LT1028d Human HH0016 12/02/2016 Escherichia coli ST-500 5252332 49.5 114 358 121189 
LT1028e Human HH0016 12/02/2016 Escherichia coli ST-500 5207435 49.4 96 304 120914 
LT1028f Human HH0016 12/02/2016 Escherichia coli ST-500 5247202 50 144 327 121134 
LT1028g Human HH0016 12/02/2016 Escherichia coli ST-500 5216141 50 111 326 112357 
LT1028h Human HH0016 12/02/2016 Escherichia coli ST-500 5247855 50 122 345 121134 
LT1029d Human HH0016 12/02/2016 Escherichia coli ST-500 5248669 49.9 147 316 119604 
LT1029e Human HH0016 12/02/2016 Escherichia coli ST-500 5264378 49.9 141 346 112400 
LT1029f Human HH0016 12/02/2016 Escherichia coli ST-500 5245042 49.9 133 312 104398 
LT1029g Human HH0016 12/02/2016 Escherichia coli ST-500 5156463 49.7 103 298 121024 
LT1029h Human HH0016 12/02/2016 Escherichia coli ST-500 5245579 50.1 158 336 104399 
LT1033c Human HH0024 11/03/2016 Escherichia coli ST-131 5161406 50.1 103 254 160632 
LT1033d Human HH0024 11/03/2016 Escherichia coli ST-131 5165516 50 85 269 159842 
LT1033e Human HH0024 11/03/2016 Escherichia coli ST-648 5274284 49.8 104 266 154029 
LT1033f Human HH0024 11/03/2016 Escherichia coli ST-131 5173677 50.1 113 281 160608 
LT1033g Human HH0024 11/03/2016 Escherichia coli ST-648 5274564 49.6 100 236 154186 
LT1033h Human HH0024 11/03/2016 Escherichia coli ST-131 5150923 50.2 121 246 160462 
LT1034a Human HH0024 11/03/2016 Escherichia coli ST-131 5104681 50.3 139 224 160490 
LT1034b Human HH0024 11/03/2016 Escherichia coli ST-131 5113673 50.3 110 250 160353 
LT1034c Human HH0024 11/03/2016 Escherichia coli ST-131 5118124 50.6 294 248 160736 
LT1034d Human HH0024 11/03/2016 Escherichia coli ST-131 5113867 50.5 172 251 160703 
LT1034e Human HH0024 11/03/2016 Escherichia coli ST-131 5104204 50.4 101 213 160814 
LT1034f Human HH0024 11/03/2016 Escherichia coli ST-131 5108057 50.5 141 228 159114 
LT1034g Human HH0024 11/03/2016 Escherichia coli ST-131 5107222 50.5 94 227 160606 
LT8052a Human HH0015 28/10/2015 Escherichia coli ST-963 5150269 50.5 134 320 115994 
LT1043a Human HH0026 8/03/2016 Escherichia coli ST-617 4897051 50.3 156 344 87883 
LT1043b Human HH0026 8/03/2016 Escherichia coli ST-617 4882334 50.2 112 284 90674 
LT1043c Animal HH0026 8/03/2016 Escherichia coli ST-617 4888721 50.4 164 294 87883 
LT1043d Human HH0026 8/03/2016 Escherichia coli ST-617 4889993 50.3 196 310 88609 
LT1043e Animal HH0026 8/03/2016 Escherichia coli ST-617 4887791 50.4 100 282 90674 
LT1043f Animal HH0026 8/03/2016 Escherichia coli ST-617 4886047 50.5 157 282 88609 
LT1043g Human HH0026 8/03/2016 Escherichia coli ST-617 4887243 50.3 121 303 88130 
LT1043h Human HH0026 8/03/2016 Escherichia coli ST-617 4886315 50.3 135 289 87669 
LT1044g Human HH0026 8/03/2016 Escherichia coli ST-1193 4985966 50.3 118 219 136965 
LT1044h Human HH0026 8/03/2016 Escherichia coli ST-1193 4978130 49.7 95 199 136965 
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Isolate ID Source Household Collection date Species MLST 
Genome 
size (bp) GC 
Read 
depth Contigs N50 
LT1089c Human HH0039 7/05/2016 Escherichia coli ST-131 5246570 50.4 116 346 154224 
LT1089d Human HH0039 7/05/2016 Escherichia coli ST-131 5245849 50.6 110 373 156060 
LT1089e Human HH0039 7/05/2016 Escherichia coli ST-131 5241731 50.7 112 348 154224 
LT1089f Human HH0039 7/05/2016 Escherichia coli ST-131 5244117 50.4 109 344 154224 
LT1090c Human HH0039 7/05/2016 Escherichia coli ST-131 5195527 51.1 115 375 135260 
LT1090d Human HH0039 7/05/2016 Escherichia coli ST-131 5189400 50.6 117 372 154224 
LT1090e Human HH0039 7/05/2016 Escherichia coli ST-131 5184690 50.1 90 333 135260 
LT1090f Human HH0039 7/05/2016 Escherichia coli ST-131 5188047 50.8 113 305 173795 
LT8062a Human HH0008 9/11/2015 Escherichia coli ST-69 5492481 51.5 48 243 285535 
LT1078c Human HH0040 6/05/2016 Escherichia coli ST-131 5167731 49.8 57 228 170471 
LT1078d Human HH0040 6/05/2016 Escherichia coli ST-131 5163690 50.6 112 191 178679 
LT1078e Human HH0040 6/05/2016 Escherichia coli ST-131 5164730 50.3 137 189 178679 
LT1078f Human HH0040 6/05/2016 Escherichia coli ST-131 5164284 50.5 129 199 178679 
LT1078g Human HH0040 6/05/2016 Escherichia coli ST-131 5165121 50.1 90 210 178679 
LT1078h Human HH0040 6/05/2016 Escherichia coli ST-131 5168065 50.4 121 211 178679 
LT1079a Human HH0040 6/05/2016 Escherichia coli ST-131 5166581 50.4 102 219 178679 
LT1079b Human HH0040 6/05/2016 Escherichia coli ST-131 5169484 50.5 123 206 178679 
LT1079c Human HH0040 6/05/2016 Escherichia coli ST-131 5168641 50.4 256 244 170471 
LT1079d Human HH0040 6/05/2016 Escherichia coli ST-131 5165281 50.4 136 216 178679 
LT1079e Human HH0040 6/05/2016 Escherichia coli ST-131 5165605 50.4 142 205 178679 
LT1079f Human HH0040 6/05/2016 Escherichia coli ST-131 5169293 50.5 136 202 178679 
LT1079g Human HH0040 6/05/2016 Escherichia coli ST-131 5172039 50.6 161 241 178679 
LT1079h Human HH0040 6/05/2016 Escherichia coli ST-131 5162297 50.2 90 204 178679 
LT1080c Human HH0040 6/05/2016 Escherichia coli ST-131 5176850 50.4 140 243 178679 
LT1080d Human HH0040 6/05/2016 Escherichia coli ST-131 5172358 50.4 133 220 180448 
LT1080e Human HH0040 6/05/2016 Escherichia coli ST-131 5172620 50.3 212 233 178679 
LT1080f Human HH0040 6/05/2016 Escherichia coli ST-131 5152282 50.4 132 197 178679 
LT1080g Human HH0040 6/05/2016 Escherichia coli ST-131 5154204 50.3 58 204 178679 
LT1080h Human HH0040 6/05/2016 Escherichia coli ST-131 5190026 50.8 175 312 181987 
LT1082a Human HH0040 6/05/2016 Escherichia coli ST-131 5173724 50.7 154 237 180448 
LT1082b Human HH0040 6/05/2016 Escherichia coli ST-131 5178377 50.7 180 253 180448 
LT1082c Human HH0040 6/05/2016 Escherichia coli ST-131 5170299 50.2 86 219 178679 
LT1082d Human HH0040 6/05/2016 Escherichia coli ST-131 5168602 50.5 124 211 180448 
LT1082e Human HH0040 6/05/2016 Escherichia coli ST-131 5167410 50.8 114 200 178679 
LT1082f Human HH0040 6/05/2016 Escherichia coli ST-131 5164692 50.3 107 181 170471 
LT1082g Human HH0040 6/05/2016 Escherichia coli ST-131 5172487 51.3 138 223 178679 
LT1097c Human HH0048 26/06/2016 Escherichia coli ST-38 5158294 51 111 349 129502 
LT1097d Human HH0048 26/06/2016 Escherichia coli ST-38 5189465 51.2 207 516 127781 
LT1097g Human HH0048 26/06/2016 Escherichia coli ST-38 5151025 51.1 129 339 127890 
LT1097h Human HH0048 26/06/2016 Escherichia coli ST-38 5163741 51.1 199 371 129722 
LT1099e Animal HH0048 26/06/2016 Escherichia coli ST-538 5099672 50.3 116 189 218404 
LT1099f Animal HH0048 26/06/2016 Escherichia coli ST-4553 5285110 50 92 173 196514 
LT1099g Animal HH0048 26/06/2016 Escherichia coli ST-38 5151070 50.7 104 344 127952 
LT1099h Animal HH0048 26/06/2016 Escherichia coli ST-38 5147806 51.1 138 301 127778 
LT1143c Animal HH0064 24/09/2016 Escherichia coli ST-2541 4969605 50.2 322 212 183218 
LT1143e Animal HH0064 24/09/2016 Escherichia coli ST-2541 4973592 51 90 230 192896 
LT1143f Animal HH0064 24/09/2016 Escherichia coli ST-2541 4969026 50.2 97 205 192896 
LT1143g Animal HH0064 24/09/2016 Escherichia coli ST-2541 4998195 50.1 103 354 175489 
LT1131c Human HH0065 24/09/2016 Escherichia coli ST-746 4914812 49.6 129 313 97240 
LT1131d Human HH0065 24/09/2016 Escherichia coli ST-10 4811550 50.7 149 243 147407 
LT1131e Human HH0065 24/09/2016 Escherichia coli ST-746 4902883 49.7 130 270 97240 
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LT1131f Human HH0065 24/09/2016 Escherichia coli ST-746 4900803 49.9 119 256 97240 
LT1131g Human HH0065 24/09/2016 Escherichia coli ST-2541 5000520 49.4 112 325 175489 
LT1132b Human HH0065 24/09/2016 Escherichia coli ST-69 5122019 50.4 127 287 164000 
LT1132c Human HH0065 24/09/2016 Escherichia coli ST-69 5127711 50.3 121 318 164000 
LT1132d Human HH0065 24/09/2016 Escherichia coli ST-69 5124906 49.8 97 302 164000 
LT1132e Human HH0065 24/09/2016 Escherichia coli ST-69 5120564 50 122 271 164000 
LT1132f Human HH0065 24/09/2016 Escherichia coli ST-69 5125099 50.1 104 307 158267 
LT8125a Human HH0016 15/12/2015 Escherichia coli ST-500 5270376 50.5 56 216 163953 
LT1132g Human HH0065 24/09/2016 Escherichia coli ST-69 5118820 50.8 134 288 164000 
LT1132h Human HH0065 24/09/2016 Escherichia coli ST-69 5127494 49.8 115 304 163970 
LT8179a Human HH0024 28/01/2016 Escherichia coli ST-131 5160657 51.1 81 178 179969 
LT8198a Human HH0026 5/02/2016 Escherichia coli ST-1193 5092266 50.3 130 574 162923 
LT8231a Human HH0039 4/03/2016 Escherichia coli ST-131 5206381 50.3 99 444 156192 
LT1171g Human HH0086 14/01/2017 Escherichia coli ST-131 5175922 50.7 92 449 180446 
LT1173c Animal HH0086 14/01/2017 Escherichia coli ST-131 5141055 50 100 301 190943 
LT8242a Human HH0040 20/03/2016 Escherichia coli ST-131 5215701 51 181 447 170471 
LT1173d1 Animal HH0086 14/01/2017 Escherichia coli ST-131 5148741 50.2 116 354 180448 
LT1173e Animal HH0086 14/01/2017 Escherichia coli ST-131 5138126 50.1 119 298 180447 
LT8320a Human HH0048 9/05/2016 Escherichia coli ST-38 5161032 51 173 381 123639 
LT8371a Human HH0064 31/05/2016 Escherichia coli ST-963 5153473 50.2 120 338 92286 
LT1173f Animal HH0086 14/01/2017 Escherichia coli ST-131 5165048 50.3 102 422 180447 
LT1173g Animal HH0086 14/01/2017 Escherichia coli ST-131 5141995 49.9 100 311 186438 
LT8455a Human HH0065 25/07/2016 Escherichia coli ST-69 5120029 50.2 151 282 164000 
LT1173h Animal HH0086 14/01/2017 Escherichia coli ST-131 5144385 50.2 128 332 186560 
LT8703a Human HH0086 29/11/2016 Escherichia coli ST-131 5083072 50.6 131 443 178654 
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Table 6.3 Appendix III chapter 5 isolates 
Isolate ID Source Country Collection Date BioProject 
Genome 
size (bp) GC Read depth Contigs N50 
1714605 Human UK 2008 PRJEB4681 5133863 50.6 59 343 159218 
1714932 Human UK 2012 PRJEB4681 5201547 50.1 65 421 160561 
1714948 Human UK 2012 PRJEB4681 5421497 50.5 70 524 161151 
1714962 Human UK 2012 PRJEB4681 5211171 50.3 88 280 181754 
1714986 Human UK 2012 PRJEB4681 5132718 50.7 63 384 159114 
1715013 Human UK 2012 PRJEB4681 5152824 50.3 92 246 159842 
1715017 Human UK 2012 PRJEB4681 5272881 50.7 86 358 143919 
1715025 Human UK 2012 PRJEB4681 5212490 50.7 81 208 168167 
1715026 Human UK 2012 PRJEB4681 5376100 50.7 63 270 165489 
1715433 Human UK 2004 PRJEB4681 5157361 50.8 69 265 180447 
1715525 Human UK 2005 PRJEB4681 5266568 50.6 83 329 161167 
1716160 Human UK 2011 PRJEB4681 5227618 50.8 66 286 166933 
1716161 Human UK 2011 PRJEB4681 5205254 50.8 74 263 181984 
08B09891 Human Thailand 12/07/2008 PRJNA297860 5213193 50.1 192 220 170358 
09B06460 Human Thailand 6/29/09 PRJNA297860 5214690 50.6 159 223 165175 
09B06576 Human Thailand 7/01/2009 PRJNA297860 5217394 50 165 239 170358 
09B09491 Human Thailand 9/12/2009 PRJNA297860 5230962 50.1 115 279 181896 
09B13160 Human Thailand 12/05/2009 PRJNA297860 5213894 50.7 257 215 172886 
1045-14 Human Germany 2014 PRJEB23663 5305259 49.7 35 155 227318 
10B05736 Human Thailand 7/29/10 PRJNA297860 5369383 50 255 373 162133 
11B00062 Human Thailand 1/11/2011 PRJNA297860 5472686 50.7 68 331 162133 
11B00134 Human Thailand 1/24/11 PRJNA297860 5114200 50.7 69 230 159208 
177-10 Human Germany 2010 PRJEB23663 5166100 51.4 74 160 290704 
399-15 Human Germany 2013 PRJEB23663 5233938 51 66 141 399638 
464-16 Animal Germany 2012 PRJEB23663 5146939 51.1 67 157 268119 
495-16 Animal Germany 2012 PRJEB23663 5141936 51 69 144 254110 
497-16 Animal Germany 2012 PRJEB23663 5392554 51 61 160 278043 
590-14 Human Germany 2014 PRJEB23663 5014253 50.5 74 121 191061 
AZ727008 Human Taiwan 6/01/2011 PRJNA297860 5459365 50.1 205 364 159279 
AZ779845 Human Spain 6/01/2011 PRJNA297860 5150376 50.2 180 237 173571 
cam_1071 Human Cambodia 8/11/2008 PRJNA297860 4989360 51.1 73 246 186350 
cam_1439 Human Cambodia 6/02/2009 PRJNA297860 5255888 50.2 73 242 133643 
cam_1814 Human Cambodia 2/03/2010 PRJNA297860 5089841 50.3 75 290 173686 
HVAST501 Human USA 2013 PRJNA327820 5316389 50 82 254 161706 
HVAST502 Human USA 2013 PRJNA327820 5314683 49.9 57 266 165196 
HVAST503 Human USA 2013 PRJNA327820 5218855 49.9 145 259 166700 
HVAST504 Animal USA 2013 PRJNA327820 5331603 49.9 44 329 161706 
HVAST656 Human USA Jan-14 PRJNA327820 5322579 50 198 319 165297 
HVAST695 Human USA Jan-14 PRJNA327820 5457351 49.9 91 381 162981 
HVAST702 Human USA Jan-14 PRJNA327820 5460866 49.9 73 765 170358 
HVAST709 Human USA Jan-14 PRJNA327820 5325091 50 65 326 181409 
HVAST736 Human USA Mar-14 PRJNA327820 5322488 50.2 60 313 180586 
HVAST737 Human USA Mar-14 PRJNA327820 5322870 50 89 306 181587 
HVAST738 Human USA Mar-14 PRJNA327820 5317384 50 41 332 189480 
HVAST740 Human USA Mar-14 PRJNA327820 5325766 50 70 304 180587 
HVAST757 Human USA May-14 PRJNA327820 5324292 50 79 316 170358 
HVAST758 Human USA May-14 PRJNA327820 5339470 49.9 67 371 181409 
HVAST760 Human USA May-14 PRJNA327820 5323983 49.9 51 326 166801 
HVAST761 Human USA May-14 PRJNA327820 5323070 50 41 327 166801 
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HVAST762 Human USA May-14 PRJNA327820 5327026 50.1 59 325 170358 
J0012 Human Japan 2014 PRJDB3868 5119860 51.7 26 232 83662 
J0019 Human Japan 2014 PRJDB3868 5336912 51.6 30 266 99181 
J0024 Human Japan 2014 PRJDB3868 5223671 51.7 25 490 29926 
J0034 Human Japan 2014 PRJDB3868 5182010 51.4 32 220 112739 
J0045 Human Japan 2014 PRJDB3868 5436972 51.4 32 320 70616 
J0061 Human Japan 2014 PRJDB3868 5212699 51 54 219 191062 
J0063 Human Japan 2014 PRJDB3868 5230437 51.3 18 240 72584 
J0064 Human Japan 2014 PRJDB3868 5289754 51.8 31 359 72836 
J0069 Human Japan 2014 PRJDB3868 5393050 51.7 24 433 38006 
J0074 Human Japan 2014 PRJDB3868 5454764 51.5 31 373 59621 
JJ2546 Human USA 2008 PRJNA327820 5173366 50.6 32 106 205897 
JJ2547 Human USA 2008 PRJNA327820 5164359 50.3 33 105 191575 
JJ2548 Human USA 2008 PRJNA327820 5165515 50.6 30 107 198590 
JJ2888 Human USA 2013 PRJNA327820 5291916 49.9 59 265 165074 
JJ2913 Human USA Jan-14 PRJNA327820 5324868 50 44 331 165297 
JJ2963 Human USA 2014 PRJNA327820 5139324 50.5 32 251 159791 
JJ2974 Human USA 2014 PRJNA327820 5141136 50.6 41 253 166801 
la_11242 Human Laos 6/26/08 PRJNA297860 5116079 50.6 55 179 167002 
la_2266-2 Human Laos 5/26/06 PRJNA297860 5176167 50.8 64 226 178793 
LT8018a Human NZ 10/10/2015 mEpiLab 5301563 50.4 137 335 180448 
LT8092a Human NZ 23/11/2015 mEpiLab 5266448 51.3 66 199 143508 
LT8103a Human NZ 30/11/2015 mEpiLab 5351299 50.1 121 735 162133 
LT8110a Human NZ 4/12/2015 mEpiLab 5144652 50.8 117 261 180447 
LT8144a Human NZ 26/12/2015 mEpiLab 5338622 50.8 59 168 191062 
LT8179a Human NZ 28/01/2016 mEpiLab 5160657 51.1 81 178 179969 
LT8205a Human NZ 8/02/2016 mEpiLab 5128998 50 104 300 160880 
LT8231a Human NZ 4/03/2016 mEpiLab 5206381 50.3 99 444 156192 
LT8242a Human NZ 20/03/2016 mEpiLab 5215701 51 181 447 170471 
LT8262a Human NZ  6/04/2016 mEpiLab 5110787 51 112 178 307664 
LT8306a Human NZ 27/04/2016 mEpiLab 5264432 50.5 110 401 208122 
LT8405a Human NZ 27/06/2016 mEpiLab 4957577 50.7 123 273 178664 
LT8519a Human NZ 30/08/2016 mEpiLab 5122957 50.9 108 269 166692 
LT8534a Human NZ 5/09/2016 mEpiLab 5093878 50.5 129 293 159414 
LT8578a Human NZ 3/10/2016 mEpiLab 5292404 50.5 111 346 133277 
LT8679a Human NZ 2/12/2016 mEpiLab 5290276 50.5 90 257 178374 
LT8703a Human NZ 29/11/2016 mEpiLab 5083072 50.6 131 443 178654 
LT8716a Human NZ 16/12/2016 mEpiLab 5086836 49.6 135 336 173801 
LT8734a Human NZ 17/01/2017 mEpiLab 5108706 50.5 91 318 181516 
LT8744a Human NZ 13/01/2017 mEpiLab 5211205 51 100 153 255513 
LT8771a Human NZ 7/02/2017 mEpiLab 5072572 50.6 139 275 186350 
LT8772a Human NZ 8/02/2017 mEpiLab 5049815 50.9 124 255 181591 
LT8793a Human NZ 21/02/2017 mEpiLab 5293870 50.4 115 358 162730 
LT8795a Human NZ 20/02/2017 mEpiLab 5227381 50.5 118 322 178637 
LT8797a Human NZ 17/02/2017 mEpiLab 5163199 50.3 111 369 159114 
LT8819a Human NZ 17/03/2017 mEpiLab 5413553 50.1 167 486 162190 
LT8825a Human NZ 24/03/2017 mEpiLab 5004821 50.5 103 323 180447 
LT8852a Human NZ 6/04/2017 mEpiLab 5113467 50.7 114 301 154937 
LT8863a Human NZ 10/04/2017 mEpiLab 5147584 50.5 118 231 181672 
LT8866a Human NZ 12/04/2017 mEpiLab 5208737 50.6 109 243 151001 
LT8868a Human NZ 6/04/2017 mEpiLab 5391709 50.3 56 318 166898 
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LT8877a Human NZ 17/04/2017 mEpiLab 5200388 49.8 79 377 159114 
LT8883a Human NZ 20/04/2017 mEpiLab 5064306 50.5 125 263 186549 
LT8887a Human NZ 24/04/2017 mEpiLab 5140493 50.6 129 270 215233 
LT8899a Human NZ 30/04/2017 mEpiLab 5293073 50.4 100 349 161706 
LT8929a Human NZ 10/05/2017 mEpiLab 5172032 50.3 140 355 170469 
LT8944a Human NZ 30/05/2017 mEpiLab 5120691 50.2 136 413 186427 
LT8957a Human NZ 10/06/2017 mEpiLab 4943026 50.4 135 316 179239 
LT8962a Human NZ 13/06/2017 mEpiLab 5268001 50.8 73 327 174580 
LT8989a Human NZ 23/06/2017 mEpiLab 5218304 50.3 124 380 173037 
LT8995a Human NZ  1/07/2017 mEpiLab 5060282 50.5 88 235 172469 
LT9007a Human NZ 8/07/2017 mEpiLab 5226954 50.5 79 294 161706 
LT9021a Human NZ 14/07/2017 mEpiLab 5140073 50.1 115 409 135107 
LT9028a Human NZ 17/07/2017 mEpiLab 5014608 50.3 74 249 182295 
LT9034a Human NZ 20/07/2017 mEpiLab 5391368 50.8 86 348 159143 
LT9039a Human NZ 22/07/2017 mEpiLab 5377760 51.1 78 394 166801 
LT9041a Human NZ 28/07/2017 mEpiLab 5047349 50.5 81 220 154568 
LT9095a Human NZ 18/08/2017 mEpiLab 5043550 50.6 90 221 180557 
MER10 Human Singapore 2014 PRJNA398288 5269828 51.3 42 367 159842 
MER101 Human Singapore 2015 PRJNA398288 5029861 50.4 77 188 182402 
MER102 Human Singapore 2015 PRJNA398288 5065233 50.2 80 236 186661 
MER103 Human Singapore 2015 PRJNA398288 5251272 50.4 73 300 163754 
MER104 Human Singapore 2015 PRJNA398288 5128356 50.4 74 228 181788 
MER105 Human Singapore 2015 PRJNA398288 5253144 49.9 82 283 165175 
MER106 Human Singapore 2015 PRJNA398288 5344314 50.5 65 883 117871 
MER107 Human Singapore 2015 PRJNA398288 5208827 50 70 168 164549 
MER110 Human Singapore 2015 PRJNA398288 5388020 50 71 337 154350 
MER111 Human Australia 2015 PRJNA398288 5208675 50.4 68 355 161706 
MER13 Human Singapore 2014 PRJNA398288 5218809 51.4 44 145 127084 
MER14 Human Singapore 2014 PRJNA398288 5090551 51.7 47 177 129226 
MER15 Human Singapore 2014 PRJNA398288 5047310 51.6 48 198 115630 
MER25 Human Australia 2014 PRJNA398288 5240179 51.5 51 178 124268 
MER27 Human Australia 2014 PRJNA398288 5246253 51.3 54 164 147565 
MER29 Human Singapore 2014 PRJNA398288 5277802 51.3 34 196 121450 
MER30 Human Singapore 2014 PRJNA398288 5350647 51.7 56 192 166561 
MER36 Human Singapore 2014 PRJNA398288 5283551 51.5 43 193 155550 
MER37 Human Singapore 2014 PRJNA398288 5286641 51.6 48 229 110569 
MER38 Human Singapore 2014 PRJNA398288 5251674 51.6 55 210 146765 
MER39 Human Singapore 2014 PRJNA398288 5295986 51.6 47 233 129180 
MER42 Human Singapore 2014 PRJNA398288 5005109 51.4 43 114 173937 
MER49 Human Australia 2014 PRJNA398288 5288341 50.4 75 328 159742 
MER51 Human Australia 2014 PRJNA398288 5202477 50.6 79 257 165188 
MER52 Human Australia 2015 PRJNA398288 5164782 50.7 66 273 159741 
MER53 Human Australia 2015 PRJNA398288 5266973 50.3 74 320 112549 
MER56 Human Australia 2015 PRJNA398288 5130224 50.6 64 249 180448 
MER58 Human Australia 2015 PRJNA398288 5179848 50.5 66 315 186350 
MER65 Human NZ 2015 PRJNA398288 5174463 50.4 72 247 167861 
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MER66 Human NZ 2015 PRJNA398288 5150672 50.5 73 225 170471 
MER68 Human Australia 2015 PRJNA398288 5084775 50.5 75 213 160730 
MER78 Human Singapore 2015 PRJNA398288 5216233 50.5 76 300 161677 
MER8 Human Singapore 2014 PRJNA398288 5231284 51.3 39 274 162133 
MER80 Human Singapore 2015 PRJNA398288 5356404 50.1 73 289 168013 
MER82 Human Singapore 2015 PRJNA398288 5253221 50.8 90 310 167861 
MER83 Human Singapore 2015 PRJNA398288 5453864 50.7 86 425 156923 
MER87 Human Singapore 2015 PRJNA398288 5296713 50.4 92 319 159842 
MER88 Human Singapore 2015 PRJNA398288 5203197 50.3 88 162 173827 
MER9 Human Singapore 2014 PRJNA398288 5389991 51.2 40 272 159943 
MER94 Human Australia 2015 PRJNA398288 5165447 50.5 75 267 161164 
MER95 Human Singapore 2015 PRJNA398288 5065070 50 73 213 159056 
MER97 Human Singapore 2015 PRJNA398288 5346843 50.1 73 154 191062 
N0241 Human Nepal 2014 PRJDB3868 5306712 50.6 61 138 198585 
N0253 Human Nepal 2014 PRJDB3868 5311538 50.7 42 164 191062 
N0256 Human Nepal 2014 PRJDB3868 5311234 50.5 40 155 191917 
N0261 Human Nepal 2014 PRJDB3868 5277170 50.7 78 140 200546 
N0282 Human Nepal 2014 PRJDB3868 5325251 50.7 43 162 191062 
N0291-1 Human Nepal 2014 PRJDB3868 5289555 50.7 47 123 229897 
N0291-2 Human Nepal 2014 PRJDB3868 5216278 50.7 49 109 191424 
N0335 Human Nepal 2014 PRJDB3868 5243853 50.6 55 133 187028 
N0348 Human Nepal 2014 PRJDB3868 5384855 50.7 47 154 178652 
N0415 Human Nepal 2014 PRJDB3868 5422539 50.6 50 137 191062 
N0422 Human Nepal 2014 PRJDB3868 5056197 50.7 44 74 229897 
N0439 Human Nepal 2014 PRJDB3868 5107365 50.7 48 105 198380 
N0491 Human Nepal 2014 PRJDB3868 5090341 50.9 63 108 198708 
N0494-1 Human Nepal 2014 PRJDB3868 5207989 50.9 41 111 190119 
N0494-2 Human Nepal 2014 PRJDB3868 5206093 50.8 46 105 276325 
N0504 Human Nepal 2014 PRJDB3868 5276818 50.6 47 119 191062 
N0512 Human Nepal 2014 PRJDB3868 5337898 50.5 62 112 191062 
N0564 Human Nepal 2014 PRJDB3868 5287023 50.6 67 158 181048 
N0574 Human Nepal 2014 PRJDB3868 5297634 50.5 42 139 178853 
N0603 Human Nepal 2014 PRJDB3868 5382640 50.4 86 133 189826 
N0716 Human Nepal 2014 PRJDB3868 5364572 51.1 44 189 124268 
N0722 Human Nepal 2014 PRJDB3868 5364424 51 37 189 111751 
N0931 Human Nepal 2014 PRJDB3868 5351249 51 63 191 191026 
N0945 Human Nepal 2014 PRJDB3868 5252593 50.8 61 138 178749 
N0951 Human Japan 2014 PRJDB3868 5300906 51.1 53 204 171991 
N0985-1 Human Nepal 2014 PRJDB3868 5142191 50.8 43 115 203384 
N0985-2 Human Nepal 2014 PRJDB3868 5227108 50.7 89 146 191062 
N1001 Human Nepal 2014 PRJDB3868 5371583 50.9 68 181 133039 
N1027 Human Nepal 2014 PRJDB3868 5258159 50.6 49 143 174012 
N1051 Human Nepal 2014 PRJDB3868 5259830 50.8 49 198 174445 
176 
 
Isolate ID Source Country Collection Date BioProject 
Genome 
size (bp) GC Read depth Contigs N50 
N1086 Human Nepal 2014 PRJDB3868 5273241 50.7 63 176 159190 
N1160 Human Nepal 2014 PRJDB3868 5350836 50.9 53 222 178188 
N1167 Human Nepal 2014 PRJDB3868 5319940 51 51 202 142115 
N1200 Human Nepal 2014 PRJDB3868 5228565 51.1 62 111 178853 
N1203 Human Nepal 2014 PRJDB3868 5214817 51 56 128 173296 
N1228 Human Nepal 2014 PRJDB3868 5199701 50.8 48 145 178643 
N1229 Human Nepal 2014 PRJDB3868 5260469 51.3 54 104 191062 
N1240 Human Nepal 2014 PRJDB3868 5355670 50.9 73 169 190708 
N1249 Human Nepal 2014 PRJDB3868 5333602 50.9 48 139 173945 
N1252 Human Nepal 2014 PRJDB3868 5283262 51.3 70 168 164069 
N1253 Human Nepal 2014 PRJDB3868 5245565 50.9 68 149 178623 
N1274 Human Nepal 2014 PRJDB3868 5290942 51.2 58 162 173945 
N1332 Human Nepal 2014 PRJDB3868 5276883 50.9 47 159 172068 
N1341 Human Nepal 2014 PRJDB3868 5438687 50.9 91 193 191062 
N1345 Human Nepal 2014 PRJDB3868 5271265 51.1 86 126 198708 
N1385 Human Nepal 2014 PRJDB3868 5280387 50.9 72 146 184484 
N1417 Human Nepal 2014 PRJDB3868 5312414 50.8 83 180 191062 
N1421 Human Nepal 2014 PRJDB3868 5315904 51.1 33 168 112552 
N1429 Human Nepal 2014 PRJDB3868 5540733 50.8 83 209 188745 
N1442 Human Nepal 2014 PRJDB3868 5160223 50.9 63 132 187028 
N1471 Human Nepal 2014 PRJDB3868 5048383 51.1 73 118 173830 
N1504 Human Nepal 2014 PRJDB3868 5179466 51 62 124 194593 
N1539 Human Nepal 2014 PRJDB3868 5362469 51.1 64 127 170502 
N1753 Human Nepal 2014 PRJDB3868 5202466 50.6 56 91 208633 
N1767 Human Nepal 2014 PRJDB3868 5264752 51.1 112 123 191062 
N1795 Human Nepal 2014 PRJDB3868 5312932 50.8 59 156 198152 
RL229 Animal Germany 2012 PRJEB23663 5518631 51.2 46 182 139447 
uk_17A7A Human UK 3/06/2009 PRJNA297860 5296746 50.5 53 251 159742 
uk_17B26A Human UK 7/05/2009 PRJNA297860 5249169 50.5 54 259 181608 
uk_17C26C Human UK 9/09/2009 PRJNA297860 5225947 50.5 45 316 157443 
uk_18A18K Human UK 11/08/2009 PRJNA297860 5129087 51 53 250 159160 
uk_18A33A Human UK 12/06/2009 PRJNA297860 5228378 50.7 64 286 159646 
uk_18B11D Human UK 1/03/2010 PRJNA297860 5344511 50.7 48 390 178792 
uk_18B18D Human UK 1/23/10 PRJNA297860 5259907 50.5 82 283 178792 
uk_18B21F Human UK 2/01/2010 PRJNA297860 5128269 50.7 56 256 159842 
uk_18B28B Human UK 2/16/10 PRJNA297860 5248594 50.7 50 249 178792 
uk_18B30B Human UK 2/20/10 PRJNA297860 5259480 50.3 49 216 180907 
uk_18C14 Human UK 4/09/2010 PRJNA297860 5344204 50.7 42 606 165175 
uk_18C29E Human UK 5/14/10 PRJNA297860 5458883 50.6 48 256 164451 
uk_18C4F Human UK 3/16/10 PRJNA297860 5258453 50 64 228 181988 
uk_19A21D Human UK 7/28/10 PRJNA297860 5262125 50.6 51 271 159742 
uk_19B17I Human UK 10/13/10 PRJNA297860 5247066 50.8 59 249 159843 
uk_7C26H Human UK 6/20/08 PRJNA297860 5236119 50.9 57 262 159742 
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uk_8A9B Human UK 7/26/08 PRJNA297860 5065639 50.7 62 399 178750 
uk_P16456 Human UK 1/01/2005 PRJNA297860 5200246 50.9 41 243 159160 
uk_P26250 Human UK 1/01/2005 PRJNA297860 5217304 50.9 51 226 174535 
uk_P34091 Human UK 1/01/2005 PRJNA297860 5233725 50.8 61 249 159742 
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Appendix IV: Questionnaire  
Questionnaire development 
This questionnaire was designed in early 2015, primarily by myself, with assistance from 
the post-doctoral fellow working on this project (Dr Zoe Grange), my PhD supervisors, 
and other external collaborators [Professor Jeroen Douwes (Massey University Centre 
for Public Health), Professor Michael Baker (Otago University Department of Public 
Health), and Dr Dragana Drinkovic (clinical microbiologist at Waitemata District Health 
Board)]. I based questions on known or suspected risk factors (e.g. healthcare contact, 
antimicrobial use, international travel) and questions around the exposure of interest (pet 
contact). The key resources for designing this questionnaire were the New Zealand and 
California Health surveys (below). I also used the experiences of Dr Patricia Jaros, who 
had recently completed her PhD and had conducted a similar prospective case control 
study (Jaros et al. 2013). 
• California health interview survey  
o http://healthpolicy.ucla.edu/chis/design/Pages/questionnairesEnglish.a
spx 
• New Zealand health Survey  
o https://www.health.govt.nz/nz-health-statistics/national-collections-
and-surveys/surveys/new-zealand-health-survey 
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Case questionnaire 
“Where you can, please answer all questions for the time-period prior to your diagnosis 
with a multi-drug resistant infection (ESBL or AmpC). Please remember that for our 
survey to be accurate, it would be better that you do not answer the question than give an 
answer you think we want to hear. 
“If you have any questions, please call Leah Toombs-Ruane  on 06-3569099 ext 84101  or 
email me at L.J.Toombs-Ruane@massey.ac.nz  
“Your input is important as it will help us to understand the risk factors associated with 
these infections, and will provide important information to help reduce future infections. 
The survey has been approved by the National Human Ethics Committee. The interview 
is confidential and will take no more than 20 minutes to complete, depending on your 
answers. By agreeing to take part, you accept that your data will be used in research that 
may be published. We will never publish your personal information and guarantee that 
your privacy is protected. In order to comply with the rules for this survey, specified by 
the National Humans Ethics Committee, can I have your verbal consent to use your 
answers for research purposes only. As I said before, your personal details and any of your 
given information will remain anonymous, it will be treated with ethical respect and not 
be revealed to any person or institute other than the researchers of this survey.” 
Please tell us your name: __________________________ 
What is the date? ____ / ____ / 2017 
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INTRO1A    Are you 16-years or older? 
 
1.            Yes  
2.            No ( If this is your answer: Sorry we are not able to include you in the study. 
Thank you for your time) 
ETHICS     Do you consent for your answers to be used for research purposes only? 
1. Yes 
No (If this is your answer: Sorry we are not able to include you in the study. Thank 
you for your time) 
2. E1         Are you happy to participate in this survey? 
1.           Yes – proceed (GO TO E2)  
2.           No – don’t proceed 
 
E2 Before we start, I need to confirm a couple of things about you. In the last 12 
months (before your diagnosis with a multidrug resistant infection), have you:            
           A) Been admitted overnight to a hospital for any reason OR 
           B) Lived in a residential care facility such as a rest home or rehabilitation facility? 
1.  ‘A’ or ‘B’ (If this is your answer: Sorry we are not able to include 
you in the study. Thank you for your time) 
2. Neither   
3. Unsure/Refused 
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HOUSEHOLD DEMOGRAPHICS 
Q1 Firstly, has there been more than one person (including yourself) living in your 
household in the past week? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q1A Thinking about the males and females that lived in your household in the last week 
including yourself, how many were.....: 
              -1- Men aged 18 or over? _________ 
 -2- Boys aged 5 to 17 years? _________ 
 -3- Boys under 5 years? _________ 
  -4- Women aged 18 or over? _________ 
  -5- Girls aged 5 to 17 years? _________ 
  -6- Girls under 5 years? _________ 
 
Q1B And how many couples live together in your household? 
_________ [ENTER NUMBER - TWO PEOPLE EQUALS ONE COUPLE] 
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ANIMAL CONTACT 
 
The following questions are regarding contact with animals. Remember that for our 
survey to be accurate, it would be better that you do not answer the question than give an 
answer you think we want to hear. 
Q2 Do you have pets that live in, at or with your household? 
 
1. Yes 
2. No   (GO TO Q21) 
3. Unsure  (GO TO Q21) 
4. Refused (GO TO Q21) 
 
Q3 Has at least one of your pets lived in, at or with your household for the last 6-
months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q4 Please tell me how many of each of the following species of pet(s) you have in your 
household at present. How many...? 
[ENTER NUMBER FOR EACH ANIMAL] 
-1- Cats ____ 
-2- Dogs ____ 
-3- Chickens ____ 
-4- Pet birds (not chickens) ____ 
-5- Rabbits ____ 
-6- Reptiles ____ 
-7- Rodents ____ 
-8- Other animals ____ 
Q4A Excluding those already mentioned, please tell me the types of other pets you have 
in your household? 
__________________________ (WRITE ANSWER) 
 
Q5 Where did your pet(s) originally come from? 
 [MULTIPLE RESPONSE OK] 
1. Breeder ____ 
2. Friend or family ____ 
3. From a previous litter ____ 
4. Found and adopted ____ 
5. Pet shop ____ 
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6. SPCA or animal shelter ____ 
7. Was already here at this address ____ 
8. Other sources ____ 
9.  Unsure ____ 
10.  Refused ____ 
Q5A What other sources were these? 
___________________________ 
Q6 Have any of your current household pet(s) ever travelled outside of New Zealand? 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q6A What countries has your pet(s) travelled to or come from? 
 
[MULTIPLE RESPONSE] 
1. Australia 
2. Canada 
3. China 
4. Fiji 
5. Germany 
6. Ireland 
7. Japan 
8. Samoa 
9. Tonga 
10. United Kingdom 
11. United States of America 
12.  Unsure 
13.  Refused 
14. Other (specify) 
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Q6B Did your pet(s) enter New Zealand within the past 12 months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
            
Q7 Do any pet(s) in your household ever sleep indoors? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q7A Do pet(s) in your household sleep in or on the same bed as you (or other people in 
the household) at any time? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q7A1 And which people do the pet(s) sleep with? 
 
1. Just you (respondent) 
2. Other people 
3. Both you (respondent) and other people 
4.  Unsure 
5.  Refused 
 
Q7A2 Which of the following animal(s) sleep with you (or other people in the 
household)? 
-1- Cats  
-2- Dogs 
-4- Pet birds (not chickens) 
-5- Rabbits 
-6- Reptiles 
-7- Rodents 
-8- Other animals 
1. Yes 
2. No 
3.  Unsure 
4.  Refused 
Q8 Do the pet(s) in your household lick your face? 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q9 Do you personally clean litter trays or collect and dispose of pet faeces or urine 
(such as handling litter, manure, droppings, or cleaning cage/kennel)? 
 
1. Yes 
2. No 
3. Not applicable 
4. Unsure 
5. Refused 
Q10 Does another adult or child in the household besides you dispose of pet faeces 
(poo) or urine (wee) (such as handling litter, manure, droppings, or cleaning 
cage/kennel)? 
 
1. Adults 
2. Children 
3. Both children and adults 
4. No other person 
5.  Unsure 
6.  Refused 
 
Q11 Have your pets visited anywhere outside your home and garden in the past 6-
months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q11A Have your pets visited any of the following places outside of your home and garden 
in the past 6-months? 
 
[MULTIPLE RESPONSE CIRCLE] 
1. Around the local streets 
2. Farm or lifestyle block 
3. Cattery or kennel 
4. Dog park 
5. Beach 
6. River/fresh waterway 
7. Campground 
8. Animal day care 
9. Hospital or residential care home 
10. Park/bush 
11. Animal shelter or pound 
12. To homes of family or friends 
13. School 
14. Other places 
15.  Unsure 
16.  Refused 
Q11A1 What other places did they visit? 
____________________________ 
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Q12 What type or types of food does your cat(s) eat as far as you know? 
 
[MULTIPLE RESPONSE] 
1. Commercial canned or sachet cat food 
2. Commercial dry cat food 
3. Raw meat diet 
4. Home-kill (e.g. from own farm: pig, lamb, bull, etc) 
5. Hunted prey 
6. Raw meat diet 
7. Table scraps 
8.  Unsure 
9.  Refused 
10. Other (specify) 
Q13 What type or types of food does your dog(s) eat as far as you know? 
[MULTIPLE RESPONSE] 
1. Commercial canned dog food 
2. Commercial chilled (dog roll) 
3. Commercial dry dog food 
4. Home-kill (e.g. from own farm: pig, lamb, bull, etc) 
5. Hunted meat 
6. Raw meat diet 
7. Table scraps 
8. Raw bones 
9.  Unsure 
10.  Refused 
11. Other (specify) 
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Q14 What does your pet bird(s) eat as far as you know? 
 [MULTIPLE RESPONSE] 
1. Commercial bird food 
2. Homemade bird food 
3.  Unsure 
4.  Refused 
5. Other (specify) 
 
Q15 As far as you know, does your cat(s) interact with wildlife (including mice, rats, 
birds or lizards)? 
1. Yes 
2. No 
3. Unsure 
4. Refused 
Q16 Do you, or someone in your household, clean your pet's FOOD bowl(s) (or the 
area they are fed) every day? 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q17 If your pet has a WATER bowl, do you, or someone in your household, clean your 
pet's WATER bowl(s) every day? 
 
1. Yes 
2. No 
3. Does not have a separate water bowl 
4. Unsure 
5. Refused 
 
 
The following questions are regarding pet healthcare. Remember, for our survey to be 
accurate, it is better that you do not answer a question than give an answer you think we 
want to hear. 
 
Q18 In the past 6-months has (have) any pet(s) in your household visited a vet? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q18A The following questions relate to any vet visit by any pet in your household during 
the last six months. What was the longest length of time ANY of your pets spent 
at a vet clinic (in a single visit)? 
 
1. General vet consultation 
2. Less than 1 day 
3. 1 to 3 days 
4. 4 to 7 days 
5. 8 or more days 
6. Unsure 
7. Refused 
 
 
Q18B Were any of your pets referred to another clinic/hospital? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q18C Did any of your pets visit the veterinarian as an emergency? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused  
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Q18D Did any of your pets have surgery in the last six months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q18E Was medication given to any of your pets by the vet or prescribed to take home? 
 
[MULTIPLE RESPONSE] 
1. By the vet 
2. Prescribed to take home 
3. No medication given by vet or to take home 
4. Unsure 
5. Refused 
 
 
Q18E1 What were the medications that was administered by the vet or prescribed to take 
home? 
 
[MULTIPLE RESPONSE] 
1. Antibiotic injection 
2. Antibiotic tablet, powder or liquid 
3. Ear/skin ointment 
4. Other 
5. Unsure 
6. Refused 
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Q18E2 What were the name of the medications that was administered by the vet or 
prescribed to take home? 
______________________________________________ 
Q18E3 How many days were the medications prescribed for? 
1. 7 days or less 
2. 8 days or more 
3. Unsure 
4. Refused 
Q18E4 Was the whole treatment course given as prescribed? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
            
Q19 Has (have) any pet(s) in the household ever been diagnosed with an infection 
which is resistant to lots of different drugs. Your vet may have called it a 
'superbug' or an infection resistant to antibiotics? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
Q19A Can you tell us the name of the pet that was diagnosed with this antibiotic resistant 
infection?_______________________________________ 
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Q20 The following questions are about how often you wash your hands with pets in 
your household. Please answer as accurately as possible. Do you wash your hands always, 
often, sometimes, or never...: CIRCLE WHERE APPROPRIATE 
-1- Before feeding animals? 
Always Often Sometimes Never Unsure N/A 
 
-2- After feeding animals? 
Always Often Sometimes Never Unsure N/A 
 
-3- Before petting animals? 
Always Often Sometimes Never Unsure N/A 
 
-4- After petting animals? 
Always Often Sometimes Never Unsure N/A 
 
-5- After a pet licks your hands? 
Always Often Sometimes Never Unsure N/A 
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-6- After collecting and disposing of faeces (poo) or urine (wee) (e.g. handling 
litter, manure, droppings, or cleaning cage/kennel)? 
Always Often Sometimes Never Unsure N/A 
 
Q21 Outside of your household pets, what animal species have you personally had 
DIRECT or INDIRECT physical contact with in the past 6-months? 
 (By DIRECT physical contact, we mean you have touched the animal itself.) 
 (By INDIRECT physical contact, we mean you may have cleaned up their faeces in your 
garden, bought bags of pony pooh for fertiliser, cleaned a cage, fed or handled feeding 
bowls or utensils for example but you have not actually touched the animal.) 
[MULTIPLE RESPONSE] 
1. Aviary birds 
2. Cats 
3. Cattle or cows or calves 
4. Chickens or poultry 
5. Deer 
6. Dogs 
7. Fish 
8. Horses or ponies or donkeys 
9. Llamas or alpacas 
10. Pigs or piglets 
11. Rodents or rabbits 
12. Sheep or lambs 
13. Wildlife or zoo animals 
14.  None 
15.  Unsure 
16.  Refused 
17. Other (specify) 
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Q21A What kind of contact did you have with these animals - was it...? 
 
[MULTIPLE RESPONSE] 
 
1. Bathing animals 
2. Riding or exercising or walking 
3. Petting or stroking or grooming 
4. Feeding 
5. Cleaning cages or kennels 
6. Cleaning stables or pens 
7. Job-related (e.g farm worker, veterinarian, trainer, slaughterhouse 
worker) 
8. Picking up manure or faeces 
9.  Unsure 
10.  Refused 
11. Other (specify) 
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HOUSEHOLD HEALTH 
The following questions are regarding you and your household's health. Please answer 
for the time prior to you diagnosis with a multi-drug resistant infection (ESBL). Please 
answer as many as you feel comfortable or are able to. Remember, for our survey to be 
accurate, it would be better if you do not answer the question than give an answer you 
think we want to hear. 
 
Q22 How would you describe your overall health in the last 6-months? 
 
1. Excellent 
2. Very good 
3. Good 
4. Fair 
5. Poor 
6.  Unsure 
7.  Refused 
 
Q23 Do you have any chronic or underlying health conditions? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q23A Please tell us if you have the following...: 
 
[MULTIPLE RESPONSE] 
 
1. Asthma 
2. Chronic Obstructive Pulmonary Disase which may include emphysema 
and chronic bronchitis or C.O.P.D 
3. Cardiac disease which may include coronary artery disease, angina or a 
previous heart attack 
4. Diabetes 
5.  Unsure 
6.  Refused 
7. Other (specify) 
 
Q24 Have you had a medical visit with a G.P. (or with a specialist as an outpatient) in 
the past 6-months including imaging or radiology? Outpatient means you were 
admitted and discharged from hospital on the same day. 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q25 Have you received treatment as an outpatient in a hospital in the last 6-months? 
Outpatient means you were admitted and discharged from hospital on the same 
day. 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
 
Q26 Have you been to a hospital emergency room (Accident and Emergency) as a 
patient in the last 6-months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
 
Q27 Have you had day surgery in the past year? This means you were admitted and 
discharged from hospital on the same day. 
 
1. Yes 
2. No 
3. Unsure 
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4. Refused 
 
Q27A Please tell us what the reason or procedure was: 
______________________________ 
            
 
Q28 In the past 6 months have you had more than one urinary tract infection (UTI)? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
 
Q29 Have you given birth in the past 6 months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q30 Have you been prescribed antibiotics in the past 6 months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q30A Have you been prescribed antibiotics in the past 3 months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
Q30B Did you complete the course(s) as prescribed? 
 
1. Yes 
2. No 
3. Still taking the antibiotics 
4. Unsure 
5. Refused           
Q30C How many days was your most recent prescribed course of antibiotics for? 
 
1. 7 days or less 
2. 8 days or more 
3. Unsure 
4. Refused 
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Q30D What was the name of your most recent antibiotic medication? 
______________________________________ 
 
 
Q31 Have you ever been told by a doctor that you have an infection which is resistant 
to lots of different antibiotics? Your doctor may have called it a 'superbug' (like an 
ESBL or MRSA).  Or have you been told you are a carrier of a bacteria like MRSA 
- a bacteria which is resistant to lots of different drugs? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
Q31A On what date and what diagnosis did your doctor give you? Please answer as fully 
as possible. 
___________________________________________ 
 
Q31B Were you treated for this antibiotic resistant (superbug) infection? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q31B1 On what date did this treatment end? Please answer accurately aspossible. 
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____________________________________ 
 
Q32 Have any members of the household (other than you) been a patient in a hospital 
or residential care facility in the past 12-months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q32A Could you please tell us the reason? 
_____________________________________ 
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Q32B Can you tell us the longest length of time that any person in your household (other 
than you) spent in a hospital or residential care facility? This should be the longest 
single visit. 
 
1. 12 hours or less 
2. Overnight (13 to 24 hours) 
3. 2 to 3 days 
4. 4 to 7 days 
5. 8 or more days 
6.  Unsure 
7.  Refused 
 
Q33 Have any members of the household (other than you) been prescribed antibiotics 
in the past 6-months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q34 Has any other person in your household ever been told by a doctor they have an 
infection which is resistant to lots of antibiotics. The doctor may have referred to 
it as a 'superbug' (or an ESBL or MRSA). Or have they been told they are a carrier 
of a bacteria like MRSA? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q34A Was this person treated for a multidrug resistant bacterial infection? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
FOOD AND HYGIENE 
 
 
The following questions are regarding food and hygiene in the household. Please answer 
as many as you feel comfortable or are able to. Remember for our survey to be accurate, 
it is better if you do not answer the question than give an answer you think we want to 
hear. 
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Q35 Do you eat meat? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q35A What types of meat do you eat, even if you don't eat it often? Do you eat...: 
 
[MULTIPLE RESPONSE] 
 
1. Chicken/poultry 
2. Lamb 
3. Beef 
4. Fish 
5. Pork 
6. Venison 
7. Home-kill (e.g. from own farm, pig, lamb, etc) 
8. Hunted meat (e.g. venison, wild pork) 
9.  Unsure 
10.  Refused 
11. Other (specify) 
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Q36 Do you drink raw (untreated or unpasteurised) milk? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
 
Q37 Where do you get fresh vegetables from? 
 
[MULTIPLE RESPONSE] 
 
1. Supermarket / Cash and Carry 
2. Farmers market or farm store 
3. Homegrown 
4. Fruit and Vegetable Shop (Greengrocer) 
5. Friends or family 
6.  Unsure 
7.  Refused 
8. Other (specify) 
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Q38 How often do you wash your hands? Please answer as accurately as possible. Do 
you wash your hands always, often, sometimes, or never...: CIRCLE WHERE 
APPROPRIATE 
-1- After going to the toilet? 
Always Often Sometimes Never Unsure N/A 
 
-2- Before handling food? 
Always Often Sometimes Never Unsure N/A 
 
-3- Before eating? 
Always Often Sometimes Never Unsure N/A 
 
-4- After coughing, sneezing or blowing your nose? 
Always Often Sometimes Never Unsure N/A 
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HOUSE AND GARDEN 
 
The following questions are regarding your home and garden. 
 
 
Q39 Would you mind telling us what the nearest primary school to your home is? 
[: This question is to help us know what area you are in, and is used as part of a social 
index for the study.] 
_____________________________________ 
 
 
Q40 Which of the following best describes your living arrangements during the last 
week? 
  
1. Lived in a house owned by me or family trust 
2. Lived in a house with the owner of the house who is not a family member 
3. Lived in a house rented from Housing NZ or Council 
4. Lived in a rented house not owned by Housing NZ or Council 
5.  Unsure 
6.  Refused 
7. Other (specify)  
_____________________________________ 
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Q41 How many bedrooms are in the house you live in, including any rooms furnished 
as a bedroom even if no one is using it? 
[ENTER NUMBER OF BEDROOMS] 
_____________________________________ 
 
 
Q42 Does the house you live in have a garden? 
[: Garden refers to grass or planted/soil areas within the household surrounds.] 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q42A Have you seen cat or dog faeces (poo) in your garden? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
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Q42B Do you have compost in the garden? This includes making compost without 
having used it yet. 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q43 Do you, or someone in your household, put out food for wild birds in your 
household surrounds? 
 
1. Yes 
2. No (GO TO QUESTION 45) 
3. Unsure 
4. Refused 
 
Q43A Where do you (they) put the wild bird food? 
[MULTIPLE RESPONSE] 
1. On the ground 
2. Dish / Plate 
3. Bird feeder 
4. Bird table 
5.  Unsure 
6.  Refused 
7. Other (specify) 
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Q43B How often do you (or someone in your household) clean the items or area you use 
to feed wild birds? 
 
1. Daily 
2. Weekly 
3. Monthly 
4. Few months a year 
5. Never 
6.  Unsure 
7.  Refused 
 
Q43C What do you (they) use to clean the items or area you use to feed wild birds? 
 
[MULTIPLE RESPONSE] 
 
1. Brush / Cloth 
2. Detergent / soapy water 
3. Plain water 
4. Disinfectant 
5.  Unsure 
6.  Refused 
7. Other (specify) 
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Q44 Do you have a wild bird water bath? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q44A How often do you (or someone in your household) clean the wild bird water bath? 
 
1. Daily 
2. Weekly 
3. Monthly 
4. Few months a year 
5. Never 
6.  Unsure 
7.  Refused 
 
Q44B What do you (they) use to clean the wild bird water bath? 
 
[MULTIPLE RESPONSE] 
 
1. Brush / Cloth 
2. Detergent / soapy water 
3. Plain water 
4. Disinfectant 
5.  Unsure 
6.  Refused 
7. Other (specify) 
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DEMOGRAPHICS 
The following questions are about where you and members of your household have 
travelled in the past year 
Q45 Have you travelled outside New Zealand in the past 12 months? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q45A What countries did you visit? 
 
[MULTIPLE RESPONSE] 
1. Australia 
2. Canada 
3. China 
4. Fiji 
5. Germany 
6. Ireland 
7. Japan 
8. Samoa 
9. Tonga 
10. United Kingdom 
11. United States of America 
12.  Unsure 
13.  Refused 
14. Other (specify) 
 
Q46 Have any members of the household (other than you) travelled outside New 
Zealand in the past 12-months? 
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1. Yes 
2. No 
3. Unsure 
4. Refused 
 
 
Q47 Are you a healthcare worker? 
[This is any job in health care including working as a nurse, doctor, midwife, 
physiotherapist, occupational therapist, dietician, speech therapist, healthcare assistant, 
cleaner, orderly, administrator or manager.] 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q47A Do you have contact with patients in your work? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q48 Where do you spend most of your time during an average working or school day? 
If you do not work, where do you spend most of your day? 
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1. Preschool childcare facility (including kohanga reo, creche, daycare 
centre, etc) 
2. Educational facility (including primary, secondary, tertiary, etc) 
3. Hospital or medical centre 
4. Veterinary hospital or clinic 
5. Farm 
6. Office 
7. Medical laboratory 
8. Home 
9. Vehicle 
10.  Unsure 
11.  Refused 
12. Other (specify) 
           
 
Q49 Have you visited a hospital or residential care facility in the past 6-months, as a 
visitor or volunteer or employee but NOT as a patient? 
 
1. Yes 
2. No 
3. Unsure 
4. Refused 
 
Q50 Have any members of your household (other than you) visited a hospital or 
residential care facility in the past 6-months, as a visitor or volunteer or employee 
but NOT as a patient? 
 
1. Yes 
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2. No 
3. Unsure 
4. Refused 
 
 
Q51 Which of the following ethnic groups do you belong to? One or several groups may 
apply to you. 
 
[MULTIPLE RESPONSE] 
 
1. NZ European 
2. NZ Maori 
3. Samoan 
4. Cook Island Maori 
5. Tongan 
6. Niuean 
7. Chinese 
8. Indian 
9.  Unsure 
10.  Refused 
11. Other (specify) 
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Just to confirm what was your age is please? 
_____________________________________ 
[IF YOU DO NOT WISH TO TELL, US: PLEASE CIRCLE BELOW WHERE 
APPROPRIATE] 
1. 16-17 
2. 18-19 
3. 20-24 
4. 25-29 
5. 30-34 
6. 35-39 
7. 40-44 
8. 45-49 
9. 50-54 
10. 55-59 
11. 60-64 
12. 65-69 
13. 70-74 
14. 75+ 
15.  Refused 
We are almost at the end of the survey. On behalf of the researchers at Massey 
University, we thank you very much for taking the time to complete our survey - your 
input has been very valuable to us. We have a couple of final questions to ask you: 
Q52 Do you give permission for a researcher from Massey University to contact you 
in the near future regarding participation in further research? 
 
1. Yes 
2. No / Unsure 
 
That's the end of this survey, thank you again for your time. Please ensure you send us 
back the consent form as well  
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Variable coding 
Variables were coded as follows: decile, ruralurban, region, gender, eth_maori, eth_asian, 
eth_pacifika, eth_european, eth_melaa, home, health_work, health_visit. Factors 
associated with other people in the home were coded as: hh_mdr, hh_hosp, hh_abx, 
hh_health_visit, hh_travel, 
Case/control participant self-reported health information was coded as follows for 
chronic disease: any, asthma, COPD, cardiac disease, diabetes, other. General health 
information was coded as follows: uti_6m, cdz_score, age3cat, health, cdz_all, 
cdz_asthma, cdz_copd, cdz_cardiac, cdz_diabetes, cdz_other, doctorcontact, 
abx_tx_all.  
Pet contact was coded as follows: pet, petcatdog, petsleepinside, petsleepbed, petlickface, 
cc_handlepoo, pet_visit, cat_food, dog_food, cat_wild, pet_vet, pet_vet, pet_vet_type,  
pet_vet_tx. Handwashing behaviour around pets was coded as follows: 
pet_hands_b4food, pet_hands_food, pet_hands_b4pet, pet_hands_b4pet2, 
pet_hands_pet, pet_hands_lick, pet_hands_poo. 
Other (non-pet) animal contact was coded as follows: animal_bird, animal_pet, 
animal_rodent, animal_fish, animal_farm, animal_equinecamelid, animal_wildother, 
animal_contact. 
International travel in previous year was coded as: travel_all, just_travel_sth_america, 
just_travel_africa, just_travel_middle_east, just_travel_eu, just_travel_asia, 
just_travel_africa, just_travel_america, just_travel_pacific, just_travel_aus. 
Diet and hygiene were coded as: vegetarian, eats_meat, rawmilk, supermarket, 
greengrocer, farmersmkt, homegrow_ffam. Handwashing behaviour was coded as: 
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hands_toilet & hands_toilet2, hands_b4food, hands_b4eat, hands_nose. Garden factors 
were coded as: garden, cdpoo_garden, compost_garden, feed_birds, birdbath.  
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Appendix V: Data analysis  
 
The R code used for data analysis is available at:  
• https://esblfamilypet.wordpress.com/2019/01/28/appendix-v-r-code/ 
 
Supplementary information for questionnaire dataset modelling of LASSO logisitic 
regression 
 
Figure 6.2 Questionnaire dataset LASSO regression modelling (λmin = 0.0123) where ln(λ) 
dotted lined indicate λ min and λ min +1SE  
Lambda (or λ) is the shrinkage parameter (i.e penalty coefficient) and the closer to 1 [i.e. 
ln(0)] this parameter is, the more conservative the model. The results of these models for 
both questionnaire and government (NHI) datasets is shown in Table 3.12. 
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Appendix VI household SNP 
distances in Chapter 4  
 
Table 6.4 Chapter 4 household HH008 SNP distances for Figure 4.3 
 
LT 1003c  
LT 1003d 
LT 1003e 
LT 1003f 
LT 1003g 
LT 1003h  
LT 8062a 
R
ef 
LT 1003c 0 2 7 89519 0 0 5 8 
LT 1003d 2 0 9 89519 2 2 7 10 
LT 1003e 7 9 0 89520 7 7 10 13 
LT 1003f 89519 89519 89520 0 89519 89519 89520 89516 
LT 1003g 0 2 7 89519 0 0 5 8 
LT 1003h 0 2 7 89519 0 0 5 8 
LT 8062a 5 7 10 89520 5 5 0 9 
Ref 8 10 13 89516 8 8 9 0 
 
 
Table 6.5 Chapter 4 household HH0015 SNP distances for Figure 4.3 
 
LT 1030c  
LT 1030d  
LT 1030e  
LT 1030f 
LT 1030g1 
LT 1030h2 
LT 8052a 
R
ef  
LT 1030c 0 16 11 18 17 14 123 16 
LT 1030d 16 0 15 20 17 14 123 14 
LT 1030e 11 15 0 15 16 11 122 13 
LT 1030f 18 20 15 0 23 18 129 18 
LT 1030g1 17 17 16 23 0 15 124 17 
LT 1030h2 14 14 11 18 15 0 121 2 
LT 8052a 123 123 122 129 124 121 0 123 
Ref 16 14 13 18 17 2 123 0 
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Table 6.6 Chapter 4 household HH0015 SNP distances for Figure 4.3 
ID
 
LT 1028a 
LT 1028b 
LT 1028c2  
LT 1028d  
LT 1028e  
LT 1028f  
LT 1028g 
LT 1028h 
LT 1029d 
LT 1029e  
LT 1029f 
LT 1029g 
LT 1029h  
LT 8125a  
R
ef  
LT 1028a 0 14 9 16 4 15 11 15 15 15 14 6 15 14 18 
LT 1028b 14 0 5 4 14 3 7 3 3 3 4 10 3 4 6 
LT 1028c2 9 5 0 7 9 6 2 6 6 6 7 13 6 5 9 
LT 1028d 16 4 7 0 12 1 5 1 1 1 2 10 1 6 4 
LT 1028e 4 14 9 12 0 11 7 11 11 11 10 6 11 14 14 
LT 1028f 15 3 6 1 11 0 4 0 0 0 1 9 0 5 3 
LT 1028g 11 7 2 5 7 4 0 4 4 4 5 13 4 7 7 
LT 1028h 15 3 6 1 11 0 4 0 0 0 1 9 0 5 3 
LT 1029d 15 3 6 1 11 0 4 0 0 0 1 9 0 5 3 
LT 1029e 15 3 6 1 11 0 4 0 0 0 1 9 0 5 3 
LT 1029f 14 4 7 2 10 1 5 1 1 1 0 8 1 6 4 
LT 1029g 6 10 13 10 6 9 13 9 9 9 8 0 9 12 12 
LT 1029h 15 3 6 1 11 0 4 0 0 0 1 9 0 5 3 
LT 8125a 14 4 5 6 14 5 7 5 5 5 6 12 5 0 6 
Ref 18 6 9 4 14 3 7 3 3 3 4 12 3 6 0 
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Table 6.7 Chapter 4 household HH0024 SNP distances for Figure 4.3 
ID
 
LT 1033c 
LT 1033d 
LT 1033e  
LT 1033f  
LT 1033g  
LT 1033h  
LT 1034a  
LT 1034b 
LT 1034c  
LT 1034d 
LT 1034e  
LT 1034f 
LT 1034g 
LT 8179a 
R
ef  
LT 1033c 0 2 89773 0 89778 0 1 1 1 1 3 2 3 18 59 
LT 1033d 2 0 89775 2 89780 2 3 3 3 3 1 4 5 16 57 
LT 1033e 89773 89775 0 89773 114 89773 89774 89774 89774 89774 89776 89775 89776 89791 89829 
LT 1033f 0 2 89773 0 89778 0 1 1 1 1 3 2 3 18 59 
LT 1033g 89778 89780 114 89778 0 89778 89779 89779 89779 89779 89781 89780 89781 89796 89836 
LT 1033h 0 2 89773 0 89778 0 1 1 1 1 3 2 3 18 59 
LT 1034a 1 3 89774 1 89779 1 0 0 0 0 2 1 2 17 58 
LT 1034b 1 3 89774 1 89779 1 0 0 0 0 2 1 2 17 58 
LT 1034c 1 3 89774 1 89779 1 0 0 0 0 2 1 2 17 58 
LT 1034d 1 3 89774 1 89779 1 0 0 0 0 2 1 2 17 58 
LT 1034e 3 1 89776 3 89781 3 2 2 2 2 0 3 4 15 56 
LT 1034f 2 4 89775 2 89780 2 1 1 1 1 3 0 1 18 59 
LT 1034g 3 5 89776 3 89781 3 2 2 2 2 4 1 0 17 58 
LT 8179a 18 16 89791 18 89796 18 17 17 17 17 15 18 17 0 41 
Ref 59 57 89829 59 89836 59 58 58 58 58 56 59 58 41 0 
 
 
Table 6.8 Chapter 4 household HH0026 SNP distances for Figure 4.3 
 
LT 1043a  
LT 1043b 
LT 1043c  
LT 1043d 
LT 1043e  
LT 1043f 
LT 1043g 
LT 1043h 
LT 1044g 
LT 1044h 
LT 8198a  
R
ef 
LT 1043a 0 54 52 54 85 45 77 60 96093 96094 96092 96094 
LT 1043b 54 0 42 52 87 51 71 46 96073 96074 96072 96074 
LT 1043c 52 42 0 32 69 35 67 34 96093 96094 96092 96094 
LT 1043d 54 52 32 0 79 41 55 48 96095 96096 96094 96096 
LT 1043e 85 87 69 79 0 86 94 91 96066 96067 96065 96067 
LT 1043f 45 51 35 41 86 0 76 45 96092 96093 96091 96093 
LT 1043g 77 71 67 55 94 76 0 75 96054 96055 96053 96055 
LT 1043h 60 46 34 48 91 45 75 0 96077 96078 96076 96078 
LT 1044g 96093 96073 96093 96095 96066 96092 96054 96077 0 3 1 7 
LT 1044h 96094 96074 96094 96096 96067 96093 96055 96078 3 0 2 6 
LT 8198a 96092 96072 96092 96094 96065 96091 96053 96076 1 2 0 8 
Ref 96094 96074 96094 96096 96067 96093 96055 96078 7 6 8 0 
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Table 6.9 Chapter 4 household HH0039 SNP distances for Figure 4.3 
ID
 
LT 1089c 
LT 1089d  
LT 1089e 
LT 1089f  
LT 1090b  
LT 1090c 
LT 1090d  
LT 1090e 
LT 1090f  
LT 8231a 
R
ef 
LT 1089c 0 2 2 0 51790 10 9 11 11 9 14 
LT 1089d 2 0 0 2 51792 12 11 9 9 7 12 
LT 1089e 2 0 0 2 51792 12 11 9 9 7 12 
LT 1089f 0 2 2 0 51790 10 9 11 11 9 14 
LT 1090b 51790 51792 51792 51790 0 51794 51793 51795 51795 51793 51798 
LT 1090c 10 12 12 10 51794 0 1 5 5 5 8 
LT 1090d 9 11 11 9 51793 1 0 4 4 4 7 
LT 1090e 11 9 9 11 51795 5 4 0 2 2 5 
LT 1090f 11 9 9 11 51795 5 4 2 0 2 3 
LT 8231a 9 7 7 9 51793 5 4 2 2 0 5 
Ref 14 12 12 14 51798 8 7 5 3 5 0 
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Table 6.10 Chapter 4 household HH0040 SNP distances for Figure 4.3 
 
LT 1078c 
LT 1078d 
LT 1078e  
LT 1078f 
LT 1078g 
LT 1078h 
LT 1079a  
LT 1079b 
LT 1079c  
LT 1079d 
LT 1079e  
LT 1079f 
LT 1079g 
LT 1079h 
LT 1080c 
LT 1080d 
LT 1080e 
LT 1080f 
LT 1080g 
LT 1080h 
LT 108 2a 
LT 1082b  
LT 1082c 
LT 1082d  
LT 1082e 
LT 1082f 
LT 1082g  
LT 8242a 
R
ef 
LT 1078c 0 0 1 4 0 0 4 2 4 4 4 0 4 4 1 0 1 2 2 1 0 1 0 2 1 1 1 1 4 
LT 1078d 0 0 1 4 0 0 4 2 4 4 4 0 4 4 1 0 1 2 2 1 0 1 0 2 1 1 1 1 4 
LT 1078e 1 1 0 5 1 1 5 3 5 5 5 1 5 5 2 1 2 3 3 2 1 2 1 3 2 2 2 2 5 
LT 1078f 4 4 5 0 4 4 0 2 0 0 0 4 0 0 5 4 5 2 2 5 4 5 4 6 5 5 5 5 8 
LT 1078g 0 0 1 4 0 0 4 2 4 4 4 0 4 4 1 0 1 2 2 1 0 1 0 2 1 1 1 1 4 
LT 1078h 0 0 1 4 0 0 4 2 4 4 4 0 4 4 1 0 1 2 2 1 0 1 0 2 1 1 1 1 4 
LT 1079a 4 4 5 0 4 4 0 2 0 0 0 4 0 0 5 4 5 2 2 5 4 5 4 6 5 5 5 5 8 
LT 1079b 2 2 3 2 2 2 2 0 2 2 2 2 2 2 3 2 3 4 4 3 2 3 2 4 3 3 3 3 6 
LT 1079c 4 4 5 0 4 4 0 2 0 0 0 4 0 0 5 4 5 2 2 5 4 5 4 6 5 5 5 5 8 
LT 1079d 4 4 5 0 4 4 0 2 0 0 0 4 0 0 5 4 5 2 2 5 4 5 4 6 5 5 5 5 8 
LT 1079e 4 4 5 0 4 4 0 2 0 0 0 4 0 0 5 4 5 2 2 5 4 5 4 6 5 5 5 5 8 
LT 1079f 0 0 1 4 0 0 4 2 4 4 4 0 4 4 1 0 1 2 2 1 0 1 0 2 1 1 1 1 4 
LT 1079g 4 4 5 0 4 4 0 2 0 0 0 4 0 0 5 4 5 2 2 5 4 5 4 6 5 5 5 5 8 
LT 1079h 4 4 5 0 4 4 0 2 0 0 0 4 0 0 5 4 5 2 2 5 4 5 4 6 5 5 5 5 8 
LT 1080c 1 1 2 5 1 1 5 3 5 5 5 1 5 5 0 1 2 3 3 0 1 2 1 3 0 2 2 2 5 
LT 1080d 0 0 1 4 0 0 4 2 4 4 4 0 4 4 1 0 1 2 2 1 0 1 0 2 1 1 1 1 4 
LT 1080e 1 1 2 5 1 1 5 3 5 5 5 1 5 5 2 1 0 3 3 2 1 2 1 3 2 2 2 2 5 
LT 1080f 2 2 3 2 2 2 2 4 2 2 2 2 2 2 3 2 3 0 0 3 2 3 2 4 3 3 3 3 6 
LT 1080g 2 2 3 2 2 2 2 4 2 2 2 2 2 2 3 2 3 0 0 3 2 3 2 4 3 3 3 3 6 
LT 1080h 1 1 2 5 1 1 5 3 5 5 5 1 5 5 0 1 2 3 3 0 1 2 1 3 0 2 2 2 5 
LT 1082a 0 0 1 4 0 0 4 2 4 4 4 0 4 4 1 0 1 2 2 1 0 1 0 2 1 1 1 1 4 
LT 1082b 1 1 2 5 1 1 5 3 5 5 5 1 5 5 2 1 2 3 3 2 1 0 1 3 2 2 0 2 5 
LT 1082c 0 0 1 4 0 0 4 2 4 4 4 0 4 4 1 0 1 2 2 1 0 1 0 2 1 1 1 1 4 
LT 1082d 2 2 3 6 2 2 6 4 6 6 6 2 6 6 3 2 3 4 4 3 2 3 2 0 3 3 3 3 6 
LT 1082e 1 1 2 5 1 1 5 3 5 5 5 1 5 5 0 1 2 3 3 0 1 2 1 3 0 2 2 2 5 
LT 1082f 1 1 2 5 1 1 5 3 5 5 5 1 5 5 2 1 2 3 3 2 1 2 1 3 2 0 2 2 3 
LT 1082g 1 1 2 5 1 1 5 3 5 5 5 1 5 5 2 1 2 3 3 2 1 0 1 3 2 2 0 2 5 
LT 8242a 1 1 2 5 1 1 5 3 5 5 5 1 5 5 2 1 2 3 3 2 1 2 1 3 2 2 2 0 5 
Ref 4 4 5 8 4 4 8 6 8 8 8 4 8 8 5 4 5 6 6 5 4 5 4 6 5 3 5 5 0 
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Table 6.11 Chapter 4 household HH0048 SNP distances for Figure 4.3 
ID
 
LT 1097c 
LT 1097d 
LT 1097g 
LT 1097h  
LT 1099e 
LT 1099f 
LT 1099g 
LT 1099h 
LT 8320a  
R
ef  
LT 1097c 0 2 1 0 100205 75728 2 1 2 0 
LT 1097d 2 0 1 2 100205 75728 4 3 2 2 
LT 1097g 1 1 0 1 100204 75727 3 2 1 1 
LT 1097h 0 2 1 0 100205 75728 2 1 2 0 
LT 1099e 100205 100205 100204 100205 0 89636 100205 100206 100205 100205 
LT 1099f 75728 75728 75727 75728 89636 0 75730 75729 75728 75728 
LT 1099g 2 4 3 2 100205 75730 0 1 4 2 
LT 1099h 1 3 2 1 100206 75729 1 0 3 1 
LT 8320a 2 2 1 2 100205 75728 4 3 0 2 
Ref 0 2 1 0 100205 75728 2 1 2 0 
 
 
Table 6.12 Chapter 4 household HH0064 SNP distances for Figure 4.3 
 
LT 1143c  
LT 1143e  
LT 1143f  
LT 1143g 
LT 8371a 
R
ef  
LT 1143c 0 81 82 83 95176 95176 
LT 1143e 81 0 91 76 95181 95181 
LT 1143f 82 91 0 87 95196 95196 
LT 1143g 83 76 87 0 95189 95189 
LT 8371a 95176 95181 95196 95189 0 2 
Ref 95176 95181 95196 95189 2 0 
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Table 6.13 Chapter 4 household HH0065 SNP distances for Figure 4.3 
 
LT 1131c 
LT 1131d  
LT 1131e 
LT 1131f 
LT 1131g  
LT 1132b 
LT 1132c 
LT 1132d  
LT 1132e 
LT 1132f 
LT 1132g 
LT 1132h 
LT 8455a  
R
ef  
LT 1131c 0 25126 48 43 48286 84380 84380 84379 84378 84377 84377 84377 84377 84378 
LT 1131d 25126 0 25130 25123 48015 83245 83245 83244 83243 83242 83242 83242 83242 83243 
LT 1131e 48 25130 0 53 48284 84372 84372 84371 84370 84369 84369 84369 84369 84370 
LT 1131f 43 25123 53 0 48293 84383 84383 84382 84381 84380 84380 84380 84380 84381 
LT 1131g 48286 48015 48284 48293 0 83704 83704 83703 83702 83701 83701 83701 83701 83702 
LT 1132b 84380 83245 84372 84383 83704 0 2 1 2 3 3 5 3 4 
LT 1132c 84380 83245 84372 84383 83704 2 0 1 2 3 3 5 3 4 
LT 1132d 84379 83244 84371 84382 83703 1 1 0 1 2 2 4 2 3 
LT 1132e 84378 83243 84370 84381 83702 2 2 1 0 3 3 3 3 2 
LT 1132f 84377 83242 84369 84380 83701 3 3 2 3 0 0 2 0 5 
LT 1132g 84377 83242 84369 84380 83701 3 3 2 3 0 0 2 0 5 
LT 1132h 84377 83242 84369 84380 83701 5 5 4 3 2 2 0 2 5 
LT 8455a 84377 83242 84369 84380 83701 3 3 2 3 0 0 2 0 5 
Ref 84378 83243 84370 84381 83702 4 4 3 2 5 5 5 5 0 
 
 
Table 6.14 Chapter 4 household HH0086 SNP distances for Figure 4.3 
 
LT 1171g 
LT 1173c 
LT 1173d1  
LT 1173e 
LT 1173f  
LT 1173g 
LT 1173h  
LT 8703a 
R
ef 
LT 1171g 0 5 4 4 6 4 8 104 8 
LT 1173c 5 0 3 3 1 3 9 101 9 
LT 1173d1 4 3 0 2 4 0 6 104 6 
LT 1173e 4 3 2 0 4 2 6 104 8 
LT 1173f 6 1 4 4 0 4 10 100 10 
LT 1173g 4 3 0 2 4 0 6 104 6 
LT 1173h 8 9 6 6 10 6 0 102 12 
LT 8703a 104 101 104 104 100 104 102 0 108 
Ref 8 9 6 8 10 6 12 108 0 
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